Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
1 
  
590-56+/0. 
Phase II Multicenter Single-arm Study of BKM120 plu s Capecitabine 
for Breast Cancer Patients with Brain Metastases 
CBKM120ZUS39T 
Sponsor: Delta Clinical Research, LLC 11-025 
 
 
 
Study Investigators: Joyce O’Shaughnessy, MD 
Baylor Sammons Cancer Center 
3410 Worth Street 
Dallas, Texas  75246 
(214) 370-1796 
 
Morris D. Groves, MD, JD 
Texas Oncology 
901 W. 38th St., Suite 200 
Austin, TX 78705 
(512) 421-4100 
 
 
Date: 
 
 
 
 
  
October 5, 2013 
February 17, 2014 (Amendment #1) 
July 22, 2015 (Amendment #2) 
June 24, 2016 (Amendment #3) 
 
 
 
CONFIDENTIAL 
Information and data included in this protocol cont ain trade secrets and privileged or confidential in formation that is 
the property of Delta Clinical Research, LLC (“Delt a”) and Novartis  Corporation. No person is authorized to make 
it public without written permission of Delta,  and Novartis Corporation. These restrictions on dis closure will apply 
equally to all future information supplied to you, which is indicated as privileged or confidential. T his material may 
be disclosed to and used by your staff and associat es as may be necessary to conduct this clinical stu dy.  
 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
2 
 Table of Contents 
 
1 Background ........................................ ................................................... .............................10  
1.1  Disease Background ................................ ................................................... ............10  
1.2  PI3K Pathway and Mechanism of Action .............. ................................................11  
1.2.1  PI3K pathway activation in MBC .................... .....................................12  
1.3  Study Treatments .................................. ................................................... ..............15  
1.3.1  Buparlisib ........................................ ................................................... ...15  
1.3.2  Capecitabine ...................................... ................................................... .39  
1.3.3  Buparlisib in combination with capecitabine ....... .................................39  
1.3.4  Buparlisib in combination with trastuzumab ........ .................................40  
1.4  Study Rationale ................................... ................................................... ................40  
1.4.1  Rationale for dose selection....................... ............................................40  
2 Study objectives .................................. ................................................... ............................41  
3 Exploratory Investigational Plan .................. ................................................... ..................41  
3.1  Overall Study Design .............................. ................................................... ............41  
3.2  Study Population .................................. ................................................... ...............45  
3.2.1  Patient population ................................ ..................................................4 5  
3.2.2  Registration procedures ........................... ..............................................46  
3.2.3  Inclusion and exclusion criteria .................. ...........................................46  
4 Treatments ........................................ ................................................... ..............................51  
4.1  Interruption or Discontinuation of Treatment ...... ..................................................5 1  
4.1.2  Known Undesirable Side Effects of Buparlisib ...... ...............................64  
4.1.3  Criteria for capecitabine dose modification ....... ...................................71  
4.1.4  Trastuzumab – Cardiac Monitoring and Cardiomyopathy  
Management Guidelines ............................. ...........................................72  
4.1.5  Reasons off treatment ............................. ...............................................72  
4.1.6  Reasons for taking patients “off study” ........... ......................................73  
4.2  Treatments ........................................ ................................................... ...................73  
4.2.1  Study treatment administration .................... ..........................................73  
4.2.2  Dosing regimen .................................... .................................................74  
4.2.3  Concomitant therapy ............................... ..............................................75  
Table 4-11 List of CYP450 Substrates to be used wit h caution ............................82  
4.3  Visit Schedule and Assessments .................... ................................................... .....83  
4.3.1  Visit schedule .................................... ................................................... .83  
4.3.2  Efficacy assessments .............................. ...............................................89  
4.3.3  Safety assessments................................. ................................................90  
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
3 
 4.3.4  Treatment compliance .............................. .............................................91  
4.3.5  Adverse events..................................... ..................................................9 1  
4.3.6  Serious adverse events ............................ ...............................................91  
4.3.7  Instructions for rapid notification of serious adve rse events .................92  
4.3.8  Laboratory evaluations ............................ ..............................................94  
4.3.9  Vital signs ....................................... ................................................... ....95  
4.3.10  Physical examination .............................. ...............................................95  
4.3.11  Neuropsychiatric assessments ...................... .........................................95  
4.3.12  ECG/EKG –ECHO/MUGA................................. ..................................95  
4.3.13  Performance status................................. ................................................95  
4.3.14  Disease-related symptom assessment ................ ....................................96  
4.3.15  Drug levels and pharmacokinetic assessments ....... ...............................96  
5 Data management ................................... ................................................... ........................96  
5.1  Data collection ................................... ................................................... .................96  
6 Statistical methods ............................... ................................................... ...........................96  
6.1  Populations for analysis .......................... ................................................... ............96  
6.1.1  Analysis populations .............................. ...............................................96  
6.1.2  Patient characteristics ........................... .................................................96  
6.1.3  Patient disposition ............................... ..................................................9 7  
6.2  Hypothesis and endpoints .......................... ................................................... .........97  
6.3  Sample size and projected study duration .......... ................................................... .97  
6.4  Statistical methods ............................... ................................................... ...............97  
6.4.1  Primary efficacy analysis ......................... .............................................97  
6.4.2  Secondary efficacy analysis ....................... ...........................................98  
7 Protocol and Data Development ..................... ................................................... ................98  
7.1  Ethics ............................................ ................................................... .......................98  
7.1.1  Institutional review board ........................ ..............................................98  
7.1.2  Patient informed consent .......................... .............................................99  
7.1.3  Confidentiality of records ........................ ............................................100  
7.2  Study Records ..................................... ................................................... ..............100  
7.2.1  Documentation ..................................... ...............................................100  
7.2.2  Electronic case report form procedures ............ ...................................100  
7.3  Monitoring/Site Visits ............................ ................................................... ...........101  
7.4  Modification of Protocol .......................... ................................................... .........101  
8 References ........................................ ................................................... .............................102  
APPENDICES ........................................ ................................................... .............................108  
  
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
4 
 List of Abbreviations 
 
AE    Adverse Event 
ADME   Absorption, Digestion, Metabolism, Excretion  
AKT    See PKB (protein Kinase B) 
ALT    Alanine aminotransferase/glutamic-pyruvic tr ansaminase/GPT 
ANC    Absolute Neutrophil Count 
ASCO   American Society of Clinical Oncology 
AST    Aspartateaminotransferase/glutamic-oxaloacet ic transaminase/GOT 
BAL   Bronchoalveolar lavage 
BC   Breast Cancer 
BRCA1/2  Breast Cancer 1/2  
BUN    Blood Urea Nitrogen 
CBC    Complete Blood Count 
CBR   Clinical Benefit Rate 
C1D1   Cycle 1 Day 1 
CK    Creatine Kinase 
CK-MB   Creatine Kinase - Muscle and Brain isoenzym e 
CNS   Central Nervous System 
CR    Complete Response 
CRD    Clinical Research and Development 
CS    Cowden Syndrome 
CT    Computed Tomography 
CTI   Clinical Trial Information 
CTCAE   Common Terminology Criteria for Adverse Eve nts 
CTMS   Clinical Trial Management System 
CYP3A4  Cytochrome P450 3A4 
CYP450  Cytochrome P450 
DLco   Diffusing capacity of the Lung for Carbon Mo noxide 
DLT    Dose Limiting Toxicity 
Delta   Delta Clinical Research, LLC 
DSMB   Drug Safety Monitoring Board 
DSTPlan  Double Precision Study Planning (software)  
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
5 
 ECG    Electrocardiogram 
ECHO    Echocardiogram 
ECOG   Eastern Cooperative Group 
eCRF                     electronic Case Report For m 
eDC   electronic Data Capture 
EGFR    Epidermal Growth Factor Receptor 
EOT   End Of Treatment 
ER   Estrogen Receptor 
18F-FDG   [18F]-Fluorodeoxyglucose 
FFPE   Formalin Fixed Paraffin Embedded 
FGF   Fibroblast Growth Factor 
FISH   Fluorescence In Situ Hybridization 
FNA   Fine Needle Aspiration 
FOXO3a  Forkhead Box O3 
FPG    Fasting Plasma Glucose 
FSH   Follicle Stimulating Hormone 
GABA   Gamma-Amino Butyric Acid 
GAD-7  Generalized Anxiety Disorder Scale 7 
GCP    Good Clinical Practice 
GGT   Gamma-Glutamyl Transferase 
GI    Gastrointestinal 
GLP   Good Laboratory Practice 
GPA   Graded Prognostic Assessment 
GSK3 beta  Glycogen Synthase Kinase-3 
HbA1c   Hemoglobin A1c 
HDL    High density lipoprotein 
HER2   Human Epidermal Growth Factor Receptor 2 
hERG   Human Ether-à-go-go Related Gene 
HIAA   5-Hydroxyindoleacetic Acid 
HIV                     Human Immunodeficiency Viru s 
HLGT   High Level Group Term 
HPF                         High Power Field 
 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
6 
 ICH    International Conference on Harmonization 
IC50   Half-maximal Inhibitory Concentration 
IEC    Independent Ethics Committee 
IGF-1   Insulin-like Growth Factor-1 
IHC   Immunohistochemistry    
INPP4B  Inositol Polyphosphate 4-phosphatase type I I 
INR   International Normalized Ratio 
IRB    Institutional Review Board 
LDL    Low density lipoprotein 
LFT   Liver Function Test 
LFU   Lost to Follow Up 
LumA   Luminal A 
LumB   Luminal B 
LVEF    Left Ventricular Ejection fraction 
MBC   Metastatic Breast Cancer 
MDASI-BT  M.D. Anderson Symptom Inventory – Brain T umor 
MEFs   Mouse Embryonic Fibroblasts 
MRI    Magnetic Resonance Imaging 
MTD    Maximum Tolerated Dose 
MTOR   Mammalian Target of Rapamycin 
MTORC2  mTOR Complex 2 
NE   Non-evaluable 
NEC   Not Elsewhere Classified 
MUGA   Multiple Gated Acquisition Scan 
ORR   Objective Response Rate 
OS   Overall Survival 
PARP   Poly (ADP-Ribose) Polymerase 
PD    Pharmacodynamic 
PDFG   Platelet Derived Growth Factor 
PET    Positron Emission Tomography 
PgR   Progesterone Receptor 
PHQ9   Patient Health Questionnaire 9 
PI3K    Phosphatidylinositol 3’-kinase 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
7 
 PIP3   Phosphatidylinositol Phosphate 3 
PK    Pharmacokinetic 
PKB    Protein Kinase B (or AKT) 
PR   Partial Response 
pS6   Phosphorylated S6 Protein of the 40S Ribosoma l Subunit 
PT    Prothrombin Time 
PTEN    Phosphatase and Tensin homolog 
PTT    Partial Thromboplastin Time (also known as A PTT) 
QTc    QT interval (corrected) 
RAD001  Everolimus 
RAS1   Rat Sarcoma Gene 1 
RBC   Red Blood Cells 
REB    Research Ethics Board 
RECIST   Response Evaluation Criteria In Solid Tumo rs 
S6K    Protein Kinase S6 
SAE    Serious adverse event 
SD   Stable Disease 
SHIP2   SH2-containing 5'-Inositol Phosphatase 2 
SI   Study Investigator 
SOP    Standard Operating Procedure 
Src   Src Nonreceptor Tyrosine Kinase 
SRS   Stereotactic Radiosurgery 
SUV    Standardized Uptake Value 
TCGA   The Cancer Genome Atlas 
TdP   Torsades de Pointes 
TNBC   Triple Negative Breast Cancer 
TR-FRET  Time Resolved-Fluorescence Resonance Energ y Transfer 
TSC1   Tuberous Sclerosis Complex 1 
TTP    Time to Progression 
ULN    Upper Limit of Normal 
UPN   Unique Patient Number 
VPs34   Class III Phosphoinositide 3-Kinase Isoform  
WBC    White Blood Count 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
8 
 WBRT   Whole Brain Radiation Therapy 
WHO    World Health Organization 
WOCBP  Women of Child-Bearing Potential 
 
 
 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
9 
 Synopsis 
 
This is a Phase 2, multicenter, single-arm study to  determine the safety and efficacy of buparlisib 
(BKM120) plus capecitabine in breast cancer patient s with brain metastases.  42 patients will be 
included, who have either ER+/HER2-, HER2+ or tripl e negative breast cancer.    
The primary objective will be to determine the clin ical benefit rate (CBR) defined as the 
proportion of patients with the best overall respon se of complete response (CR) or of partial 
response (PR) or of stable disease (SD) lasting at least 24 weeks.  The Graded Prognostic 
Assessment (GPA) is a recently developed, validated  prognostic score for patients with brain 
metastases (Sperduto 2008, Sperduto 2012b).  The Gr aded Prognostic Assessment will be 
utilized to evaluate efficacy in this clinical stud y.  Secondary objectives include an assessment of 
objective response rate (ORR) in the CNS, the media n time to progression (TTP) and the median 
overall survival (OS) as well as the usual requirem ent to characterize the safety and tolerability 
of the combined buparlisib plus capecitabine therap y.   
Capecitabine is a prodrug which is enzymatically co nverted to 5-fluorourocil in its tumor target 
where it inhibits DNA synthesis and slows tumor gro wth.  It is currently FDA approved for both 
colorectal and breast cancer.  Buparlisib is a pan phosphatidylinositol-3-kinase inhibitor being 
developed under IND# 102,823 by Novartis Corporatio n.  As of September 2012 over 600 
patients had been enrolled in fourteen separate Nov artis sponsored monotherapy or combination 
therapy clinical studies of buparlisib which are su mmarized in Section 1.3.1.3.1.   
Phosphatdyinositol-3-kinase (PI3K) signaling regula tes diverse cellular functions including cell 
proliferation, survival, translational regulation o f protein synthesis, glucose metabolism, cell 
migration, and angiogenesis (Katso, et. al., 2001).   PI3K signaling also serves a central role in 
the pathogenesis of numerous cancers.  Constitutive  activation of PI3K signaling is known to be 
a critical step in mediating the transforming poten tial of oncogenes and tumor suppressors in 
many tumor types (Liu 2009).  Resistance to a varie ty of therapeutic interventions, including 
hormonal therapyanti-HER2 therapies and chemotherap y can also be linked to constitutive 
activation of the PI3K pathway (McCubrey 2006).   
Preliminary data suggest that activation of the PI3 K pathway is a predictor of a poor prognostic 
outcome in many cancer types.  Thus, as a pan-PI3K inhibitor, buparlisib may provide a 
therapeutic benefit to patients with MBC.  Both cap ecitabine and buparlisib have previously 
shown activity in patients with MBC.  Like capecita bine, buparlisib is also effective in crossing 
the blood brain barrier making it a preferred candi date for its evaluation in patients with MBC. 
Current clinical experience with buparlisib has sho wn that its most frequent adverse events 
(AEs) include fatigue, decreased appetite, diarrhea , hyperglycemia, nausea, rash and mood 
alteration disorders.  Therefore patients will be c losely monitored for fasting plasma glucose 
(FPG) HbA1c, and insulin C-peptide.  Patients will also be frequently and routinely evaluated 
for mood disorders and disturbances.  The remaining  most frequent AEs will be detected by 
regular, frequent monitoring with symptomatic treat ment to be provided as required.   
  
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
10 
 1 Background 
1.1  Disease Background 
Breast cancer (BC) is the most common form of malig nant tumor in women worldwide, and 
incidence rates are as high as 99.4 per 100,000 wom en (World Health Organization 2011). 
Subtypes of BC are distinguished by expression of e strogen receptors (ER), progesterone 
receptors (PgR) and human epidermal growth factor r eceptor-2 (HER2), as well as by distinct 
gene expression profiles (Perou 2000; Sotiriou and Pusztai 2009). 
Patients with metastatic ER-negative breast cancer have a high risk of developing brain 
metastases. In one retrospective cohort study, 46% of patients with metastatic triple negative 
breast cancer (TNBC) were found to have central ner vous system (CNS) metastases at some 
point before death, and 14% had a CNS metastasis at  first metastatic presentation (Lin 2008). A 
second retrospective study reported a 25% incidence  of CNS metastases in patients with TNBC 
(Kennecke 2010). Outside of surgery and radiation t herapy there are no proven therapies which 
improve overall survival (OS) of patients with brai n metastases. In patients with HER2+ MBC, 
retrospective studies have documented an incidence of CNS metastases of approximately 25% - 
40%, and this frequently occurs while systemic dise ase is still well controlled by effective 
HER2-targeted therapies (Lin 2007). A study of brea st cancer patients in the British Columbia 
Cancer Agency reported a 15 year incidence rate of CNS metastases of 5% and 2% in estrogen 
receptor-positive Luminal B and Luminal A subtypes,  respectively (Kennecke 2010).   However, 
patients with ER+ breast cancer brain metastases ar e more prevalent than patients with TNBC or 
HER2+ brain metastases because the majority of meta static disease is ER+ HER2-negative 
(Sperduto 2012)  
The American Society of Therapeutic Radiation Oncol ogy (ASTRO)’s guidelines regarding 
radiation therapy for breast cancer brain metastase s have changed, in recent years now de-
emphasizing the role of whole brain radiation (WBRT ) and expanding the role of stereotactic 
radiosurgery (SRS) (Tsao M, et al.,2012)    
In this new guideline, any number of brain metastas es are appropriate for SRS provided they are 
not over 3cm in size and provided they can be treat ed in one radiation therapy session.   WBRT 
is administered only for the development of new met astases following SRS, and only if there are 
more than 3 new metastases.  If 1-3 new metastases following previous SRS, repeated SRS is 
preferred and WBRT is reserved for patients with mo re than 3 new metastases following WBRT.   
ASTRO has emphasized SRS over WBRT because of the c onsiderable toxicity of WBRT and the 
lack of improved survival or other clinical outcome s with WBRT compared with SRS.  
Most systemic therapies are ineffective due to the impenetrability of the blood/brain barrier, the 
intrinsic resistance of CNS metastases, and express ion of the P-glycoprotein efflux pump. In the 
published natural history studies, the median OS ti me for patients with triple negative (TN) brain 
metastases is approximately 4 months (Lin 2008; And ers 2007; Adamo 2007, Nam 2008; Eichler 
2008). Another retrospective study of outcomes in p atients with breast cancer-associated CNS 
metastases by subtype reported mean OS times of 61. 2 and 39.0 months for luminal A and 
luminal B estrogen receptor-positive cancers, respe ctively, and a mean OS of 20.3 months for 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
11 
 HER2+ cancers (Wiens 2014).   The Sperduto Graded P rognostic Assessment Tool further 
refines OS estimates based on age and performance s tatus.  ER+ brain metastases in woman with 
symptoms and/or over age 60 is associated with OS r ates less than 2 years (Sperduto 2008 and 
Appendix 1). 
The Graded Prognostic Assessment (GPA) is a recentl y developed, validated prognostic score 
for patients with brain metastases (Sperduto 2008).  The GPA has been further refined and 
updated to create diagnosis-specific indices, inclu ding a breast cancer-specific GPA (Sperduto 
2012a; Sperduto 2012b; Barnholtz-Sloan 2012). GPA s cores range from 4.0 (best prognosis) to 
0.0 (worst prognosis), based on weighted significan t prognostic factors, and can be used to 
estimate survival for individual patients. The comp onents for the breast cancer GPA are tumor 
subtype, Karnofsky performance score, and age.  A r ecent study that utilized the GPA showed 
that patients with TNBC and brain metastases had a median survival time of 6.4 months 
(Sperduto 2012b).  
Brain metastases in patients with TNBC are life-lim iting metastases. Therapies which change the 
natural history of this condition are urgently need ed. 
1.2  PI3K Pathway and Mechanism of Action 
The phosphatidylinositol-3-kinase (PI3K) signaling regulates diverse cellular functions, 
including cell proliferation, survival, translation al regulation of protein synthesis, glucose 
metabolism, cell migration, and angiogenesis (Katso , et al 2001). PI3K signaling also serves a 
central role in the pathogenesis of numerous forms of neoplasia. At the structural level, the 
enzyme PI3K is composed of a 110-kDa catalytic subu nit and an 85-kDa adaptor subunit. The 
PI3K signaling is modulated by multiple regulators,  including growth factors (such as EGF, IGF-
1, and FGF), hormones (such as estrogen and thyroid  hormone), integrins, intracellular calcium 
levels, and RAS signaling. PI3K signaling is negati vely regulated at the level of PIP3 clearance 
by phospholipid phosphatases, such as the phosphata se and tensin homologue (PTEN) protein 
and the inositol 5-phosphatase-2 (SHIP2) protein.   
Constitutive activation of PI3K signaling is known to be a critical step in mediating the 
transforming potential of oncogenes and tumor suppr essors and in many tumor types (Liu 2009). 
Resistance to a variety of therapeutic intervention s, including chemotherapy, hormonal therapy 
and anti-HER2 therapies, can also be linked to cons titutive activation of the PI3K pathway 
(McCubrey 2006). Moreover, preliminary data suggest  that activation of the PI3K pathway may 
be a predictor of poor prognostic outcome in many c ancers.  
Molecular changes leading to constitutive activatio n of the PI3K pathway are diverse and 
include, but are not limited to: 
a. Gain-of-function mutations of PI3K subunits ( P I K 3 C A  encoding the PI3K catalytic 
subunit p110 α; genes encoding the p85 regulatory subunit) or onc ogenes encoding 
positive regulators of PI3K (e.g., HER2, EGFR, RAS,  Src-family proteins) or  
b. Loss-of-function mutations or epigenetic alteration s affecting negative regulators of PI3K 
signaling (e.g., loss of PTEN expression or functio n) (Chow 2006, Cully 2006).  
Together, these observations suggest that PI3K path way could be a critical therapeutic target for 
the treatment of patients with advanced solid malig nancies who often have limited therapeutic 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
12 
 options beyond institutional standard of care. Henc e, treatment with the pan-PI3K inhibitor  
buparlisib (BKM120) potentially addresses an unmet medical need in such patients.  
A schematic representation of these PI3K components  is shown in Figure 1-1. 
Figure 1-1 Schematic representation of the PI3K pat hway 
 
 
1.2.1  PI3K pathway activation in MBC 
The PI3K pathway can be alternatively activated thr ough various receptor classes or cross-talk 
with other pathways. In TNBC, the PI3K pathway appe ars to be modulated by the EGFR. 
Preclinical models have demonstrated that EGFR sign aling through the PI3K pathway leads to a 
higher level of Akt phosphorylation in TNBC cell li nes (Umemura 2007; Marty 2008; reviewed 
by Moulder 2010). Interestingly, TNBC cell lines ha ve also been associated with lower 
expression of PTEN, which correlates with increased  activation of Akt and portends a favorable 
response to PI3K inhibition. Indeed, cell lines whi ch are wild type for PIK3CA, but have lost 
PTEN expression can be sensitive to a PI3K inhibito r (O’Brien 2010). These agents, therefore, 
present an intriguing class of targeted anti-cancer  therapy for patients with TNBC. The 
epidemiology data reported so far present significa nt variation (Stemke-Hale 2008; Humphrey 

Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
13 
 Gardner unpublished; Lopez-Knowles 2010; Hernandez- Aya and Gonzalez-Angulo 2011) (Table 
1.1), however, based on these numbers, approximatel y 48% of triple negative breast cancers 
should be PI3K pathway activated (either P I K 3 C A  mutated or PTEN loss).   
Up to 40% of HR+/HER2- cancers also exhibit activat ion of PI3K pathway, via PIK3CA 
mutation or PTEN loss (Stemke-Hale 2008; Humphrey G ardner unpublished; Lopez-Knowles 
2010; Hernandez-Aya and Gonzalez-Angulo 2011). Bidi rectional crosstalk between the ER/PR 
and PI3K pathways has been shown to influence ER/PR  levels and activity, including 
phosphorylation and genomic activation of the ER, w hile membrane ER signaling can activate 
PI3K/Akt (Hernandez-Aya and Gonzalez-Angulo 2011). Experimentally, PI3K pathway 
activation has been associated with de novo and acq uired resistance to endocrine therapy 
(Campbell 2001) including AI resistance ( Shoman 2005 ; Crowder, 2009 ; Miller, 2011 ). 
A substantial fraction of HER2-amplified breast can cers also demonstrate activation of the PI3K 
pathway, primarily through loss of PTEN (Table 1-1) . Activation of this pathway, either by 
PIK3CA mutation or PTEN loss, has been associated w ith resistance to trastuzumab, and cell 
line research suggests that inhibition of the PI3K pathway is an important mechanism of action 
for trastuzumab (Hernandez-Aya and Gonzalez-Angulo 2011). Further, synergistic activity has 
been observed with combinations of trastuzumab and PI3K inhibitors in breast cancer cell line 
studies (Hernandez-Aya and Gonzalez-Angulo 2011). 
Genomic and phosphoproteomic analysis of human prim ary breast cancers in the TCGA showed 
strong activation of PI3K pathway signaling in the majority of basal breast cancers, as well as 
PIK3CA mutations in 45% of Luminal A cancers, 29% o f luminal B cancers, and 39% of HER2-
enriched cancers (Cancer Genome Atlas Network 2012) . 
Table 1-1 PI3K signaling pathway mutations and alte rations in breast cancer [1; 2; 3; 4]  
 Mutation Alteration 
P I K 3 C A  P T E N  Mutation 
[1] PTEN loss of 
expression 
All Breast 
Tumors 10-40% ~2% 29-50% 
HR(+) HER2(-) 7-40% 2-4% 19-29% 
Triple Negative 6-9% 0% 15-66% 
HER2-amplified 20-25% - 30-40% 
([1] Stemke-Hale 2008, [2] Humphrey Gardner, Oncolo gy Translational Laboratories, Novartis, unpublishe d [3] 
Lopez-Knowles 2010 [4] Hernandez-Aya and Gonzalez-A ngulo, 2011. Ranges represent the minimum and 
maximum incidence reported in these trials. Trial i ncidence calculations were made using the midpoint of the range. 
 
 
A study of the PI3K pathway specifically in breast cancer brain metastases found activation of 
this pathway in the majority of cases, regardless o f breast cancer subtype, although PTEN loss 
was most common in the TNBC subtype (37%, vs 17% in  HR_/HER2- and 25% in HER2+) 
(Adamo 2011).  
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
14 
 In addition to mutation of P I K 3 C A , and loss or mutation of P T E N , loss of the tumor suppressor 
I N P P 4 B  (inositol polyphosphate 4-phosphatase-II) is emerg ing as an important activator of PI3K 
signaling in triple-negative or basal-like breast c ancers. Preclinical studies in breast cancer cell 
lines showed that inactivation of INPP4B leads to A kt activation, cell proliferation, and growth 
of tumor xenografts (Fedele 2010). Investigation of  INPP4B protein expression in primary breast 
cancers found loss of expression most frequently in  basal-like primary breast cancers (84%); 
INPP4B loss was also associated with high clinical grade and tumor size (Fedele 2010). The 
Cancer Genome Atlas study, which used a variety of genomic and proteomic methods of 
analysis, found that P I K 3 C A  mutations occurred in 7% of basal-like breast canc er, P T E N  
mutation or loss occurred in 35%, and loss of I N P P 4 B  occurred in 30% (Cancer Genome Atlas 
Network). In another study, DNA copy number aberrat ion analysis combined with breast cancer 
intrinsic subtyping found loss of I N P P 4 B  in 40% - 47.5% of basal-like breast cancers, and l oss of 
P T E N  in 22.5% - 34%, using two different datasets conta ining 40 and 61 patient samples, 
respectively (Weigman 2012). Finally, a recent stud y that used whole genome and transcriptome 
sequencing to analyze 14 metastatic TNBCs revealed that the PI3K/Akt/mTOR pathway was 
activated due to genomic changes in 5 cases, most f requently through loss of P T E N  or I N P P 4 B , 
as well as at the transcription level with decrease d INPP4B or PTEN mRNA levels in nearly all 
patients (Craig 2013).  
Another pathway that has been associated with metas tatic colonization of the central nervous 
system (CNS) in breast cancer is the HER3/neureguli n 1 axis which strongly activates the PI3K 
pathway. Neuregulin 1 (heregulin), a ligand for HER 3, is abundant in brain tissue, and one study 
reported overexpression and activation of HER3 in b rain metastases compared with matched 
primary breast cancer samples (Da Silva 2010). With in the HER family of receptors, activation 
of PI3K signaling is driven primarily through trans phosphorylation of the kinase-inactive HER3 
receptor, which has also been implicated in resista nce to HER2-targeted therapies in HER2+ 
breast cancers (Hsieh 2007). HER3 expression has al so been associated with a poorer prognosis 
in both TNBC and HER2+ breast cancers (Bae 2013). I n addition, signaling through HER3 has 
been implicated in resistance to the estrogen recep tor downregulator fulvestrant in an ER+ breast 
cancer xenograft model system (Osipo 2007). 
These studies suggest that through a variety of mec hanisms, activation of the PI3K signaling 
pathway is likely to occur in the vast majority of metastatic breast cancers, and thus rendering 
PI3K a promising therapeutic target. 
 
 
 
 
 
 
Delta Clinical Research, LLC  
BKM120 for MBC with Brain Metastases 
 
 1.3  Study Treatments 
1.3.1  Buparlisib 
NVP-BKM120 (BKM120 ; buparlisib 
inhibitor that is a 2,6-dim orpholino pyrimidine derivative 
extensively in non- clinical models and is currently being evaluated in  clinical trials.
1.3.1.1  Preclinical studies 
Buparlisib activity against class I PI3K (p110 
mTOR related PI3K or PI4K β, was assessed using either a luciferase luminescen ce (class I or III 
PI3Ks and PI4K β) or a TR-FRET assay (Class IV 
below in Table 1.2. 
Table 1.2 Inhibitory activities (IC50) of buparlisi b a 
kinases 
Buparlisib significantly inhibits p110 
E454K, E542K), p110 β, p110 δ and p110 
inhibitor. Enzymatic characterization of 
buparlisib is a mixed inhibitor of PI3K 
Vmax). The cocrystal X- ray structure of 
interacts with PI3K into the ATP catalytic cleft.
selective (50- fold difference) toward p110 
 
 
 
 
 
  Study No. 11- 025/CBKM120ZUS39T 
BKM120 for MBC with Brain Metastases   
15 ; buparlisib ) is a potent and highly specific oral pan 
orpholino pyrimidine derivative . This compound has 
clinical models and is currently being evaluated in  clinical trials.
activity against class I PI3K (p110 α, - β, - δ and - γ), Class III (Vps34), the class IV 
β, was assessed using either a luciferase luminescen ce (class I or III 
FRET assay (Class IV mTOR ). The IC50 in these assays 
Table 1.2 Inhibitory activities (IC50) of buparlisi b a gainst other PI3K or related 
significantly inhibits p110 α and the most common p110 α mutations (H1047R, 
β δ and p110 γ. Buparlisib is classified as a pure pan 
inhibitor. Enzymatic characterization of the inhibitory properties of the compound revealed that 
is a mixed inhibitor of PI3K α with a strong competitive component (largest 
ray structure of buparlisib with PI3K γ confirmed that 
interacts with PI3K into the ATP catalytic cleft.   As shown in Table 1.3 , buparlisib 
fold difference) toward p110 α compared to other protein kinases.  
025/CBKM120ZUS39T   
[24JUN2016] 
) is a potent and highly specific oral pan -class I PI3K 
. This compound has been studied 
clinical models and is currently being evaluated in  clinical trials.  
), Class III (Vps34), the class IV 
, was assessed using either a luciferase luminescen ce (class I or III 
). The IC50 in these assays is outlined 
gainst other PI3K or related 
 
α mutations (H1047R, 
is classified as a pure pan -class I PI3K 
the inhibitory properties of the compound revealed that 
 with a strong competitive component (largest for 
 confirmed that buparlisib 
, buparlisib  is also 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
16 
  
Table 1.3 Activity of buparlisib in the Novartis ki nase panel 
 
Activity in mechanistically driven cell-based model s 
The PI3K pathway regulates the activity of the mTOR C1 complex, when cells are challenged 
through mitogenic stimuli. In order to assess in ce lls the potential impact of the buparlisib on the 
mTORC1 complex, the compound was tested in TSC1 nul l cells. These cells express a 
constitutively activated mTORC1 complex that uncoup les the mTOR pathway from the PI3K 
upstream input (Kwiatkowski 2003). When exposed to TSC1 null MEFS, buparlisib reduced the 
S235/236P-RPS6 levels with an IC50 of 1785 nM, in a greement with the data obtained in the 
mTOR biochemical assay. In contrast, and as expecte d the allosteric mTORC1 inhibitor 
RAD001 displayed sub-nanomolar inhibitory activity in this assay. 
PI3K pathway inhibition potency and specificity in relevant cell-based disease models 
In contrast to molecules with a distinct mechanism of action (e.g., the BCR-Abl inhibitor 
STI571, mTORC1 allosteric inhibitor RAD001), buparl isib is able to decrease the 
phosphorylation status of various either direct (GS K3 β, FKHRL1/FOXO3a) or indirect 
downstream Akt effectors (p70S6K, through mTOR) in the PTEN null U87MG cell line, as 
efficiently as prototypical PI3K inhibitors such as  LY294002 and Wortmannin. 
In all cases, buparlisib showed specific PI3K pathw ay attenuation as demonstrated by specific 
attenuation of S473P-Akt levels without affecting t he non-PI3K-driven read–outs such as 
activated receptors (EGFR, PDGFR), MAP kinases (ERK , JNK and p38) or Jak cytosolic 
tyrosine kinases responsible for Stat transcription  factor phosphorylation. 

Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
17 
 1.3.1.2  Preclinical Safety 
Please refer to the Investigator’s Brochure for add itional information on the preclinical testing of 
buparlisib. 
1.3.1.2.1  Pharmacodynamics 
Buparlisib inhibits wild-type PI3K a (IC 50 : 35 nM), with at least 50-fold selectivity towards  this 
compared to activity against other protein kinases outside the PI3K family.  The compound is 
equipotent against somatic PI3K a mutants (H1047R-, E542K-, and E545K-p110 a), and is active 
against the other three PI3K paralogs (PI3K β, - γ, - δ; IC50 108 to 348 nM range). Buparlisib does 
not significantly inhibit the related kinases mTOR or Vps34, nor does it inhibit (IC 50  >10 µM) 
other receptors and ion channels profiled. 
Buparlisib reduces the phosphorylation of the direc t downstream effector Akt in relevant tumor 
cell lines (e.g., IC 50  93 nM for S473P-Akt in Rat1-p110 a cells). This biological activity 
correlates with inhibition of various other downstr eam signaling components and with 
antiproliferative activity in a variety of tumor ce ll lines. 
Buparlisib demonstrates significant tumor growth in hibition in relevant tumor xenografts in mice 
and rats when administered orally, including models  of breast cancer, lung cancer (A549, NCI-
H1975), colorectal cancer (HCT116, HCT-15), gliobla stoma multiforme (U87MG), melanoma 
(A2058, A375), ovarian cancer (A2780), pancreatic c ancer, prostate cancer (PC3M),  and renal 
cell cancer (RENCA, 786-0, Caki-1). I n  v i v o  PK/PD analyses of tumor tissues shows a good 
correlation between exposure, PI3K pathway blockade  (S473P-Akt levels), and anti-tumor 
activity. 
Antitumor activity of buparlisib in breast cancer 
Preclinical data in models of breast cancer are eme rging that support buparlisib evaluation in 
clinical studies. In a series of 20 basal breast ca ncer cell lines, 4 lines carrying a loss of a 
phosphatase related to PTEN, INPP4B, displayed sens itivity to buparlisib (between 17 and 30% 
cell death) (Gerwinner 2009). The sensitivity to bu parlisib has been confirmed in xenograft 
models where stasis and regressions have been obser ved in models mostly driven by loss of 
PTEN.  Treatment of TNBC cell lines and patient-der ived TNBC xenografts with buparlisib has 
also been shown to increase DNA damage, downregulat e BRCA1/2, and increase poly-ADP-
ribosylation (Ibrahim 2012). Likewise, in a BRCA1-r elated breast cancer mouse model, 
buparlisib delayed tumor doubling time, and reduced  AKT phosphorylation, tumor proliferation, 
and angiogenesis (Juvekar 2012). 
Preclinical in vitro and in vivo models suggest tha t buparlisib has an inhibitory effect in breast 
cancer models (Maira et al 2012).. In a panel of 44  cell lines, buparlisib induced cell death in the 
majority of luminal breast cancer lines (12/18) as well as 4/20 basal-type cell lines. This was 
confirmed in xenograft models, where HER2+ and ER+ models displayed tumor control for up 
to 120 days (O’Brien et al 2011), and triple-negati ve primary tumor models displayed stasis or 
occasional regression. 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
18 
 Furthermore, AI resistance has been associated with  activation of PI3K pathway (Crowder 2009, 
Miller 2011) and i n  v i t r o  response to buparlisib was also observed in ER-pos itives cell lines 
before and after long-term estrogen deprivation (Sa nchez 2011). These cell lines included 
various mechanisms of PI3K pathway activation (i.e. , PIK3CA mutation, HER2 amplification, or 
PTEN mutation. 
Finally, buparlisib was also shown to be efficaciou s in controlling brain metastasis in a 
preclinical model of human HER2 ⁺ breast cancer in Rag2 ⁻/ ⁻;Il2rg ⁻/ ⁻ mice (Nanni 2012). 
This activity of buparlisib observed in pre-clinica l models provides strong molecular evidence 
for the role of PI3K signaling in MBC and supports the exploration of buparlisib in this disease 
setting. 
1.3.1.2.2  Nonclinical pharmacokinetics and metabolism 
Buparlisib showed favorable pharmacokinetic propert ies in all animal species tested. The 
absorption of [14 C]-buparlisib -related radioactivity was >84% in th e rat. Oral bioavailability was 
moderate to high in rats, dogs, monkeys (42-100%). The estimated steady state plasma volume 
of distribution (Vss) was moderate in all species ( 3.0-3.5 L/kg). Buparlisib penetrates the blood 
brain barrier in rats with a tissue-to-plasma ratio  about 2. Buparlisib is moderately bound to 
plasma protein across all species examined (free fr action ~15% and independent of concentration 
in humans). 
Oxidative metabolism of buparlisib is predominantly  mediated by CYP3A4 (estimated fraction 
metabolized >0.9). Direct phase II metabolism (gluc uronidation) via UGT1A4 is also observed 
in human liver microsomes supplemented with UDPGA. All phase I metabolites identified in 
human hepatocytes and microsomes were also detected  in animals. Buparlisib and identified 
metabolites have a low potential for covalent bindi ng to protein.  
Buparlisib is weak reversible inhibitor of CYP3A4 ( Ki = 13.6 µM) and it also weakly inhibits the 
CYP2C family (2C8, 2C9 and 2C19) with IC50 values r anging from 35 –65 µM.  Buparlisib 
does not show time-dependent inhibition of CYP450 e nzymes. With respect to transporter-based 
drug-drug interactions, buparlisib is neither a sub strate for MRP-2, OATP1A2, OATP1B1, 
OATP1B3, OATP2B1, P-gp nor an inhibitor for BCRP, M ATE1, MATE2K, MRP2, OAT1, 
OAT3, OCT2, P-gp in the observed range of clinicall y relevant concentrations. It is possible that 
buparlisib activates the pregnane X receptor (PXR) in vivo and induces CYP3A4 at 
concentrations ≥50 µM, however, the absence of any time dependent chang es in the 
pharmacokinetics of buparlisib in the relevant ther apeutic dose range in humans, suggests that 
this may not be relevant in vivo. Finally, experime nts showed a potential for buparlisib to induce 
UGT1A1 at concentrations between 0.5 and 100 µM. The mean maximum free concentration 
calculated at steady state for the 100 mg qd dose i n the study [CBKM120X2101] was 0.671 µM 
(Cmax,tot=4.20 µM). Therefore a potential induction of UGT1A1 canno t be formally excluded 
however the clinical relevance of observed activati on of UGT1A1 activity is unclear. 
In GLP toxicology studies, buparlisib exposure in t erms of AUC0-24h and Cmax increased in a 
dose proportional manner in rat and dog. There was no noticeable drug accumulation in dog or 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
19 
 male rats after 13 weeks of daily dosing. There was  a slight accumulation in female rats (<2 
fold). 
1.3.1.2.3  Safety pharmacology and toxicology 
Safety pharmacology studies in rats revealed no eff ects on neuronal (behavior) or respiratory 
functions. When using a microdialysis technique to investigate the effect of a single or 2-week 
repeated dosing of buparlisib in various brain regi ons of rats, a marked increase in extracellular 
levels of gamma-aminobutyric acid (GABA) were obser ved in the ventral hippocampus (vHPC) 
and median prefrontal cortex (mPFC), both under acu te as well as repeated dosing conditions. In 
the same brain regions, smaller increases in levels  of dopamine, serotonine and noradrenaline 
were observed in the vHPC, with a trend to decrease d corticosterone. Cardiac safety studies, 
conducted i n  v i t r o  and i n  v i v o  did not indicate a prominent electrophysiological risk. The only 
effect considered relevant was a trend towards an i ncrease in systolic and diastolic blood 
pressure, which was observed in two dog telemetry s tudies, in the absence of an 
electrophysiological effect.  
Repeated-dose studies (up to 13 weeks of duration) were performed in rats and dogs. In rats, 
clinical pathology and histopathology findings show ed a decrease in lymphocyte counts in the 
peripheral blood, decreases in germinal center deve lopment in different lymph nodes, and 
lymphocytolysis in the thymus. In dogs, similar fin dings were made. In both species, 
erythropoiesis was affected, as evidenced by reduce d erythrocyte counts accompanied by bone 
marrow suppression observed in rats. 
The pancreas was affected by treatment with buparli sib, particularly in dogs, where acinar cell 
toxicity was seen in the exocrine part of this orga n. At higher doses in the 2-week dose-range-
finding study in rats, there were histopathological  findings in both the endocrine and in the 
exocrine pancreas. 
Male reproductive organs and associated tissues wer e found to be targets of toxicity in both rats 
and dogs. Changes included minimal to slight germ c ell depletion, formation of spermatic giant 
cells and abnormal spermatids, plus cellular debris  in epididymal tubules. Testicular toxicity did 
not fully reverse after the 4-week treatment-free p eriod in rats, although a clear trend towards 
recovery was seen. In individual female rats, minim al to slight cyst formation occurred in the 
Graafian follicles. In dogs, there was no effect on  female reproductive organs.  
Glucose homeostasis was affected in various species  (mice, rats, dogs), as expected from the 
mode of action of buparlisib. However, these effect s were minimal in both rats and dogs at the 
doses used in the 4-week studies. 
Buparlisib does not have sensitizing or irritative potential in the skin. 
No evidence for a direct DNA interaction was found in an Ames test and two chromosome 
aberration tests in vitro with buparlisib. However,  a potential for genotoxicity was identified 
based on the observation of an aneugenic potential and was confirmed by fluo rescence in situ 
hybridization of centromeric sequences within micro nuclei induced in human peripheral 
lymphocytes in vitro. In line with this result, bup arlisib treatment resulted in an elevated 
frequency of micronucleated polychromatic erythrocy tes in the bone marrow of rats. In 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
20 
 summary, evidence of a genotoxic potential with bup arlisib has been seen in vitro and in vivo 
and is likely due to an aneugenic effect. 
In a rat embryofetal dose-range finding study, bupa rlisib treatment induced embryolethality and 
implantation loss, together with foetal pathology c hanges at doses that were only minimally 
maternally toxic. No phototoxic potential or any ef fect on wound healing has been identified 
with buparlisib in pre-clinical studies. 
In summary, the toxicity and safety pharmacology pr ofile of buparlisib can be associated 
primarily to the expected pharmacodynamics activity  of buparlisib. Main target organs for toxic 
effects were the hematopoietic and lymphopoietic sy stems and the reproductive tract.  Buparlisib 
is genotoxic via an aneugenic mechanism, and it int erferes with insulin signaling and the 
associated metabolic disturbances. The compound may  have an influence on central 
neurotransmitter levels, but this effect needs to b e further evaluated. Overall, these findings are 
compatible with the treatment of advanced cancer an d do not preclude the use in the foreseen 
indications. 
1.3.1.2.4  Pharmacodynamic biomarkers 
The preclinical i n  v i v o  studies with xenograft tumors in mice indicate tha t detectable inhibition 
of AKT phosphorylation, which is an accurate readou t of PI3K activity, and further suppression 
of downstream signaling (e.g., phosphorylation of S 6) was obtained soon after buparlisib 
administration. PI3K is known to serve a pivotal ro le in the regulation of glucose homeostasis, 
and preclinical studies in which oral glucose and i ntraperitoneal insulin tolerance tests were 
performed suggested post-treatment induction of ins ulin insensitivity/resistance. Therefore, 
throughout the trial the circulating levels of seve ral markers for glucose metabolism (e.g., 
glucose, insulin, C-peptide) will be assessed as an  additional measure of PI3K signaling 
modulation. 
1.3.1.3  Clinical experience 
1.3.1.3.1  Clinical experience with buparlisib 
As of 15 September 2013, approximately1469 patients  and healthy volunteers have been enrolled 
into twenty-two clinical studies with buparlisib (a s single agent or in combinations). The 
Novartis sponsored clinical studies were: 
• Phase I single agent studies [CBKM120X2101], [CBKM1 20X1101], and 
[CBKM120Z2102], [CBKM120C2110], [CBKM120C2104], [CB KM120C2106], 
[CBKM120C2111], and [CBKM120C2102]. 
• Phase II single agent studies [CBKM120C2201] and [C BKM120D2201] 
• Phase I combination studies [CBKM120B2101], [CBKM12 0X2107], [BKM120E2101], 
[CBEZ235A2118], [LDE225X2114], [CSTI571X2101], [CME K162X2101], 
[CMEK162X2101], [CINC424A2104], and [CBEZ235D2101. 
• Phase II combination study [CBKM120F2202] 
• Phase III combination studies [CBKM120F2302] and [C BKM120F2303]. 
With regard to the current protocol, results presen ted below will focus on phase I single agent 
studies ([CBKM120X2101], [CBKM120X1101]), and phase  I combinations in breast cancer 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
21 
 patients ([CBKM120X2107], [CBEZ235A2118]). Please r efer to the current version of the IB for 
more detailed information. 
1.3.1.3.1.1  Human safety and tolerability data  
Recruitment in study [CBKM120X2101] has been comple ted with forty (40) patients included in 
the dose escalation phase at 6 dose levels (all onc e daily) (12.5 mg (1 patient); 25 mg (2), 50 mg 
(5), 80 mg (11), 100 mg (17), 150 mg (4)). Dose lim iting toxicities were hyperglycemia, skin 
rash, epigastric pain, mood disorder and joint pain . The MTD for buparlisib given as single 
agent, once daily was established at 100 mg/day (Be ndell, 2012).  Forty-three additional patients 
were treated in the expansion cohort at 100 mg/day.  At the cut-off date of July 4th 2011 (Graña 
2011), patient characteristics for the 82 patients analyzed were as follows: median age 55 years 
(range 30–78); ECOG performance status 0/1/2 for 35 /46/1 patients, respectively. The safety 
experience for this single agent trial of buparlisi b is described in Table 1-3: 
Table 1-3  Most frequent AEs (>  15%) related to study drug study CBKM120X2101 
(n=81): 
Event All grades Grade 3/4 
Fatigue/asthenia  31(38.3%) 3 (3.7%) 
Decreased appetite  24 (29.6%) - 
Diarrhea  24 (29.6%) 3 (3.7%) 
Hyperglycemia  24 (29.6%) 4 (4.9%) 
Nausea  24 (29.6%) - 
Rash  22 (27.2%) 4 (4.9%) 
Mood altered/emotional 
disorder/affective disorder  17 (21.0%) 4 (4.9%) 
Transaminases increased  16 (19.8%) 9 (11.1%) 
Anxiety  14 (17.3%) 1 (1.2%) 
Depression 14 (17.3%) 1 (1.2%) 
A second single agent trial, [CBKM120X1101] was a p hase I dose escalation study in Japanese patients w ith 
advanced solid tumors who received dose levels rang ing from 25 to 100mg/day (Doi 2011). Enrollment of 15 
patients has been completed, including 9 patients a t 100 mg/day. One DLT (G4 hepatic function abnormal ) was 
observed in the 100 mg/day group. The most common G 3 or G4 adverse events occurring in at least 2 pati ents were 
hepatic function abnormalities in 6 patients includ ing transaminase increase in 2 patients, G3 anemia in 2 patients, 
and hypokalemia in 2 patients. The recommended phas e 2 dose (RP2D) for the Japanese study has been det ermined 
at 100 mg/day, as in the western population.  
 
The safety and efficacy of buparlisib combined with  trastuzumab in patients with relapsing 
HER2-overexpressing BC who have previously failed t rastuzumab are being explored in a phase 
Ib/II, multi-center study [CBKM120X2107]. The combi nation of buparlisib and trastuzumab was 
shown to be tolerable, and with one dose-limiting t oxicity (G3 asthenia) the MTD for buparlisib 
was declared at 100 mg/day (Saura 2011). Among the 18 patients evaluated in the PhIb part, the 
following G3/G4 AEs were observed: asthenia, ALT el evation, hyperglycemia, mood alteration, 
affective disorder, hypersensitivity, photosensitiv ity reaction, and rash. These AEs were all 
short-lived and reversible with either dose interru ption or modifications as needed. In the phase 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
22 
 II portion of the study, as of June 2012, 53 patien ts have been enrolled and received buparlisib at 
the recommended phase 2 dose (RP2D) of 100 mg/day i n combination with trastuzumab (Pistilli 
ESMO 2012). Overall the treatment was well tolerate d. Most common AEs (>15%) included 
gastro-intestinal toxicity (e.g. diarrhea, nausea, stomatitis), rash, fatigue, transaminase increase, 
hyperglycemia, depression and anorexia. No G4 AEs h ave been reported. Most common G3 
treatment related AEs included transaminase increas e (~10%), rash (9%) and fatigue (6%), and 
were consistent with phase Ib findings with as well  as single agent buparlisib. 
Details on liver toxicity, mood alterations, pneumo nitis, hyperglycemia, skin rash and 
hypersensitivity as side effects of buparlisib are presented below.  
Liver Toxicity 
Liver toxicity has been analyzed based on a search of multiple MedDRA event terms (SMQ 
pertinent to hepatobiliary toxicity), and is presen ted in Table 1.5 Liver function test (LFT) 
alterations observed during ongoing and completed s tudies have been mostly reversible 
transaminase increases (ALT and/or AST), and have b een rarely associated with signs or 
symptoms of impaired liver function. The increase i n AST/ALT values typically occurred within 
the first 6 to 8 weeks of study treatment. 
The highest rates of transaminase increase have bee n observed on the Phase I Japanese and 
Chinese studies [CBKM120X1101] and [CBKM120Z2102] a s well as in combination with 
fulvestrant in the randomized Phase 3 study [CBKM12 0F2302]. In contrast, the rate of 
transaminitis appeared to be lower in combination s tudies with taxanes (e.g. studies 
[CBKM120D2205], [CBKM120F2202] and [CBKM120H2201]) in which also steroids have 
been administered regularly as part of the standard  premedication. In addition, transaminitis was 
infrequent in the lymphoma study [CBKM120Z2402]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
23 
 Table 1.5 Number (%) of patients with liver toxicit y regardless of study treatment 
relationship, occurred at 100 mg / day in BKM120 st udies - Safety Set 
 
 
Although transaminase increases are relatively comm on, only a few of the patients with LFT 
alterations had simultaneous observations indicativ e of impaired liver function (e.g. bilirubin 
increase or clinical symptoms). 
A search and review of potential drug-induced liver  injury (DILI) cases in Novartis-sponsored 
trials with buparlisib using conservative biochemic al criteria (e.g. AST/ALT >3.0x ULN and 
TBL>2.0xULN) has shown that most of these cases occ urred in the context of disease 
progression in advanced cancer patients and/or were  confounded by other causes. However, for 
some of the DILI candidates causal relationship wit h study treatment cannot be ruled out.  An 
aggregated safety findings report (ASFR) has been s ent to all investigators/health authorities 
participating in buparlisib trials in May 2015 info rming them about the liver toxicity findings. 

Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
24 
 As of 08-Sep 2015, in total 8 DILI cases consistent  with Hy’s Law have been identified upon 
medical review across the buparlisib program. Six o ut of these cases occurred in combination 
with fulvestrant, one in combination with letrozole  and one in combination with LDE225. All 
patients have recovered upon treatment discontinuat ion except one patient for whom the outcome 
is not available because the patient refused to ret urn for safety follow-up. A summary of the 8 
cases is provided in below Table 1.6 Thus far, no f atal cases have been reported in the context of 
DILI.  
  
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
25 
 Table 1.6 DILI cases consistent with Hy’s Law, as o f 08-Sep-2015 
Study/ 
Subject number  Summary  
CBKM120F2302 
- 
patient 5018001 
(fulvestrant + 
100 mg/d 
buparlisib) 59 year-old female patient with breast cancer and n o pre-study history of hepato-biliary 
conditions disorders. At study baseline, the patien t had no known metastases in the liver. 
Under study medication the patient developed 34 fol d increase of ALT and AST, 16 fold 
increase in total bilirubin and 2 fold increase in ALP. The patient was asymptomatic. Study 
treatment with BKM120 was permanently discontinued due to elevated liver function tests. 
The patient fully recovered. The investigator repor ted that the event was suspected to 
treatment with BKM120 and not suspected to fulvestr ant 
CBKM120F2302 
– 
patient 2302002 
(fulvestrant + 
100 mg/d 
buparlisib) 60 year-old female patient with metastatic breast c ancer (bone metastasis), history of 
depression, osteoporosis, headaches, dyspnea, back- pain and elevated AST/ALP (Grade 1) 
and GGT (Grade 2) at baseline. On Day 43, the patie nt developed Grade 3 transaminitis 
which worsened to Grade 4 on Day 48; treatment with  buparlisib/placebo was permanently 
discontinued due to this event. Bilirubin was incre ased to Grade 2 from Day 48 to 50. The 
patient received ciprofloxacin for infection (from Day 48 to 52), dexamethasone for 
transaminitis (from Day 50 to 63) and spironolacton e for abdominal distention/ ascites (from 
Day 48 to 53). She further took 3 herbal preparatio ns during 1 week prior to the event, and 
received zoledronic acid medication for bone metast asis. The patient recovered from the 
event. 
CBKM120F2302 
– 
patient 2700014 
(fulvestrant +100 
mg/d buparlisib) 65 year-old-female patient with metastatic breast c ancer (liver and bone metastasis), history 
of rheumatoid arthritis and elevated AST (Grade 1) at baseline. On Day 42 she developed 
Grade 1 transaminitis which worsened to Grade 4 on Day 64; study treatment was 
permanently discontinued due to this event. Bilirub in was increased to Grade 2 on Day 64. 
Patient decided to withdraw from the study and did not return for post treatment safety 
follow-up; consequently, outcome of the liver event  remains unknown. She died 3 months 
after the end of treatment due to disease progressi on. 
CBKM120F2302 
– 
patient 3080012 
(fulvestrant + 
100 mg/d 
buparlisib) 53 year-old female patient with metastatic breast ( liver, lung, bone and lymph-node 
metastasis), history of hypothyroidism, migraine, n ausea, mood alteration, hot flashes, 
weakness, constipation and fibromyalgia; normal bas eline liver chemistries. On Day 15, she 
developed Grade 1 ALT increase that worsened to Gra de 2 on Day 39 (buparlisib/placebo 
dose reduced to 80 mg/d), and to Grade 4 on Day 46 upon which study treatment was 
permanently discontinued. Bilirubin was increased t o Grade 2 on Days 53 and 55. The patient 
was taking levothyroxine for hypothyroidism, metami zole and ibuprofen for pain and 
clodronate for bone metastasis (before and during t he study). The patient further had 
concurrent disease progression by RECIST on Day 50 (new liver lesions). The patient 
recovered from the event. 
CBKM120F2302 
– 
patient 5037006 
(fulvestrant + 
100 mg/d 
buparlisib) 54 year-old female patient with metastatic breast c ancer (bone metastasis), history of 
vomiting/nausea, anemia, GERD, and elevated GGT (Gr ade 1) at baseline. On Day 43 she 
developed Grade 2 AST and Grade 1 ALT increase (tre atment with buparlisib/placebo 
interrupted). Transaminitis worsened to Grade 4 on Day 50 upon which study treatment was 
permanently discontinued. Bilirubin was increased t o Grade 2 from Day 50 to 56. The patient 
received ibuprofen for headache and fever (from Day  49), prophylactic 
piperacillin/tacobactam/vancomycin (from Day 50 to 53) and zoledronic acid for bone 
metastasis. The patient recovered from the event. 
CLDE225X2114 
– 
patient 1514005 
(80 mg/d 
buparlisib + 400 
mg/d LDE225) 71 year-old male patient with stage IV glioblastoma  multiforme and no relevant medical 
history; normal baseline liver chemistries. On Day 44, he developed Grade 4 transaminitis 
and Grade 1 bilirubin increase upon which study tre atment was permanently discontinued. 
Bilirubin briefly increased to Grade 2 on Day 57 ba sed on local labs. Patient received 
paracetamol for pain, metoclopramide and ondansetro n for nausea from Day 58 to 60; he was 
further on dexamethasone for seizure prophylaxis du ring the study. The patient recovered 
from the event. 
 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
26 
 In the randomized Phase 3 study [CBKM120F2302] in c ombination with fulvestrant, 13 vs 4 
patients in the buparlisib vs placebo arm reported AST/ALT >3x ULN and total bilirubin >2x 
ULN regardless of causality and temporal relationsh ip. Based on medical review, 5 out of these 
cases were consistent with Hy’s law criteria, all o f which were in the buparlisib arm.  These 5 
cases are part of the 8 total cases described above . 
 
 
 
 
Management of hepatotoxicity (ALT and/or AST >3.0x ULN and total bilirubin >2.0x 
ULN) in patients receiving BKM120/placebo  
 
Criteria for interruption and re-initiation of BKM1 20/placebo treatment in case of the occurrence 
of AST, ALT or bilirubin increase are detailed in S ection 6.2, Dose Modification (Table 6-X).  
 

Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
27 
 Patients with clinically significant liver test abn ormalities should perform liver-directed medical 
history, physical examination and other tests as me dically indicated to assess potential 
relationship with study treatment and rule out othe r underlying causes (e.g. disease 
progression/obstruction, infection/hepatitis or oth er liver diseases, sepsis, metabolic diseases 
including diabetes, concomitant medications includi ng herbals, alcohol, drug-drug interaction, 
cardiovascular disease/ischemia, other organ injuri es, etc.). Any pre-existing liver conditions or 
risk factors should be reported in the respective m edical history and concomitant medication 
CRF pages (if not done already).  
All patients with ALT or AST >3.0 x ULN and total b ilirubin > 2.0 x ULN in the absence of 
cholestasis (elevation of ALP in patients without b one metastasis or if bone metastasis are 
present elevation of 5’-nucleotidase and ALP liver fraction) must be immediately withdrawn 
from BKM120/placebo, and every attempt should be ma de to carry out locally the liver event 
follow-up assessments as described below:  
 
• Inform the sponsor about the event immediately afte r its occurrence by reporting the 
event immediately in the clinical database if it me ets the criteria for an AE or SAE.  
• Evaluate if associated with the appearance or worse ning of clinical symptoms of hepatitis 
or hypersensitivity such as fatigue, nausea, vomiti ng, right upper quadrant pain or 
tenderness, fever, rash or eosinophilia, or other o rgan involvement.  
• Obtain fractionated bilirubin, serum Alkaline Phosp hatase (ALP), creatine phosphokinase 
(CPK), lactate dehydrogenase (LDH), and blood count  with differential to assess 
eosinophilia.  
• Perform liver imaging (ultrasound, magnetic resonan ce, or computerized tomography) to 
evaluate liver disease including metastasis or new lesions, obstruction/compression, etc.  
• Perform viral hepatitis and other serology tests:  
• Hepatitis C (HCV) serology and viral RNA, Hepatitis  B (HBV) serology and viral DNA, 
Hepatitis A (HAV) Immunoglobulin M (IgM) and HAV to tal  
• Hepatitis E (HEV) serology: IgM and IgG, viral RNA  
• Herpes Simplex Virus (HSV), Cytomegalovirus (CMV), Epstein-Barr viral (EBV) 
serology  
• Obtain PK sample, as close as possible to last dose  of study drug if PK analysis is 
performed in the study. Record the date/time of the  PK blood sample draw and the 
date/time of the last dose of BKM120/placebo prior to blood sample draw on the eCRF  
• Verify and record the use of concomitant medication s, acetaminophen, herbal remedies, 
and other over the counter medications, or putative  hepatotoxins, on the concomitant 
medications report form.  
• Consultation with a specialist(s) or a hepatologist (s) is recommended.  
• Liver biopsy as clinically indicated to assess path ological change and degree of potential 
liver injury  
• LFTs should be followed-up weekly until resolve to ≤ grade 1, baseline or stabilization 
(no CTCAE grade change over 4 weeks) and outcome do cumented on the respective AE 
and lab chemistry pages.  
 
Patient demographics and other baseline characteris tics  
Furthermore the following assessments will be perfo rmed to assess the eligibility of the patient:  
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
28 
 • Viral hepatitis serology [e.g. HAAb, HBsAg, HBsAb H BcAb, HCV RNA or HDV RNA 
(where needed), HEAb, CMVAb, EBcAb] and other tests  (see Section 6.2.4.X 
Management of hepatotoxicity (ALT and/or AST >3.0x ULN and total bilirubin >2.0x 
ULN) in patients receiving BKM120/placebo and Secti on 7.2.X.X.X Viral hepatitis 
serology and other tests for hepatotoxicity follow- up)  
 
Assessment types  
Laboratory evaluations  
Hepatotoxicity follow-up testing will be performed when needed (refer to Section 6.2.4.X 
Management of hepatotoxicity (ALT and/or AST >3.0x ULN and total bilirubin >2.0x ULN) in 
patients receiving BKM120/placebo).  
 
Table 1-7 Clinical laboratory parameters collection  plan Test Category  
Test Category  Test Name  
*Viral hepatitis serologic tests and other tests 
for hepatotoxicity follow-up *  HAAb, HBsAg, HBsAb HBcAb, HCV RNA 
or HDV RNA (where needed), HEAb, 
CMVAb, EBcAb, ALP, CPK, LDH, WBC 
(eosinophilia), and others.  
* Hepatotoxicity follow-up testing/procedures will be performed locally (refer to Section 6.2.4.X Mana gement of 
hepatotoxicity (ALT and/or AST >3.0x ULN and total bilirubin >2.0x ULN) in patients receiving BKM120/p lacebo 
and Section 7.2.X.X.X Viral hepatitis serology and other tests for hepatotoxicity follow-up).  
 
 
Viral hepatitis serology and other tests for hepato toxicity follow-up  
Viral hepatitis serologic tests are performed confi rm patient’s eligibility when needed per clinical 
judgment and specific patient’s clinical circumstan ces.  
During study treatment, viral hepatitis serologic a nd other tests will be performed as per the 
guidelines of management of hepatotoxicity (ALT or AST >3.0x ULN and total bilirubin > 2.0x 
ULN) in patients receiving BKM120/placebo, refer to  Section 6.2.4.X Management of 
hepatotoxicity (ALT and/or AST >3.0x ULN and total bilirubin >2.0x ULN) in patients 
receiving BKM120/placebo for details.  
Viral hepatitis serology includes the following:  
• Hepatitis A IgM antibody and hepatitis A serology t otal  
• Hepatitis B surface antigen, Hepatitis B Core Antib ody (IgM) and viral RNA  
• Hepatitis C serology and viral RNA  
• Hepatitis D RNA (where needed)  
• Hepatitis E IgM and IgG antibody and viral RNA  
Obtain fractionated bilirubin, serum Alkaline Phosp hatase (ALP), creatine phosphokinase 
(CPK), lactate dehydrogenase (LDH), and blood count  with differential to assess eosinophilia. 
Additional viral serology tests may include:  
• Cytomegalovirus IgM antibody  
• Epstein-Barr viral capsid antigen IgM antibody (or if unavailable, obtain heterophile 
antibody or monospot testing)  
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
29 
 • Herpes Simplex Virus  
Liver toxicity has been analyzed based on a search of multiple MedDRA event terms and is 
presented in Table 1-6. Liver function test (LFT) a lterations observed during ongoing and 
completed studies have been mostly transaminase enz yme increases (ALT and/or AST). Data 
suggest a higher rate of grade 3/4 liver enzyme ele vations in Japanese patients (44.4%) in the 
[CBKM120X1101] study, however, the number of patien ts (9 patients) treated at 100mg in this 
study was limited. 
 
 
Table 1-8  Number (%) of patients with Liver toxici ty, regardless of study drug   
relationship, by preferred term and treatment – occ urred at 100 mg/day in 
ongoing buparlisib studies          
 
 
 
 
Although transaminase increases are relatively comm on, only a few of the patients with LFT 
alterations had other simultaneous observations rel ated to impaired liver function (e.g., bilirubin 
increase or clinical symptoms). Based on these find ings, conservative inclusion criteria and 
guidelines to monitor and to follow patients with L FT alterations (including dose and schedule 
modifications) are currently implemented in study p rotocols investigating buparlisib. 
 
Please refer to the respective inclusion/exclusion criteria. 
Mood disorders 
Recently, a number of publications demonstrated tha t the modulation of AKT/GSK3 signaling 
pathway by neurotransmitters is important for the r egulation of behavior (Beaulieu 2009). 
Preclinical studies conducted in rats to investigat e the effect of buparlisib on different 
neurotransmitters have shown that repeated administ ration of buparlisib resulted in an enhanced 

Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
30 
 decrease in glutamate, dopamine, serotonin and epin ephrine as well as in an enhanced increase in 
GABA and HIAA. 
Psychiatric side effects events have been reported in patients treated with buparlisib and are 
currently under investigation. The current data doe s not allow the identification of any sign or 
symptom which could predict patient susceptibility to buparlisib induced psychiatric disorders.  
A broad range of AEs including (but not limited to)  depression, anxiety, mood alteration, 
confusion, affective disorders, insomnia, hallucina tion, panic disorders, irritability or difficulties  
to concentrate have been reported. 
Considering the initial symptoms reported during th e first-in-man [CBKM120X2101] study, 
mood disorders have been analyzed based on HLGT 'Mo od disorders and disturbances NEC' or 
HLGT 'Personality disorders disturbances in behavio r' or HLGT “Psychiatric and behavioral 
symptoms NEC” or HLGT “suicidal and behaviors NEC”.  The frequency of mood disorders thus 
defined, regardless of study drug relationship, ran ged from 6.3% in [CBKM120B2101] study to 
50.0% in dose escalation part of [CBKM120X2107] stu dy, however, the majority of events were 
of grade 1 or 2 severity (Table 1-7). 
 
Table 1-7  Number (%) of patients with Mood disorde rs, regardless of study drug 
relationship, by preferred term and treatment occur red at 100 mg/day in 
ongoing buparlisib studies 
 
 
Therefore, patients must be regularly and closely m onitored for signs and symptoms of 
neuropsychiatric disorders with particular attentio n to changes in mood and personality. To 
support the identification and the assessment of ps ychiatric disorders, two self-assessment 
questionnaires, the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 
(GAD-7), are part of the protocol. Any AEs (symptom /diagnosis) should be accurately reported 
using CTCAE toxicity/grading. A consultation with a  psychiatrist is strongly recommended for 
any psychiatric adverse event grade ≥ 1. Protocol guidelines further disqualify patients  with an 

Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
31 
 active and/or history of major psychiatric disorder .  Please refer to the respective 
inclusion/exclusion criteria. 
Lung Toxicity/ Pneumonitis 
Lung changes compatible with pneumonitis have not b een observed in the preclinical setting.  
Among the current studies, pneumonitis was reported  in five cases and interstitial lung disease in 
one further case. One case of pneumonitis had a fat al outcome in a complex clinical context, 
combining progression of lung metastases and possib le infection with pneumocystis carinii or 
cytomegalovirus. Apart from this fatal case, the co nditions were resolved or improving at the 
latest report (except one non-suspected SAE which w as unchanged). 
The currently available data still do not enable a clear assessment about the causal relationship of 
pneumonitis with buparlisib treatment. Newly appear ing or significant changes in pulmonary 
symptoms (which cannot be explained by the underlyi ng disease), should be carefully followed 
with appropriate management as per institutional gu idelines and the guidelines provided in the 
protocol. 
Please refer to Table 4-5 for a more detailed guide line on the diagnosis and management of 
Pneumonitis.   
Hyperglycemia events 
The PI3K/AKT pathway plays a significant role in re gulating glucose metabolism, particularly 
by regulating glucose transport into adipocytes and  muscle tissue. Therefore, hyperglycemia is 
considered as an “on target” effect of buparlisib. Regular monitoring of FPG, HbA1c, and insulin 
C-peptide is implemented in buparlisib protocols to  evaluate this pharmacodynamics effect. 
Transient increases of plasma glucose levels have b een reported commonly in patients treated 
with buparlisib. Hyperglycemia observed at 100 mg/d ay, regardless of study drug relationship, in 
ongoing buparlisib studies are summarized in Table 1-8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
32 
 Table 1-8  Number (%) of patients with Hyperglycemi a (narrow search), regardless of 
study drug relationship, by preferred term and trea tment occurred at 100 
mg/day in ongoing buparlisib studies  
 
 
The highest rate of hyperglycemia (57.1%) was repor ted in [CBKM120C2201], a Phase II study 
conducted in patients with advanced endometrial car cinoma, as this was the only study among 
those listed allowing the enrollment of patients wi th controlled diabetes mellitus. However, so 
far, there were only two patients that experienced a grade 4 hyperglycemia, and they both were 
treated at the highest dose level (150mg/day) in [C BKM120X2101] study. In order to mitigate 
the potential risk of developing uncontrolled hyper glycemia, only patients with normal 
glycaemia defined as fasting plasma glucose (FPG) ≤ 120 mg/dL are eligible for study entry. 
Patients who have a poorly controlled diabetes mell itus defined as (HbA1c >8%) are excluded. 
In addition, detailed guidelines to monitor patient s are recommended including: regular 
monitoring of FPG to early identify hyperglycemia a nd prevent acute/sub-acute complications, 
caution warranted for patients with history of DM, or taking corticosteroids, or with other severe 
medical conditions (e.g., infections). Hyperglycemi a management guidance also includes: 
dietetic measures and appropriate anti-diabetic med ications as per investigator’s decision and/or 
local guidelines, consider oral anti-diabetics such  as metformin as first-line treatment for 
sustained and more severe hyperglycemia (other drug s as appropriate), if sulfonylurea or insulin 
are initiated, patients should be instructed on how  to recognize (and treat) hypoglycemia, for 
patients with history of DM, management should be b ased on prior anti-DM treatment. 
Detailed guidelines to monitor and manage patients who develop hyperglycemia are provided in 
Table 4-1.  
Skin rash and hypersensitivity 
Skin rash is commonly observed in patients treated with buparlisib. The rate of skin rash and 
other related event terms ranged from 18.4% to 41.4 % in single agent studies with a 

Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
33 
 representative number of patients treated with 100m g of buparlisib. In one study with nine 
evaluable patients, seven patients (77.8%) reported  such events (Table 1-9). 
Studies of buparlisib in combination with other age nts tended to report slightly higher 
frequencies (e.g. combination with MEK inhibitor). The skin rashes seen have no typical location 
or distribution pattern, are mainly papulo-macular (only a minority are acneiform) and are 
frequently associated with pruritus. Events have be en reversible after treatment interruption and/ 
or dose reduction. Effective medications have inclu ded antihistamines, topical corticosteroids 
and/or low-dose systemic corticosteroids (the latte r should be used with caution due to the 
increased risk of hyperglycemia). There have been f ew cases reported of allergic reactions and 
DRESS (drug rash with eosinophilia and system sympt oms), but these have not been of acute 
onset or of a severe nature. 
 
Complementary information collected suggests that s un exposure may exacerbate the condition 
and should be avoided; however, genuine photosensit ivity reaction has not been confirmed and 
no phototoxic potential has been seen pre-clinicall y. Patients are advised (e.g., in the written 
patient information) to avoid sun exposure, or take  measures to protect themselves from intense 
sunlight, during study treatment. 
 
 
Table 1-9 Number (%) of patients with Hypersensitiv ity, rash, regardless of study drug 
relationship, by preferred term and treatment occur red at 100 mg/day in ongoing 
buparlisib studies  
 
 
Guidelines for the treatment of buparlisib induced hyperglycemia 
Hyperglycemia is a common site effect of PI3K and a lso mTOR inhibitors. Hyperglycemia often 
occurs during the first weeks after treatment start  and is dose-dependent. Transient increase of 
glucose levels have been observed in some patients.  Regular monitoring of FPG to early identify 
hyperglycemia and prevent acute/sub-acute complicat ions is important. Caution is warranted for 

Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
34 
 patients with history of DM, or taking corticostero ids, or with other severe medical conditions 
(e.g. infections), or patients who show potential a cute signs such as poly-noctiuria, polidypsia, 
confusion, etc.  Hyperglycemia management guidance includes patient education and dietetic 
measures/life-style changes as well as appropriate anti-diabetic medications as per investigator’s 
decision and/or local guidelines.  
Oral anti-diabetics such as metformin should be con sidered as first-line treatment for sustained 
and more severe hyperglycemia (other drugs as appro priate). Provided hyperglycemia is 
asymptomatic and there are no acute complications, sufficient time should be given to install 
optimal management (e.g. uptitrate metformin, addit ion of a second oral anti-diabetic agent to be 
considered as needed, etc.). Patients initiated on sulfonylurea or insulin should be instructed on 
how to recognize (and treat) hypoglycemia. Patients  with history of DM, management should 
take prior anti-DM treatments into account. Note th at some oral anti-diabetic drugs are CYP2C9 
substrates and should be used with caution; others are CYP3A inducers or inhibitors and may be 
prohibited (see Appendix 1 and Appendix 2 for more details). Patients who develop Grade 3 or 4 
or symptomatic hyperglycemia should be managed urge ntly as per standard clinical practice, 
with the goal of stabilizing glycemic control withi n 24 hours. More guidance on dose reductions 
and interruptions is provided in Table 3 above.  
Guidelines for the treatment of study drug induced stomatitis/oral mucositis 
General guidance and management include patient awa reness and early intervention. Evaluation 
for herpes virus or fungal infection should be cons idered. 
Patients should be informed about the possibility o f developing mouth ulcers/ oral mucositis and 
instructed to report promptly any signs or symptoms  to their physician, Patients should be 
educated about good oral hygiene, instructed to avo id spicy/acidic/salty foods, and should follow 
the following guidelines:  
• For mild toxicity (grade 1), use conservative measu res such as non-alcoholic mouth wash 
or salt water (0.9%) mouth wash several times a day  until resolution. 
• For more severe toxicity (grade 2 in which case pat ients have pain but are able to 
maintain adequate oral alimentation, or grade 3 in which case patients cannot maintain 
adequate oral alimentation), the suggested treatmen ts are topical analgesic mouth 
treatments (i.e., local anesthetics such as benzoca ine, butyl aminobenzoate, tetracaine 
hydrochloride, menthol, or phenol) with or without topical corticosteroids, such as 
triamcinolone oral paste 0.1% (Kenalog in Orabase ®), or as per local practice. 
• Agents containing alcohol, hydrogen peroxide, iodin e, and thyme derivatives may tend to 
worsen mouth ulcers. It is preferable to avoid thes e agents. 
Antifungal agents should be avoided unless a fungal  infection is diagnosed as they may interfere 
with buparlisib metabolism. 
Guidelines for the treatment of buparlisib induced diarrhea 
The investigator should consider/investigate potent ial concomitant medication, food or 
comorbidity driven causes of diarrhea (including in fectious causes) and remedy these causes if 
possible (e.g. discontinuation of concomitant medic ation, dietary modification, treatment of 
comorbidity). 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
35 
 The patient should be monitored for signs of dehydr ation and instructed to take preventive 
measures against dehydration as soon as diarrhea oc curs. Concomitant medication for the 
treatment of diarrhea should be considered, as per local practice and best investigator’s judgment 
and may consist for example, as per “the recommende d guidelines for the treatment of cancer 
treatment-induced diarrhea” (Benson 2004), of loper amide given at a standard dose (e.g. initial 
administration of 4mg, then 2mg every 4 hours, maxi mum of 16 mg/day), along with oral 
hydration and dietetic measures could be considered  for Grade 1-2 diarrhea. More severe 
diarrhea should be treated appropriately according to investigator discretion, including for 
example IV fluids. 
Dose adaptations of buparlisib in case of treatment  related diarrhea should follow the guidelines 
presented above for other non-hematological adverse  events. 
Guidelines for the treatment of buparlisib induced psychiatric disorders 
Psychiatric adverse events will be closely monitore d and evaluated at each planned visit until 
recovery to Grade ≤ 1 or baseline status. The grading of psychiatric a dverse events/mood 
alterations must be based on the clinical interpret ation of severity according to the NCI- CTCAE 
(v 4.03) guidelines. 
For patients who experience new or worsening of exi sting psychiatric AEs of Grade ≥1, 
psychiatric consultation should be considered as de scribed in Table 3. 
Patient self-reported mood questionnaires (GAD-7 an d PHQ-9) will be used for screening and 
during the study treatment phase to aid the investi gator in identifying new or worsening of 
events. For additional information regarding safety  assessments based on patient self-reported 
mood questionnaires, please refer to Section Patien t self-rating mood questionnaires. 
If question 9 in the PHQ-9 has a positive response (as indicated by selecting "1", "2", or "3"), 
omit treatment with buparlisib and refer the patien t for psychiatric consultation for optimal 
management regardless of the total questionnaire sc ore or CTCAE grading to confirm if study 
drug should be interrupted or permanently discontin ued. In this specific case, the psychiatric 
advice can overrule the patient’s PHQ-9 self-assess ment. During the study, subjects will be 
monitored at regular scheduled visits (e.g., Day 15  of Cycle 1, Day 1 and Day 15 of Cycles 2, 
Day 1 of each subsequent cycle, and at the End of T reatment visit) by the investigator/site staff 
through personal interaction and the two self-repor ted questionnaires. Additional assessments 
may be done according to the clinical judgment of t he investigator if desired. 
Guidelines for the treatment of study drug induced skin toxicity 
Skin toxicity is a class-effect observed with PI3Ki /mTORi agents. Close monitoring of potential 
skin reactions will be performed at each planned vi sit and will be reported as adverse event. The 
most frequent skin adverse events reported are: mac ulopapular rash (only a minority present 
acneiform rash) (refer to Table 3 for clinical mana gement); pruritus and dry skin. The onset is 
typically within the first 2 months of treatment st art and is reversible with adequate comedication 
and treatment interruption if needed. Photographs o f a skin rash event as well as skin biopsy are 
recommended, if possible. According to the investig ators discretion, a paired skin biopsy could 
be obtained (from both an affected and an unaffecte d skin area for local histopathology 
assessment) to further assess rash if clinical appr opriate. 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
36 
 Recommended therapies for skin toxicity events (ref er to Table 3 for specific guidance according 
to the type of skin toxicity): 
• Topical steroids of moderate potency (face and fold s): triamcinolone 0.025%; 
aclometasone 0.05% (< 8 weeks continuously), for mi ld and moderate rashes. 
• Topical steroids of high potency (trunk/extremities ): fluocinonide 0.05%; clobetasol 
0.05% cream or spray (< 8 weeks continuously), for mild and moderate rashes. 
• Oral antihistamines (sedating, evening): diphenhydr amine 25 to 50mg t.i.d; hydroxizine 
25mg tid or q.i.d;  
• Oral antihistamines (non-sedating, day time): fexof enadine 180mg q.d. or 60mg tid 
(monitor the use of this class of drugs since skin toxicity has also been reported) 
• Oral corticosteroids: prednisone 0.5mg/kg or equiva lent up to 5 days of treatment 
• In case of mild acneiform rashes topical antibiotic s: clindamycin 1% to 2%; erythromycin 
1% to 2% (gel or solution formulation can be used, ointments cannot be used); 
metronidazole 1%; silver sulphadiazine. 
• For more severe acneiform rashes oral antibiotics: doxycycline 100mg b.i.d.; minocycline 
100mg b.i.d.; oxytetracycline 500mg b.i.d. for 6 we eks can be considered. If infection 
suspected (yellow crusts, purulent discharge, painf ul skin/nares), then switch to broad 
spectrum/gram negative antibiotics; consider skin s wab for bacterial culture. 
• Topical antipruritics (pramoxine 1%, doxepin 5% cre am) applied twice daily 
• For severe pruritus GABA Agonists: Gabapentin 300mg  every 8 hours, or pregabalin 50 
to 75 mg every 8 hours (to adjust of renal impairme nt) can be considered. Dose should be 
adjusted depending on patient’s clinical condition be of potential and common side 
effects observed with GABA agonists such as: somnol ence, dizziness (both drugs) and 
peripheral edema (Gabapentin) among others AEs. 
 
Dry skin has been reported, it is recommended that patients with dry skin use mild and fragrance 
free soaps and detergents. According to the severit y and BSA extension patients may apply mild 
moisturizers, ammonium lactate cream 12% or salicyl ic acid cream 6% b.i.d.  
Photosensitivity has been described in patients alt hough preclinical experiments demonstrated 
that buparlisib has no potential phototoxic effect.  Patients should be advised to take measures to 
protect themselves from direct exposure to sunlight , including regular use of sunscreen (factor 20 
at least), wearing of sunglasses, using of hats, an d protective clothes when outdoors. 
Guidelines for the management of Posterior Reversib le Encephalopathy Syndrome (PRES) 
There have been rare reports of PRES occurring unde r treatment with buparlisib. Signs and 
symptoms may include severe headache, confusion or seizures, altered consciousness, visual 
disturbances, with or without associated high blood  pressure. Patients are instructed in the 
written patient information to inform their treatin g physician if they suspect such an event. Take 
appropriate measures in such cases to assess the si gns and symptoms. If PRES is suspected based 
on the signs and symptoms, buparlisib should be int errupted and a brain MRI should be 
performed to confirm the diagnosis. 
1.3.1.3.1.2  Human pharmacokinetic and metabolism data 
Preliminary clinical pharmacokinetic data of buparl isib after single and multiple daily dosing are 
available from the first-in-human trial [CBKM120X21 01]. Buparlisib was administered as a 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
37 
 capsule (doses ranging between 12.5 and 150 mg) and  full pharmacokinetic profiles were 
collected on Day 1, Day 8 and Day 28 of Cycle 1.  
Buparlisib was rapidly absorbed, with the median ti me to reach the peak plasma concentration 
(Tmax) ranging from 1.0 to 1.75 hours after adminis tration. Tmax was independent of dose and 
was not altered after multiple oral doses. Variabil ity in systemic drug exposure was moderate at 
all dose levels. At 100 mg the variability in syste mic drug exposure and Cmax (CV %) at steady-
state was moderate, about 36% and 25%, respectively . 
During once daily dosing, plasma buparlisib concent rations were found to accumulate in 
reaching steady-state. After one week of oral daily  dosing (day 8), both Cmax and AUC0-24h 
were approximately 3-fold higher than after a singl e dose (day 1). The mean accumulation ratio 
(Racc) of buparlisib at 100 mg was 2.7 and 3.3 on d ays 8 and 28, respectively, indicating the 
absence of significant drug accumulation after day 8.  
The decay in buparlisib plasma concentration over t ime was bi-exponential, with an apparent 
long terminal half-life. The mean T1/2,acc (effecti ve half-life, obtained from drug accumulation) 
calculated from exposure data at day 28 ranged betw een 38 and 49 hours across all dose levels. 
T1/2,acc was found to be independent of dose. Based  on the effective half-life, steady state 
buparlisib plasma levels can be expected to be reac hed after 1 week of daily dosing. 
Furthermore, the preliminary PK data within the Jap anese population [CBKM120X1101] show 
no significant differences in Cmax or AUC0-24h comp ared with the PK data for the Caucasian 
population [CBKM120X2101]. A preliminary population  PK analysis, including data from 
studies [CBKM120X2101] and [CBKM120X1101] confirmed  these findings (Novartis internal 
data). 
In study [CBKM120X2107] a daily dosing regimen of b uparlisib was tested in combination with 
weekly infusions of trastuzumab in patients with re lapsed HER2-overexpressing breast cancer. 
Preliminary pharmacokinetic data indicated that the  systemic drug exposure (Cmax and AUC) of 
oral buparlisib in combination with trastuzumab was  similar to that for the single agent data. 
Trastuzumab trough levels were consistent with thos e previously reported to be therapeutic (i.e., 
generally greater than 20 µg/ml). 
In the current study, corticosteroids and other CYP 3A4 inducers will be prohibited in order to 
maintain buparlisib exposure in the expected range.  In addition, anti-acids will be dosed at least 
one hour after buparlisib administration to avoid a  decrease of pH during the absorption phase of 
buparlisib and thus avoid any possible solubility l imitations.  
1.3.1.3.1.3  Clinical efficacy data 
Sixty six patients were evaluable for response in s tudy [CBKM120X2101] where all patients in 
the expansion cohort were required to have mutated and/or amplified PIK3CA and/or mutated 
PTEN or null/low PTEN protein expression: partial t umor responses (PR) were observed in 3 
patients, one of which was a RECIST v1.0 confirmed PR in a patient with triple negative breast 
cancer and the other 2 patients’ responses were not  confirmed (1 patient with metastatic breast 
cancer and 1 patient with parotid carcinoma) (Graña  2011). 
The first patient was a 61 year-old female with poo rly differentiated ductal metastatic breast 
cancer assessed as triple negative (ER-, PgR-, HER2 -), PI3KCA wild type, PTEN IHC positive. 
Since 2006 she received many previous anticancer ag ents (cyclophosphamide, doxorubicin, 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
38 
 gemcitabine, docetaxel, paclitaxel, vinorelbine, ca pecitabine, etoposide, anastrozole). As 
progressive disease developed (bulky lymph node inv olvement and local breast relapse), she was 
enrolled (April 2009) in the Phase I study of bupar lisib in the 100 mg/day cohort. A metabolic 
response (61% decrease in SUV) was observed after 2  cycles, followed by a RECIST partial 
response (66% tumor shrinkage) after 4 cycles. This  patient continues to receive treatment 
beyond 32 cycles.  
The second patient was a 52 year-old female with mo derately differentiated ductal metastatic 
breast cancer, assessed as ER positive, HER2 negati ve, PI3KCA mutated (E545K & H1047Y), 
PTEN IHC positive. She had been previously treated with several antineoplastic agents. When 
she received buparlisib at 100 mg/day (January 2010 ), she had measurable metastases in the 
brain, lung and liver. At the second radiological a ssessment after receiving 4 cycles of buparlisib 
treatment, a 45% reduction of the sum of the lesion s was recorded. The TTP for this patient was 
24 weeks.  
The third patient was a 45 year-old man with grade 4 parotid gland ductal carcinoma, PI3KCA 
wild type, PTEN IHC positive. He had been previousl y treated with doxorubicin and adriamycin. 
After disease progression was observed on this regi men he was enrolled in the 100mg/day cohort 
(July 2010) in the [CBKM120X2101] study. At the fir st radiological assessment after receiving 2 
cycles of buparlisib treatment, a 33% reduction of the sum of the lesions was recorded. The TTP 
for this patient was 16 weeks. 
As of the data cut-off 04July2011, preliminary anal ysis shows forty-five percent of patients (30 
of 66 evaluable) had stable disease as their best r esponse, with 20 patients (30%) having a 
disease stabilization of 3 months or longer. A tren d towards better activity (long-term 
stabilizations) has been observed at the higher dos e cohorts, also expressed in metabolic FDG-
PET response. However, considering the impact of a PI3K inhibitor on glucose metabolism, 
further data are needed to understand whether the c urrent FDG-PET assessment data can be used 
as a predictive factor for efficacy. 
With regard to pharmacodynamic markers observed in study [CBKM120X2101], down 
regulation of pS6 in skin by 30-80% was demonstrate d in 28 out of the 38 evaluable patients at 
100 and 150 mg/d with more than a 25% FDG-PET signa l decrease in patients at doses greater 
than the MTD.  
With regards to the PI3K pathway activation, two of  the three responders described above had a 
cancer with a PIK3CA mutation. Moreover, 18 patient s had a stable disease lasting for 16 weeks 
or longer, including 8 patients who had tumors with  an activated PI3K pathway. These data are 
promising and continued exploration of the activity  of buparlisib in patients with activated PI3K 
pathway is warranted.  
More specifically, in [CBKM120X2101], 25.3% (21/83)  of patients had metastatic breast cancer. 
At the cut-off date of July 4th , 2011, twenty breast cancer patients were evaluabl e for objective 
tumor response by RECIST 1.0. Two breast cancer pat ients (11%), described above exhibited 
partial responses. For these 2 patients, the treatm ent duration was 27+ (ongoing) and 5 months, 
respectively. An additional 8 breast cancer patient s (40%) had stable disease. Median 
progression-free survival was 60 days and the 6-mon th PFS rate was 33% (Rodon 2011). 
Other than [CBKM120X2101], two trials are ongoing i n breast cancer patients with preliminary 
data available: 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
39 
 • In [CBKM120X2107], buparlisib is combined with tras tuzumab in metastatic breast 
cancer patients with trastuzumab resistance. As of September 30, 2011, out of 17 
patients enrolled, 2 PR and 8 SD were observed in t he dose escalation portion of this 
study, with a disease control rate (CR+PR+SD) of 59 %. (Saura 2011). 
• Buparlisib has been combined with letrozole in ER+ post-menopausal breast cancer 
patients (Mayer 2011). Out of the 20 patients enrol led, 12 were evaluable for 
efficacy; 1 PR, and 7 SD were observed. Over 50% of  patients had >25% reduction in 
their peak SUV at the 2-week FDG-PET scan. 
 
Please refer to the Investigator’s Brochure for add itional information on the available 
clinical experience with buparlisib. 
1.3.2  Capecitabine 
Capecitabine is a prodrug that is enzymatically con verted to 5-fluorouracil in the tumor where it 
inhibits DNA synthesis and slows growth of tumor ti ssue (Xeloda package insert). Capecitabine 
is approved in both colorectal and breast cancer. C apecitabine demonstrated single-agent activity 
in subjects with MBC with an ORR of about 20% in su bjects whose disease had progressed 
during or following anthracycline and taxane-based therapy (Xeloda package insert).  
Capecitabine is also indicated as a combination tre atment with docetaxel in early-line treatment 
for MBC and in combination with ixabepilone or lapa tinib as second-line treatment after failure 
of prior anthracycline and taxane-containing chemot herapy (Xeloda package insert). 
The recommended, approved dose of capecitabine is 1 250 mg/m 2 daily BID for 14 days, 
followed by 7 days without treatment (Xeloda packag e insert). This dose/schedule necessitates 
dose interruptions or reductions in approximately 3 0% of patients, and in clinical trials, 
approximately 17% of patients discontinued the drug  due to toxicities (primarily hand-foot 
syndrome, diarrhea and stomatitis) (Mackean 1998; O ’Shaughnessy 2001).  
There have been isolated case reports of responses to single agent capecitabine in patients with 
breast cancer-related CNS metastases (Ekenel 2007; Hikino 2006; Rogers 2004; Wang 2001; 
Fabi 2006; Tham 2006).  In addition, in a phase II trial of patients with HER2+ MBC with CNS 
metastases, the combination of capecitabine plus la patinib was associated with a higher objective 
response rate (20%) compared with 6% observed with lapatinib alone (Lin 2009). Further, this 
combination produced a 66% partial CNS response rat e in patients with previously untreated 
HER2+ CNS metastases in the phase II LANDSCAPE tria l (Bachelot 2013). 
1.3.3  Buparlisib in combination with capecitabine 
Investigators at the University of North Carolina a nd Duke are conducting a phase I study of 
capecitabine plus buparlisibin patients with MBC.  Although the study is not yet completed, 16 
patients have been enrolled as of January 3, 2013.  Based on assessment of toxicities in cycle 
1, the investigators believe that the recommended p hase II dose from this study will likely be 
capecitabine 1000 mg/m 2 PO BID 14 days on and 7 days off plus buparlisib 1 00 mg PO 
QD. Additional patients are being enrolled to this dose level presently.   Dose limiting toxicities 
(DLT) to date have included one patient each with p sychosis, photosensitivity "sunburned" rash, 
fatigue, and mucositis.  Several patients who did n ot have a cycle 1 DLT, and whose disease had 
not progressed, withdrew from study therapy due to capecitabine-related toxicities including 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
40 
 diarrhea and hand foot syndrome, which occurred aft er cycle 1.  Several patients needed a dose 
reduction of capecitabine in cycles 2-5, and dose r eductions of buparlisib to 80 mg PO QD were 
required in some patients due to grade 2 psychiatri c or cognitive side effects. Evidence of 
antitumor activity has been observed in triple nega tive and ER+ MBC patients.  Overall, 
administration of the combination of capecitabine a nd buparlisib is feasible with doses of the two 
agents that are their single agent MTDs. Toxicities  observed to date have been generally 
manageable with dose reduction although some patien ts have withdrawn from study therapy due 
to cumulative toxicity (Claire Dees, MD. personal c ommunication).  
1.3.4  Buparlisib in combination with trastuzumab 
 
A phase Ib/II trial by Pistilli et al ESMO 2012 com bining trastuzumab plus buparlisib (100mg 
QD) showed acceptable safety in 52+ pts with basica lly no overlapping toxicities (Pistilli 2012).  
Of note, 5 patients had brain metastasis at study e ntry and 2 had SD still ongoing at the time of 
the abstract; 2 others had SD for 90 and 106 days a nd the fifth was not evaluable.  
 
1.4  Study Rationale 
CNS metastases occur with high frequency in patient s with metastatic MBC, developing in 
approximately one-fourth to one-half of patients. C urrently there are no effective systemic 
therapies that have been shown to improve OS for pa tients with MBC with brain metastases. (see 
Section 1.1.1) Thus, there is an urgent unmet need for more effective treatments for this patient 
population.  
Dysregulation of the PI3K signaling pathway occurs in the majority of MBCs, through a variety 
of mechanisms including mutation of PIK3CA or PTEN,  or loss of PTEN or INPP4B, as well as 
through activation by upstream receptor activation.  PTEN loss and activation of PI3K signaling 
has also been documented specifically in MBC brain metastases, making inhibition of this 
pathway an attractive therapeutic strategy for inve stigation. (see section 1.2.1) 
Capecitabine and buparlisib have both individually demonstrated the ability to penetrate the 
blood-brain barrier, and have shown activity in MBC , making this a rational combination to 
evaluate for the treatment of MBC brain metastases.  In addition, this combination is currently 
being evaluated in a phase I study in MBC, includin g patients with MBC, with  evidence of 
activity as well as tolerability. (see Section 1.3. 3) 
Given this background, we have decided to proceed w ith a phase II study to test the combination 
of capecitabine plus buparlisib in metastatic breas t cancer with HER2+ or ER+/HER2- or triple 
negative brain metastases. The purpose of this stud y is to evaluate the effect of buparlisib plus 
capecitabine on clinical benefit rate in this patie nt population. 
1.4.1  Rationale for dose selection 
 
Buparlisib will be administered at a dose of 100 mg  orally (PO) daily, the MTD/RP2D 
determined in single agent ([CBKM120X2101] and [CBM K120X1101]) and combination 
([CBKM120X2107], [CBEZ235A2118] and [CBKM120XUS13T] ) studies (Buparlisib 
Investigator Brochure). This dose has also shown pr eliminary tolerability in combination with 
capecitabine in the ongoing phase I study in MBC. C apecitabine will be administered at a dose 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
41 
 of 1000 mg/m 2 PO BID (rounded down to the nearest 500 mg pill) 1 4 days on and 7 days off, 
based on the recommended phase II dose determined i n the phase I study of capecitabine plus 
buparlisib in MBC (Claire Dees, MD. personal commun ication). 
2 Study objectives 
Primary Objectives 
• To determine the clinical benefit rate (CBR) based on local investigator assessment 
associated with buparlisib once daily plus capecita bine (1000 mg/m 2 PO BID 14 days 
on/7 days off) in patients with metastatic breast c ancer with a  brain metastasis at 
least 5mm in size following whole brain radiation t herapy (WBRT)  or stereotactic 
radiosurgery (SRS) or both. The target lesion that is at least 5mm in size must not 
have undergone treatment with SRS and may represent  residual disease following 
SRS or WBRT, or may represent progression of diseas e following SRS or WBRT.  
Clinical benefit rate is defined as the proportion of patients with best overall response 
of complete response (CR) or partial response (PR) or stable disease (SD) in the CNS 
lasting at least 24 weeks based on local investigat or assessment.  
Secondary Objectives 
• To assess ORR in the CNS based on local investigato r assessment associated with 
buparlisib plus capecitabine. 
• To assess median time to progression (TTP) associat ed with buparlisib plus 
capecitabine. 
• To determine median overall survival (OS) associate d with buparlisib plus 
capecitabine. 
• To determine if buparlisib plus capecitabine prolon gs OS compared with expected 
survival of patients with brain metastases, estimat ed using the breast-GPA (See 
Appendix 1). 
• To characterize the safety and tolerability of bupa rlisib plus capecitabine, with or 
without trastuzumab. 
• To assess median time to deterioration of neurologi c function. 
• To monitor changes in symptom occurrence using the M.D. Anderson Symptom 
Inventory-Brain Tumor Module (MDASI-BT), and to pro vide results of PHQ-9 
Depression Scale. 
• To investigate whether there is a correlation betwe en PI3K pathway-related 
biomarkers and clinical response. 
3 Exploratory Investigational Plan 
3.1  Overall Study Design 
This is a Phase 2, multicenter, single-arm study to  determine the efficacy and safety of buparlisib 
plus capecitabine in approximately 42 patients with  metastatic breast cancer with measurable 
brain metastases at least 5mm in size following WBR T or SRS or both.   The target lesion that is 
at least 5mm in size must not have undergone treatm ent with SRS and may represent residual 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
42 
 disease following SRS or WBRT, or may represent pro gression of disease following SRS or 
WBRT. 
 
This study will consist of 2 phases: a Screening Ph ase where the informed consent will be 
collected and eligibility criteria will be assessed  followed by a Treatment Phase that includes 
end-of-treatment follow-up assessments. The Screeni ng Phase will include assessments before 
the first dose of study drugs (Cycle 1/Day 1) to es tablish eligibility and baseline values. The 
Treatment Phase will commence for each subject with  the first dose of buparlisib plus 
capecitabine, with or without trastuzumab, and cont inue through the end of treatment. After 
discontinuing all study treatment, the patient will  be followed for a mandatory 30-day safety 
follow-up, efficacy (tumor assessments, if applicab le) follow-up and survival follow-up.  
During the treatment phase:  
• Patients with HER2- MBC will receive buparlisib ora lly (PO) at a dose of 100 mg 
daily continuously in combination with capecitabine  1000 mg/m 2 PO BID 14 days 
on/7 days off.   
• For patients with HER2+ MBC, standard every 3-weekl y trastuzumab (6 mg/kg IV) 
will be added to the capecitabine/buparlisib.   
Patients will receive treatment until disease progr ession, unacceptable toxicity, death, or 
discontinuation from the study treatment for any ot her reason. Patients will be followed for 
survival regardless of treatment discontinuation fo r any reason for up 2 years from date of 
registration (except if consent is withdrawn or pat ient is lost to follow-up).  
Note: Information from procedures that may have bee n previously performed as part of the 
patient’s routine disease care (prior to enrolling in the trial) is allowed to be used to satisfy 
inclusion criteria as long as the procedures were p erformed within 28 days of registration. 
 
Screening phase 
All patients will undergo screening assessments to determine study eligibility. Within 28 days 
before initiation of treatment, the patient will pr ovide a signed informed consent form prior to 
any study related activities. All screening evaluat ions must be performed during the screening 
period (day −28 to day −1). Receptor status may be obtained anytime before enrollment on 
study. Collection and shipment of tumor sample (new  biopsy or archived tissue) to designated 
lab (check the CTI) should occur as soon as possibl e and no later than Day −1. Check Table 4-12 
for details of tests to be done at screening. 
Screening procedures are to be performed within 28 days of the start of study treatment. 
Receptor status may be obtained any time before enr ollment on study. Baseline values for those 
assessments (e.g., physical examination, ECOG perfo rmance status, weight, vital signs, 
hematology, biochemistry and fasting plasma glucose ) may be used for Cycle 1 assessments as 
long as they are performed within 2 weeks prior to the patient receiving their first dose of the of 
study drug. 
 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
43 
 Treatment phase 
Once inclusion and exclusion eligibility criteria h ave been confirmed, study treatment will be 
initiated. Patients will receive buparlisib orally (PO) at a dose of 100 mg daily continuously in 
combination with capecitabine 1000 mg/m 2 PO BID 14 days on/7 days off, then repeat the cycl e. 
Patients with HER2+ MBC will also receive trastuzum ab by IV administration every 3 weeks.   
Capecitabine needs to be rounded down to the neares t 500 mg pill.  Buparlisib and capecitabine 
dose modifications will be allowed (see Section 4-1 ). Safety will be monitored as outlined in 
Section 4-3. 
Cycle treatment and evaluations will be performed d uring therapy at the start of each cycle, 
unless otherwise specified. Cycle 2 and subsequent cycles, has a window of +/-3 business days 
(after the scheduled time) for treatment administra tion and cycle assessments (e.g., the physical 
examination, performance status (ECOG), weight, vit al signs, and labs) during the study 
treatment. Any delay within this window is NOT a de viation. 
Patients will receive treatment until disease progr ession (assessed by RECIST 1.1), unacceptable 
toxicity, death or discontinuation from treatment f or any other reasons. Efficacy and safety 
monitoring will continue as per the visit schedule (Table 4-12). Tumor assessments will be 
performed every 8 weeks after treatment initiation date until clinical or radiological progression. 
Disease progression in the brain and other sites sh ould always be documented radiologically, 
adding an earlier than planned imaging time point f or tumor assessments as clinically indicated. 
Note: Cycle 1 only, the baseline values for those a ssessments (e.g., the physical examination, 
performance status (ECOG), weight, vital signs hema tology, biochemistry, and fasting plasma 
glucose,) that are to be done for screening may be used for Cycle 1 assessments as long as they 
are completed within 2 weeks prior to the patient r eceiving their first dose of study drug. If more 
than 2 weeks have elapsed since the baseline assess ment, the assessment must be repeated.  
Assessments need to be put in the order in which th ey appear in eCRF.  Treatment must begin 
within 5 working days after patient registration to  the study, not including weekends or holidays. 
End of Treatment Phase 
After the end of the treatment visits, all patients  will be followed up for safety up to 30 days after  
the last dose of study treatment (buparlisib plus c apecitabine).  There is window of +/- 7 business 
days for end of treatment assessments.  Any delay w ithin this window is NOT a deviation.  End 
of treatment will continue as per the visit schedul e (Table 4-12). 
Follow up phase 
After the end of the treatment visits, all patients  will be followed up for safety up to 30 days after  
the last dose of study treatment (buparlisib plus c apecitabine).   
All patients who discontinue from study treatment d ue to disease progression must have their 
progression clearly documented according to the cri teria specified in RECIST 1.1. 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
44 
 If a patient did not discontinue study treatment du e to disease progression, death, adverse event, 
start of new anti-neoplastic therapies, lost to fol low-up, or withdrawal of consent for efficacy 
follow-up then tumor assessments should continue to  be performed every 8 weeks until the start 
of new anti-cancer therapy, disease progression, de ath, lost to follow-up or withdrawal of 
consent for efficacy follow-up. 
All patients will be followed for survival every 2 months from last date of treatment regardless of 
treatment discontinuation reason (except if consent  is withdrawn or patient is lost to follow-up) 
until death or for up to 2 years from date of regis tration. Survival information can be obtained via 
phone and information will be documented in source document. 
There is window of +/- 7 business days for end of t reatment assessments.  Any delay within this 
window is NOT a deviation.  For details on required  assessments, please refer to Table 4-12. 
 
 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
45 
 Figure 3-1 Study design  
Patients with metastatic breast cancer with a brain m etastasis at least 5mm in size who have  been treat ed with WBRT 
Screening 
From day -28 to day -1
Treatment 
BKM120 + Capecitabine 
+ trastuzumab if HER2+ ~ 40 Patients 
End of treatment (EoT)
EoT 1due to disease 
progression Other reason for EoT 2
Safety follow-up 
(up to 30 days after EoT)Safety follow-up 
(up to 30 days after EoT)
Efficacy follow-up tumor assessments 
Every 8 weeks 
Survival follow-up: every 2 months (or 
more frequently if necessary) Survival follow-up: every 2 months (or 
more frequently if necessary) 
1End of treatment (EoT) is due to disease progressio n, start of new cancer therapy, lost to follow-up o r withdrawal of consent for efficacy 
follow-up 
2EoT is for reasons other than disease progression, l ost to follow-up or withdrawal of consent for effic acy follow-up or started new anti-
cancer treatment 
SCREENING TREATMENT FOLLOW UP 
 
 
 
Definition of end of the study 
The end of study is defined as the time point when data collection will stop and the final analysis 
of the study will occur. The end of study will be d eclared depending on the results of the primary 
analysis.  
 
 
3.2  Study Population 
3.2.1  Patient population 
The primary analysis patient population consists of  patients with MBC with a non-progressing 
brain metastasis that is at least 5mm in size and w ho have undergone treatment with WBRT or 
SRS or both at any time for their brain metastases and who do not have evidence of impending 
visceral crisis outside of brain.  The target lesio n that is at least 5mm in size must not have 
undergone treatment with SRS and may represent resi dual disease following SRS or WBRT, or 
may represent progression of disease following SRS or WBRT. Evidence of progression of 
disease following WBRT or SRS is allowed but is not  required.  Patients may be symptomatic as 
long as ECOG performance status is ≤2. There is no limit on the number of chemotherapy 
regimens previously received and prior treatment wi th capecitabine is allowed.   The patients 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
46 
 must not have active cardiac disease, or clinically  significant GI disease that impairs GI function. 
The patients must provide tumor tissue (archival or  new biopsy) for the analysis of PI3K 
pathway-related biomarkers unless previously discus sed with the study principal investigator. 
The investigator or designee must ensure that only patients who meet all the following inclusion 
and none of the exclusion criteria are offered enro llment in the study.  Eligible patients must 
have measurable disease by Response Evaluation Crit eria in Solid Tumors (RECIST v1.1) 
criteria. 
The patients are not permitted to participate in ad ditional parallel investigational drug or device 
studies.  
3.2.2  Registration procedures 
Written documentation of full IRB and FDA approval must be on file before a patient can be 
registered. The registration process begins when th e coordinator has obtained a signed informed 
consent. Please enter patient demographics into the  Clinical Trial Management System (CTMS); 
this is the Web-based intranet system for the deliv ery of trial information between Delta and 
used across all sites. A  UPN will be assigned to the patient at that time. E ntering a patient into 
CTMS does not signify that you have registered the patient in the study. If you have any 
difficulty with CTMS please contact the Clinical Tr ial Manager. 
Once the patient has an UPN number, the coordinator  can go to their Patient Report and select 
the patient that they want to register.  Located to  the left of the patient’s UPN will be the letters 
“Reg” in blue.  The coordinator will click on the b lue “Reg” to open up that patient’s 
information.  Each page that needs to be completed will be in yellow.  The site will answer the 
questions on the Inclusions and Exclusions.  Once a ll questions on each page are answered, that 
page will turn green.  Once all the pages turn gree n, click on the “verify data” tab, then click the 
“register” tab.  The register page will open, “clic k to register”.  An ID number will be directly 
assigned. For any difficulties with entering the da ta, please contact the Project Manager of the 
study. 
 
Treatment must begin within 5 working days after th e patient’s registration on the study, 
not including weekends or holidays. 
 
3.2.3  Inclusion and exclusion criteria 
Patients must have baseline evaluations performed p rior to the first dose of study drug and must 
meet all inclusion and exclusion criteria. Results of all baseline evaluations, which assure that all 
inclusion and exclusion criteria have been satisfie d, must be documented on the checklist and 
signed by the treating physician. In addition, the patient must be thoroughly informed about all 
aspects of the study, including the study visit sch edule and required evaluations and all 
regulatory requirements for informed consent. The w ritten informed consent must be obtained 
from the patient prior to enrollment. Patients elig ible for enrollment in the treatment phase of this 
study must meet all  of the following criteria: 
 
 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
47 
 Inclusion criteria  
1. Age ≥ 18 years 
2. Female 
3. Histologically and/or cytologically confirmed diagn osis of inoperable breast cancer 
4. ER+/HER2- OR HER2+ OR triple-negative breast cancer , assessed as ER-, PgR-, and 
HER2-negative by local laboratory testing; HER2 neg ative status (based on most recently 
analyzed biopsy) is defined as IHC status of 0, 1+ or 2+ (if IHC 2+, a negative FISH test is 
required, i.e.,  HER2 FISH ratio < 2.0 with an aver age HER2 copy number <4.0 signals/cell);  
ER-negative and PR-negative status is defined as ER  and PgR <1% nuclei positive by IHC 
(per ASCO guidelines). HER2-positive status is defi ned as 3+ staining in ≥10% of cells  by 
immunohistochemistry or a HER2/CEP17 ratio ≥2 or an average of ≥6 HER2 gene copies per 
cell by in situ hybridization (ISH) according to th e 2013 ASCO/CAP guidelines 
5. At least one CNS lesion that is at least 5mm in siz e in at least one dimension in the setting of 
prior WBRT or SRS or both: 
• Prior WBRT or SRS or both is required and may have been administered at any time in 
patient’s treatment history.  Patients must have co mpleted WBRT at least 3 weeks prior 
to study entry and a minimum of a 5 days window is required following SRS before 
beginning study therapy.  
• The target lesion that is at least 5mm in size must  not have undergone treatment with SRS 
and may represent residual disease following SRS or  WBRT, or may represent 
progression of disease following SRS or WBRT or bot h. 
6. ECOG performance status £ 2   
7. Adequate bone marrow function as shown by: ANC ≥ 1.5 x 10 9/L, Platelets ≥ 100 x 
10 9/L, Hb >9 g/dL  
8. Total calcium (corrected for serum albumin) within normal limits (biphosphonate use 
for malignant hypercalcemia control is not allowed)  
9. Magnesium ≥ the lower limit of normal  
10. Potassium within normal limits for the institution 
11. Alanine aminotransferase (ALT) and aspartate aminot ransferase (AST) within normal 
range (or ≤  3.0 x upper limit of normal (ULN) if liver metast ases are present) 
12. Serum bilirubin within normal range (or ≤  1.5 x ULN if liver metastases are present; or 
total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal rang e in patients with  
known Gilbert Syndrome) 
13. Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 mL/min 
14. Serum amylase ≤ ULN 
15. Serum lipase ≤ ULN 
16. Fasting plasma glucose ≤ 120 mg/dL (6.7 mmol/L) 
17. Negative serum pregnancy test within 72 hours befor e starting study treatment in 
women with childbearing potential 
18. INR ≤ 2 
19. Life expectancy > 12 weeks 
20. Available tissue (blocks and/or slides) samples unl ess discussed in advance with study 
principal investigator 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
48 
 21. Patient is able to swallow and retain oral medicati on 
22. Signed most recent patient informed consent form 
23. Signed Patient HIPAA Authorization Form  
Exclusion criteria   
Patients eligible for enrollment into the treatment  phase of this study must not meet any  of 
the following criteria: 
1. Patient received prior treatment with a PI3K inhibi tor.  
2. Patient with known hypersensitivity to buparlisib, capecitabine, or their excipients. 
3. Patient has evidence of impending herniation on bas eline brain imaging. 
4. Patient has evidence of diffuse leptomeningeal dise ase on brain MRI or by previously 
documented CSF. 
5. Patients has acute or chronic liver, renal disease or pancreatitis (liver metastases are 
allowed) 
6. Patients has a mood disorder as judged by the Inves tigator or a psychiatrist, or as a 
result of patient’s mood assessment questionnaire ( PHQ-9 and/or GAD-7):  
• Medically documented history of or active major dep ressive episode, bipolar 
disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of 
suicidal attempt or ideation, or homicidal ideation  (immediate risk of doing 
harm to others) or patients with active severe pers onality disorders (defined 
according to DSM- IV) are not eligible .  Note: for patients with psychotropic 
treatments ongoing at baseline, the dose and the sc hedule should not be 
modified within the previous 6 weeks prior to start  of study drug.  
•  ≥ CTCAE grade 3 anxiety  
• Meets the cut-off score of ≥ 12 in the PHQ-9 or a cut-off of ≥ 15 in the GAD-7 
mood scale, respectively, or selects a positive res ponse of “1, 2, or 3” to 
question number 9 regarding potential for suicidal thoughts in the PHQ-9 
(independent of the total score of the PHQ-9)  
7. Patients has diarrhea ≥ CTCAE grade 2 
8. Patients with uncontrolled hypertension defined as systolic blood pressure 170 or 
greater or diastolic blood pressure over 100. 
9. Patient has active cardiac disease including any of  the following:  
• Left ventricular ejection fraction (LVEF) < 50% as determined by Multiple 
Gated acquisition (MUGA) scan or echocardiogram (EC HO)  
• QTc > 480 msec on screening ECG (using the QTcF for mula) 
• Angina pectoris that requires the use of anti-angin al medication 
• Ventricular arrhythmias except for benign premature  ventricular contractions 
• Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled 
with medication 
• Conduction abnormality requiring a pacemaker 
• Valvular disease with document compromise in cardia c function  
• Symptomatic pericarditis 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
49 
 10. Patient has a history of cardiac dysfunction includ ing any of the following: 
• Myocardial infarction within the last 6 months, doc umented by persistent 
elevated cardiac enzymes or persistent regional wal l abnormalities on 
assessment of LVEF function 
• History of documented congestive heart failure (New  York Heart Association 
functional classification III-IV) 
• Documented cardiomyopathy 
11. Patient has poorly controlled  diabetes mellitus or  steroid-induced diabetes mellitus 
12. Patient has other concurrent severe and/or uncontro lled concomitant medical conditions 
(e.g., active or uncontrolled infection) that could  cause unacceptable safety risks or 
compromise compliance with the protocol 
• Significant symptomatic deterioration of lung funct ion.  If clinically indicated, 
pulmonary function tests including measures of pred icted lung volumes, DLco, 
O2 saturation at rest on room air should be conside red to exclude pneumonitis 
or pulmonary infiltrates.  
13. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter 
the absorption of buparlisib (e.g., ulcerative dise ases, uncontrolled nausea, vomiting, 
diarrhea, malabsorption syndrome, or small bowel re section). Patients with unresolved 
diarrhea will be excluded as previously indicated 
14. Patient was treated with any hematopoietic colony-s timulating growth factors (e.g., G-
CSF, GM-CSF) ≤ 2 weeks prior to starting study drug. Erythropoiet in or darbepoetin 
therapy, if initiated at least 2 weeks prior to enr ollment, may be continued 
15. Patient is currently receiving treatment with medic ation with a known risk to prolong 
the QT interval or inducing Torsades de Pointes and  the treatment cannot either be 
discontinued or switched to a different medication prior to starting study drug.  Please 
refer to Table 3-2 or a list of prohibited QT prolo nging drugs with risk of Torsades de 
Pointes.   
16. Patients receiving chronic treatment with steroids or another immunosuppressive agent. 
Patients must have been off all corticosteroids (ex cept for physiologic doses of 
hydrocortisone as replacement therapy) for at least  2 weeks prior to study entry. 
• Note: Single doses, or topical applications (e.g. rash), inhaled sprays (e.g. 
obstructive airways diseases), eye drops or local i njections (e.g. intra-articular) are 
allowed.   
17. Patient has taken herbal medications and certain fr uits within 7 days prior to starting 
study drug. Herbal medications include, but are not  limited to St. John’s wort, Kava, 
ephedra (ma huang), gingko biloba, dehydroepiandros terone (DHEA), yohimbe, saw 
palmetto, and ginseng.  Fruits include the CYP3A in hibitors Seville oranges, grapefruit, 
pummelos, or exotic citrus fruits. Regular orange j uice is permitted.  
18. Patient is currently treated with drugs known to be  moderate and strong inhibitors or 
inducers of isoenzyme CYP3A, and the treatment cann ot be discontinued or switched 
to a different medication prior to starting study d rug.  Please refer to Table 4-8 for a list 
of prohibited inhibitors and inducers of CYP3A (Ple ase note that co-treatment with 
weak inhibitors of CYP3A is allowed). 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
50 
 19. Patient received chemotherapy or targeted anticance r therapy ≤ 3  weeks (6 weeks for 
nitrosourea, antibodies or mitomycin-C) prior to st arting study drug, and have related 
side effects must recover to a grade 1 or less befo re starting the trial  
20. Patient received any continuous or intermittent sma ll molecule therapeutics (excluding 
monoclonal antibodies) with ≤ 5 effective half lives prior to starting study dru g or who 
have not recovered from side effects of such therap y 
21. Patient received wide field radiotherapy ≤ 4 weeks or limited field radiation for 
palliation ≤ 2 weeks prior to starting study drug or who have n ot recovered from side 
effects of such therapy 
22. Patient underwent major surgery ≤ 2 weeks prior to starting study drug or who have n ot 
recovered from side effects of such therapy.  
23. Patient is currently taking therapeutic doses of wa rfarin sodium or any other coumadin-
derivative anticoagulant.  
24. Patient is pregnant or breast feeding or is of repr oductive potential and not employing 
an effective method of birth control.  
• Note: Double barrier contraceptives must be used th rough the trial by both sexes. 
Oral, implantable, or injectable contraceptives may  be affected by cytochrome 
P450 interactions, and are therefore not considered  effective for this study. Women 
of child-bearing potential, defined as sexually mat ure women who have not 
undergone a hysterectomy or who have not been natur ally postmenopausal for at 
least 12 consecutive months (i.e., who has had mens es any time in the preceding 12 
consecutive months), must have a negative serum pre gnancy test ≤ 72 hours prior 
to initiating treatment. 
• Note: Women are considered post-menopausal and not of child bearing potential if 
they have had 12 months of natural (spontaneous) am enorrhea with an appropriate 
clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months 
of spontaneous amenorrhea with serum FSH levels > 4 0 mIU/mL [ f o r  U S  o n l y : and 
estradiol < 20 pg/mL] or have had surgical bilatera l oophorectomy (with or without 
hysterectomy) at least six weeks ago. In the case o f oophorectomy alone, only when 
the reproductive status of the woman has been confi rmed by follow up hormone 
level assessment is she considered not of child bea ring potential. 
• Note: Women of child-bearing potential, defined as all women physiologically 
capable of becoming pregnant, must use highly effec tive contraception during 
treatment for 4 weeks (5 T1/2) after stopping treat ment. The highly effective 
contraception is defined as either: 
1. True abstinence: When this is in line with the pref erred and usual lifestyle of 
the subject. Periodic abstinence (e.g., calendar, o vulation, symptothermal, post-
ovulation methods) and withdrawal are not acceptabl e methods of 
contraception. 
2. Sterilization:  have had surgical bilateral oophore ctomy (with or without 
hysterectomy) or tubal ligation at least six weeks ago.  In case of oophorectomy 
alone, only when the reproductive status of the wom an has been confirmed by 
follow up hormone level assessment. 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
51 
 3. Male partner sterilization (with the appropriate po st-vasectomy documentation 
of the absence of sperm in the ejaculate). For fema le subjects on the study, the 
vasectomized male partner should be the sole partne r for that patient. 
4. Use of a combination of any two of the following (a +b): 
a) Placement of an intrauterine device (IUD) or intrau terine system (IUS) 
b) Barrier methods of contraception: Condom or Occlusi ve cap (diaphragm or 
cervical/vault caps) with spermicidal foam/gel/film /cream/vaginal 
suppository 
• Note: Oral contraception, injected or implanted hor monal methods are not 
allowed as buparlisib potentially decreases the eff ectiveness of hormonal 
contraceptives. 
25. Patient has known diagnosis of human immunodeficien cy virus (HIV) infection  
26. Patient has history of another malignancy within 5 years, except cured basal cell 
carcinoma of the skin or excised carcinoma in situ of the cervix 
27. Patient is unable or unwilling to abide by the stud y protocol or cooperate fully with the 
investigator 
28. Patient is concurrently using other approved or inv estigational antineoplastic agent. 
29. Patient taking or needing enzyme-inducing anti-epil eptic medication. 
30. Patients with an acute viral hepatitis or a history  of chronic or active HBV or HCV 
infection  
 
4 Treatments 
4.1  Interruption or Discontinuation of Treatment 
 
For patients who do not tolerate the protocol-speci fied dosing schedule, dose adjustments are 
permitted in order to allow the patient to continue  the study treatment. Any changes in buparlisib 
or capecitabine administration must be recorded on the eCRF. If administration of buparlisib 
must be interrupted because of unacceptable toxicit y, drug dosing will be interrupted or modified 
according to rules described in Table 4-0 and Table  4-1. Toxicity will be assessed using the NIH-
NCI Common Terminology Criteria for Adverse Events,  version 4.0. (CTCAEv4.0), 
(http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-0 6-14_QuickReference_5x7.pdf ). The 
dose of buparlisib does not need to be reduced for toxicities that the physician believes are due to 
capecitabine.  
 
Capecitabine dose modification guidelines are descr ibed in Section 4.1.3. Please refer to the local 
approved prescribing information. Any planned varia nce from these guidelines in the view of 
patient safety must be previously discussed with th e sponsor unless there is an urgent need for 
action. All dose modifications, interruptions or di scontinuations must be based on the worst 
preceding toxicity as graded by the NCI Clinical To xicity Criteria (NCI-CTCAE version 4.03). 
Once a dose has been reduced during a treatment cyc le, re-escalation will not be permitted 
during any subsequent cycle. The dose of capecitabi ne does not need to be reduced for toxicities 
that the physician believes are due to buparlisib.  
 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
52 
 Trastuzumab dose modifications will be per physicia n’s discretion and standard of care..  
 
If the administration of buparlisib or capecitabine  is interrupted for reasons other than toxicity, 
then treatment with the respective study drug may b e resumed at the same dose. The same 
applies if the patient experiences an unacceptable toxicity not specifically described, provided 
this toxicity resolved to ≤ CTCAE grade 1, unless otherwise specified. 
 
If one or both study drugs are being withheld due t o toxicity, scheduled visits and all assessments 
should continue to be performed (with the exception  of the dosing of the held study drug), as 
described in Table 4-12. If administration of bupar lisib or capecitabine dosing is held for more 
than 21 days, then this withheld study drug should be permanently discontinued. Patients who 
permanently discontinue one of the withheld study d rugs for any reason other than disease 
progression may continue the other study drug as pa rt of the trial therapy at the investigator’s 
discretion. 
 
Table 4-0   Buparlisib dose level modification guid elines 
Dose level Dose and schedule 
* 0 100 mg daily   
-1 80 mg daily 
-2 60 mg daily 
* Starting Dose  
 
 
  
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
53 
 Table 4-1 Criteria for interruption and re-initiati on of Buparlisib treatment 
Recommended Dose Modifications for Buparlisib  
Worst toxicity (CTCAE 
Grade)** Recommended Dose Modifications 
No toxicity Maintain dose level 
HEMATOLOGICAL 
Neutropenia (ANC) 
Grade 1 (ANC < LLN - 1.5 x 
10 9/L) 
Grade 2 (ANC < 1.5 - 1.0 x 
10 9/L) Maintain dose level 
Grade 3 (ANC < 1.0 - 0.5 x 
10 9/L) 
Grade 4 (ANC < 0.5 x 10 9/L) Omit dose until resolved to ≤ Grade 1, then: 
• If resolved in ≤ 7 days, then maintain dose level 
• If resolved in > 7 days, then  1 dose level 
Febrile neutropenia  
(ANC < 1.0 x 10 9/L, fever ≥ 
38.5°C) Omit dose until resolved, then  1 dose level 
Thrombocytopenia  
Grade 1 (PLT < LLN - 75 x 
10 9/L) 
Grade 2 (PLT < 75 - 50 x 10 9/L) Maintain dose level 
Grade 3 (PLT < 50-25 x 10 9/L) Omit dose until resolved to ≤ Grade 1, then: 
• If resolved in ≤ 7 days, then maintain dose level 
• If resolved in > 7 days, then  1 dose level 
Grade 4 (PLT < 25 x 10 9/L) Omit dose until resolved to ≤ Grade 1, then  1 dose 
level 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
54 
 Recommended Dose Modifications for Buparlisib  
Worst toxicity (CTCAE 
Grade)** Recommended Dose Modifications 
HEPATIC 
Bilirubin 
(*for patients with Gilbert 
Syndrome these dose 
modifications apply to changes in 
direct bilirubin only) 
 Will be fractionated if elevated 
Grade 1 (> ULN - 1.5 x ULN) Maintain dose level wit h LFTs* monitored as per 
protocol 
Grade 2 (> 1.5 - 3.0 x ULN) with 
ALT or AST ≤ 3.0 x ULN Omit dose until resolved to ≤ Grade 1, then: 
• If resolved in ≤ 7 days, then maintain dose level 
• If resolved in > 7 days, then  1 dose level 
Grade 3 (> 3.0 - 10.0 x ULN) with 
ALT or AST ≤ 3.0 x ULN Omit dose until resolved to ≤ Grade 1, then: 
• If resolved in ≤ 7 days,  1 dose level 
• If resolved in > 7 days discontinue patient from study 
treatment 
Grade 4 (> 10.0 x ULN) Omit dose and discontinue pa tient from study treatment 
AST or ALT 
Grade 1 (> ULN - 3.0 x ULN) 
 Maintain dose level with LFTs* monitored as per 
protocol 
Grade 2 (> 3.0 - 5.0 x ULN) 
without bilirubin elevation to > 2.0 
x ULN Omit dose until resolved to ≤ grade 1, then 
• If resolved in ≤ 7 days, then maintain dose level 
• If resolved in > 7 days, then ↓ 1 dose level 
Grade 3 (> 5.0 - 20.0 x ULN) 
without bilirubin elevation to > 2.0 
x ULN Omit dose until resolved to ≤ Grade 1 then: 
• If resolved in ≤ 7 days, then maintain dose level 
• If resolved in > 7 days, then  1 dose level 
Grade 4 (> 20.0 x ULN) without 
bilirubin elevation to > 2.0 x ULN Omit dose until resolved to ≤ Grade 1 , then  1 dose 
level 
AST or ALT and concurrent 
Bilirubin  
AST or ALT > 3.0 x ULN and 
total bilirubin > 2.0 x ULN Discontinue study treatment permanently. 
* LFTs include albumin, ALT, AST, total bilirubin ( fractionated if total bilirubin > 2.0 x 
ULN), alkaline phosphatase (fractionated if alkalin e phosphatase is grade 2 or higher) and 
GGT. 
 
Monitoring  (*for patients with Gilbert Syndrome: total and di rect bilirubin must be 
monitored, intensified monitoring applies to change s in direct bilirubin only; the monitoring 
includes the following LFTs: albumin, ALT, AST, tot al bilirubin (fractionated if total 
bilirubin > 2.0 x ULN), alkaline phosphatase (fract ionated if alkaline phosphatase is grade 2 
or higher) and GGT. 
  
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
55 
 Recommended Dose Modifications for Buparlisib 
Worst toxicity (CTCAE 
Grade)** Recommended Dose Modifications 
ENDOCRINE/METABOLIC 
Fasting Plasma Glucose (FPG) 
Grade 1 (> ULN - 160 mg/dL) [> 
ULN - 8.9 mmol/L] Maintain dose level, check FPG every week 
• initiate or intensify medication with appropriate a nti-
diabetic treatment. as per investigator’s discretio n 
• instruct patient to follow dietary guidelines accor ding 
to local and/or institutional standards for managem ent 
of diabetes mellitus (such as those provided by the  
American Diabetes Association) during the study 
• Consider use of oral anti-hyperglycemic therapy suc h 
as metformin (or intensify existing medications) 
• check FPG at least weekly for 8 weeks, then continu e 
checking every at least 2 weeks 
Grade 2 (>160 – 250 mg/dL) [> 
8.9 - 13.9 mmol/L] • If signs or symptoms of hyperglycemia (for example,  
mental status changes, excessive thirst, polyuria) 
manage as for Grade 3 hyperglycemia (see below). 
• If asymptomatic, maintain dose and re-check FPG 
within 24 hours. If grade worsens or improves then 
follow specific grade recommendations. If FPG 
remains at Grade 2:  
• maintain dose level and monitor FPG at least 
weekly until FPG resolves to ≤ Grade 1 
• initiate or intensify medication with appropriate 
anti-diabetic treatment such as metformin; 
consider adding a second oral agent if no 
improvement after several days 
• instruct patient to follow dietary guidelines 
according to local and/or institutional standards 
for management of diabetes mellitus (such as 
those provided by the American Diabetes 
Association) during the study 
• If FPG does not resolve to ≤ Grade 1 within 14 
days after institution of appropriate anti-diabetic  
treatment reduce  buparlisib by 1 dose level 
Continue with anti-diabetic treatment and check FPG  
at least weekly for 8 weeks, then continue checking  at 
least every 2 weeks  
Grade 3 (> 250 - 500 mg/dL) [> 
13.9 - 27.8 mmol/L] • Omit buparlisib, initiate or intensify medication w ith 
appropriate anti-diabetic treatment, re-check FPG 
within 24 hours.  If grade worsens or improves then  
follow specific grade recommendations.  If FPG 
remains at Grade 3: 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
56 
 Recommended Dose Modifications for Buparlisib 
Worst toxicity (CTCAE 
Grade)** Recommended Dose Modifications 
• administer intravenous hydration and intervention 
for electrolyte/ketoacidosis/hyperosmolar 
disturbances as clinically appropriate 
• continue to omit buparlisib 
• monitor FPG at least twice weekly until FPG 
resolves to ≤ Grade 1  
• If FPG resolves to ≤ Grade 1 in 7 days or less, 
then re-start buparlisib and reduce 1 dose level 
• If FPG remains greater than Grade 1 severity for 
more than 7 days, then discontinue patient from 
buparlisib 
• initiate or continue anti-diabetic treatment as 
appropriate 
• instruct patient to follow dietary guidelines 
according to local and/or institutional standards 
for management of diabetes mellitus (such as 
those provided by the American Diabetes 
Association) during the study 
• consider use of oral anti-hyperglycemic therapy 
such as metformin 
• check FPG at least weekly for 8 weeks, then 
continue checking at least every 2 weeks 
For non-fasting plasma glucose >250-500 mg/dL (> 13 .9 
- 27.8 mmol/L) accompanied by signs/symptoms of 
hyperglycemia (for example, mental status changes, 
excessive thirst, polyuria), or presence of blood o r urine 
ketones, omit buparlisib and following guidance for  
management of Grade 3 fasting plasma glucose (FPG) 
Grade 4 (> 500 mg/dL) [ ≥ 27.8 
mmol/L] • Immediately omit buparlisib, initiate or intensify 
medication with appropriate anti-diabetic treatment , 
re-check within 24 hours.  If grade improves then 
follow specific grade recommendations.  If FPG is 
confirmed at Grade 4: 
• administer intravenous hydration and intervention 
for electrolyte/ketoacidosis/hyperosmolar 
disturbances as clinically appropriate 
• discontinue patient from buparlisib 
• instruct patient to follow dietary guidelines 
according to local and/or institutional standards 
for management of diabetes mellitus (such as 
those provided by the American Diabetes 
Association) during the study 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
57 
 Recommended Dose Modifications for Buparlisib 
Worst toxicity (CTCAE 
Grade)** Recommended Dose Modifications 
• consider use of oral anti-hyperglycemic therapy 
such as metformin 
• check FPG at least weekly for 8 weeks, then 
continue checking at least every 2 weeks if 
clinically indicated 
For non-fasting plasma glucose >500 mg/dL (> 27.8 
mmol/L) accompanied by signs/symptoms of 
hyperglycemia (for example, mental status changes, 
excessive thirst, polyuria), or presence of blood o r urine 
ketones, discontinue buparlisib and following guida nce 
for management of Grade 4 fasting plasma glucose 
(FPG). 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
58 
 Recommended Dose Modifications for Buparlisib 
Worst toxicity (CTCAE 
Grade)** Recommended Dose Modifications 
CARDIAC 
Cardiac – Left Ventricular 
systolic dysfunction  
Asymptomatic,  
resting ejection fraction 50 – 
40%; 
or 10-20% drop from baseline Maintain dose level 
 
 
Repeat LVEF within 4 weeks or as clinically appropr iate 
Symptomatic,  
responsive to intervention,  
ejection fraction 39 – 20% 
or > 20% drop from baseline • Omit dose until resolved to ≤ Grade 1, then  1 dose 
level 
• LVEF measurement to be repeated, if not resolved to  
≤ Grade 1 within 3 weeks, permanently discontinue 
patient from buparlisib 
Refractory or poorly controlled,  
ejection fraction < 20% Omit dose and discontinue patient from buparlisib 
Cardiac – QTc prolongation  
QTcF > 500 ms ( ≥ Grade 3)  
or > 60 ms change from baseline 
on at least two separate ECGs First Occurrence: 
• omit buparlisib  
• Perform an analysis of serum potassium and 
magnesium, and if below lower limit of normal, 
correct with supplements to within normal limits. 
Concomitant medication usage must be reviewed. 
• Perform a repeat ECG within one hour of the first 
QTcF of > 500 ms 
• If QTcF remains > 500 ms, repeat ECG as clinically 
indicated, but at least once a day until the QTcF 
returns to < 480 ms. 
• Once QTcF prolongation has resolved, buparlisib 
may be restarted at a one lower dose level  
Second Occurrence: 
• discontinue patient from buparlisib 
 
Other Cardiac Events  
Grade 1 or 2 Maintain dose level 
Grade 3 Omit dose until resolved to ≤ Grade 1, then  1 dose 
level 
Grade 4 Omit dose and discontinue patient from bupa rlisib 
  
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
59 
 Recommended Dose Modifications for Buparlisib 
Worst toxicity (CTCAE 
Grade)** Recommended Dose Modifications 
OTHER 
Fatigue (asthenia)  
Grade 1 or 2 Maintain dose level 
Grade 3 Omit dose until resolved to ≤ Grade 1, then: 
• If resolved in ≤ 7 days, maintain dose level 
• If resolved in > 7 days,  1 dose level 
Grade 4 Omit dose and discontinue patient from bupa rlisib 
Other non-hematological 
adverse events  
Grade 1 or 2 Maintain dose level 
Grade 3 Omit dose until resolved to ≤ Grade 1, then  1 dose 
level 
Grade 4 Omit dose and discontinue patient from stud y 
Note: Omit dose for ≥ Grade 3 vomiting or Grade 3 
nausea only if the vomiting or nausea cannot be 
controlled with optimal antiemetic 
Pneumonitis See Table 4.6 
** Common Terminology Criteria for Adverse Events ( CTCAE) version 4.0. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
60 
 Mood alteration/Psychiatric Disorders 
* Note: For all grades, if question 9 on the PHQ-9 has a positive response (as indicated by selecting "1", "2", 
or "3"), omit study drug and refer patient for psyc hiatric consult regardless of the total questionnai re score 
or CTCAE grading to confirm if study drug should be  interrupted or permanently discontinued. 
Grade 1* ● Maintain dose level 
● Consider psychiatric consultation at the 
investigator’s discretion and introduce optimal 
management except in presence of suicidal ideation 
where dose must be interrupted and psychiatric 
consultation is required to provide optimal 
management (e.g. as per local guidelines and/or 
psychiatric/expert consultation) 
Grade 2* ● Omit dose until resolved to ≤ Grade 1 or baseline 
status 
● Consider psychiatric consultation at the 
investigator’s discretion and introduce optimal 
management except in presence of suicidal ideation 
where dose must be interrupted and psychiatric 
consultation is required to provide optimal 
management (e.g. as per local guidelines and/or 
psychiatric/expert consultation) 
 
● First event:  if the condition resolved to Grade ≤ 1 or 
to baseline status, continue to co-medicate and the n 
maintain the dose level  
● Second and further events:  if the condition resol ved 
to Grade ≤ 1 or to baseline status, continue to co-
medicate and then ↓ 1 dose level 
Grade 3* Omit dose until resolved to ≤ Grade 1 or baseline 
status 
● Psychiatric consultation is required and introduce  
optimal management  
● if the condition resolved to Grade ≤1 or to baseline 
status, continue to co-medicate and then  1 dose level 
Grade 4* Permanently discontinue patient from bupar lisib 
● Psychiatric consultation is required  
● Introduce optimal management (e.g. as per local 
guidelines) 
 
  
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
61 
  
Skin toxicity 
Rash (maculo-papular) 
Grade 1 
(<10% body surface area BSA; 
no associated erythema or 
pruritus) Maintain dose level. Consider to initiate appropria te 
skin toxicity therapy, e.g. with topical corticoste roids 
b.i.d. and oral antihistamines 
Grade 1 Maintain dose level. Consider to initiate a ppropriate 
skin toxicity therapy with antihistamines and topic al 
corticosteroids 
Grade 2 
(10 to 30% BSA and associated 
with erythema or pruritus; 
limited instrumental activities of 
daily living (ADL)) Tolerable Grade 2: 
• Initiate/intensify appropriate skin toxicity therap y, 
e.g. with topical steroids b.i.d. and oral 
antihistamines. 
• Maintain dose level. 
Intolerable Grade 2: 
• Omit dose and initiate/intensify appropriate skin 
toxicity therapy, e.g. with topical steroids b.i.d. , 
oral antihistamines and oral steroids. 
• First occurrence: 
• If resolved to grade ≤ 1 in ≤ 2 weeks, maintain 
dose level. 
• If resolved grade ≤ 1 in more than 2 weeks, ↓ 1 
dose level. 
• Consider continuing skin toxicity therapy up to 2 
weeks after re-introduction of BKM120/placebo. In 
case of flare after cessation of skin toxicity ther apy, 
consider prompt re-implementation. 
Second occurrence: omit dose and follow treatment 
guidance above, 
• Once resolved to grade ≤ 1,  1 dose level 
Grade 3 
(Macules or papules covering 
>30%BSA with or without 
symptoms) • Omit dose and initiate/intensify appropriate skin 
toxicity therapy, e.g. with topical steroids b.i.d. , 
oral antihistamines and oral steroids. 
• Once resolved to grade ≤ 1,  1 dose level. 
• Consider continuing skin toxicity therapy up to 2 
weeks after re-introduction of BKM120/placebo. In 
case of flare after cessation of skin toxicity ther apy, 
consider prompt re-implementation 
Grade 4 
(including other skin toxicity 
than maculo-papular rash) Permanently discontinue patient from 
BKM120/placebo 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
62 
 Acneiform rash 
Grade 1 
(<10% body surface area BSA; 
no associated erythema or 
pruritus) Maintain dose level. Consider to initiate appropria te 
treatment, e.g. with topical steroids (moderate pot ency) 
and topical antibiotics b.i.d. 
Grade 2 
(10 to 30% BSA and associated 
with erythema or pruritus; 
limited instrumental activities of 
daily living (ADL)) Tolerable Grade 2: 
• Same management as Grade 1. 
Intolerable Grade 2: 
• Omit dose and initiate/intensify appropriate skin 
toxicity therapy, e.g. with oral antibiotics for 6 
weeks; stop topical antibiotics if being used and 
start with topical steroids of moderate potency. 
• If resolved to grade ≤ 1 in ≤ 2 weeks, maintain 
dose level. 
• If resolved grade ≤ 1 in more than 2 weeks, ↓ 1 
dose level. 
Second occurrence: omit dose and follow treatment 
guidance above 
• Once resolved to grade ≤ 1,  1 dose level 
Grade 3 
(>30% BSA And associated with 
pruritus; limiting self ADL) • Omit dose and initiate/intensify appropriate skin 
toxicity therapy, e.g. with oral antibiotics for 6 
weeks potency. 
• If infection suspected (yellow crusts, purulent 
discharge, painful skin / nares) then switch to 
broad spectrum/gram negative antibiotics; 
consider skin swab for bacterial culture; add 
topical steroid of moderate. 
• Once resolved to grade ≤ 1,  1 dose level. 
Grade 4 
(Papules and/or pustules covering 
any % BSA, associated with 
symptoms or not but associated 
with extensive superinfection) Permanently discontinue patient from 
BKM120/placebo 
Fatigue (asthenia) 
Grade 1 or 2 Maintain dose level 
Grade 3 Omit dose until resolved to ≤ Grade 1, then: 
● If resolved in ≤ 7 days, maintain dose level 
● If resolved in > 7 days,  1 dose level 
Pneumonitis  please see section for additional foll ow up for selected 
toxicities 
Other non- hematological adverse events 
Delta Clinical Research, LLC  Study No. 11-025/CBKM 120ZUS39T  
BKM120 for MBC with Brain Metastases  [24JUN2016] 
 
63 
 Grade 1 or 2 Maintain dose level 
Grade 3 Omit dose until resolved to ≤ Grade 1, then  1 dose 
level 
Grade 4 Permanently discontinue patient from buparl isib 
N o t e :  Omit dose for ≥ Grade 3 vomiting or Grade 3 
nausea only if the vomiting or nausea cannot be 
controlled with optimal antiemetic 
 
Stomatitis/Oral mucositis 
Grade 1 / Tolerable Grade 2 Maintain dose level. 
Non-alcoholic or salt water mouth wash (see also 
section for additional follow up for selected toxic ities) 
Intolerable Grade 2 or Grade 3 First occurrence: ho ld until resolved to grade ≤ G1 and 
 1 dose level (if stomatitis is readily manageable with 
optimal management, re-introduction at the same lev el 
might be considered at the discretion of the 
investigator).  
Second occurrence: hold until resolved to grade ≤ G1 
and  1 dose level. 
Grade 4 Permanently discontinue patient from buparl isib. 
** Common Terminology Criteria for Adverse Events ( CTCAE) version 4.03. 
These changes must be recorded on the Dosage Admini stration section of the patient record. 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases   [10JUN2016] 
 
64 
 4.1.1.3  Monitoring of buparlisib suspected toxicities   
Patients whose treatment is interrupted or permanen tly discontinued due to an adverse event 
or clinically significant laboratory value, must be  followed as outlined in Table 3-1, at least 
once a week for 4 weeks, and subsequently at 4-week  intervals, until resolution or 
stabilization of the event, whichever comes first. If a patient requires a dose delay of > 21 
days from the intended day of the next scheduled do se, then the patient should be 
discontinued from the study. If the patient require s more than 2 dose reductions, the patient 
should be discontinued from the study (i.e., patien ts cannot be treated below dose level -2). 
All patients must be followed for adverse events an d serious adverse events for 30 days 
following the last dose of buparlisib. All SAEs mus t be reported to Delta as detailed in 
Section 4.3.7. 
 
4.1.2  Known Undesirable Side Effects of Buparlisib 
4.1.2.3  Neuropsychiatric events  
 
In an ongoing Phase Ia study of buparlisib in patie nts with solid tumors (CBKM120X2101), 
neuro-psychiatric adverse events, including reversi ble and generally mild to moderate mood 
alterations, described as anxiety, agitation with c rying episodes and depression have been 
reported in patients treated with buparlisib. (Bupa rlisib Investigators Brochure) In this study, 
three out of five patients with moderate to severe mood alterations had a history of depression 
and/or anxiety. All patients with a documented medi cal history of depression/anxiety also 
developed mood alterations while treated with bupar lisib at the 100 mg dose level, thus 
reflecting a potential risk group of patients.  
 
In order to lower the risk of experiencing signific ant mood alterations within the proposed 
study, cancer patients with an active or history of  major depressive episode, bipolar disorder, 
obsessive-compulsive disorder, schizophrenia, a his tory of suicide attempt or ideation, or 
homicide/homicidal ideation as judged by the invest igator and/or based on recent psychiatric 
assessment will not qualify for study participation . Patients with corresponding symptoms 
CTCAE Grade ≥ 2 should immediately be examined by a psychiatrist  and closely followed 
medically. Medical treatment with mood stabilizers (2nd generation antipsychotics) such as 
olanzapine and quetiapine may be applied as per inv estigator’s discretion and following 
consultation with a psychiatrist.  
4.1.2.3.1  Management of mood alteration 
Patient self-rating mood questionnaires PHQ-9 (depr ession) and GAD-7 (anxiety) will be 
administered by the study nurse or CRC and will be used: 
• to support assessment of eligibility at Screening 
• to monitor for newly occurring or worsening mood al terations during the study. 
 
The following grading system will be used for this study (Table 4-2): 
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases   [10JUN2016] 
 
65 
 Table 4-2 Toxicity grading based on mood questionna ire scores 
PHQ-9 GAD-7 
Score Severity CTCAE 
grading Score Severity CTCAE 
grading 
0-4 None Normal 0-4 None Normal  
5-9 Mild Grade 1 5-9 Mild  Grade 1 
10-19 Moderate Grade 2 10-14 Moderate Grade 2 
20-27 Severe Grade 3 ≥ 15 Severe Grade 3 
 
At Screening, a patient as judged by the investigat or or who meets the cut-off score of ≥ 12 in 
the PHQ-9 or a cut-off of ≥ 15 in the GAD-7 mood scale, respectively, or who s elects a 
positive response of ‘1, 2, or 3’ to question numbe r 9 regarding suicidal thoughts or ideation 
will be excluded from the study.  
 
During the study, patients who meet the cut-off sco re of ≥ 10 ( ≥ CTCAE grade 2 mood 
alteration) in either questionnaire or who indicate  a positive response by selecting ‘1, 2, or 3’ 
to question number 9 on the PHQ-9 (Table 4-4) must see a psychiatrist for diagnosis and 
determination of most appropriate medical treatment . For anxiety, this applies only if status 
has worsened from baseline. Patients who experience  ≥ grade 2 mood alteration will be 
followed twice weekly by the patient self-rating mo od scale and will be seen weekly by the 
psychiatrist until resolved ≤ grade 1 or baseline (for anxiety). Questionnaire r esponses will be 
checked at weekly visits until resolution to Grade 1 or baseline (for anxiety).  
 
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases   [10JUN2016] 
 
66 
 Table 4-3 GAD-7 anxiety scale  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases   [10JUN2016] 
 
67 
  
Table 4-4 PHQ-9 depression scale  
 
4.1.2.4  Hyperglycemia 
In preclinical studies, insulin/glucose homeostasis  was impacted in various species (mice, rats, 
dogs), as expected from the mode of action of bupar lisib (Buparlisib Investigators Brochure). 
In both rats and dogs, at the doses used in the 4-w eek studies, these effects were minimal. 
However, in mice treated at high doses (30 or 60 mg /kg/day) a clear induction of insulin 
resistance/insensitivity was observed, without clea r influence of the dose or the time point of 
testing. Histopathologic changes were seen in anima l pancreas and liver samples which are in 
concordance with this activity.  
Grade 4 Hyperglycemia was also observed in an ongoi ng Phase Ia study of buparlisib in 
patients with solid tumors (CBKM120X2101). Therefor e, no patients with uncontrolled 
diabetes mellitus will be enrolled in this study. I n all patients, fasting plasma glucose will 
obtained at screening and will be monitored through out the trial. For the treatment of glucose 
disturbances occurring under buparlisib treatment i nvestigators are advised to adhere to the 
protocol guidelines outlined in Table 4-1. 
4.1.2.4.1  Management of Hyperglycemia 
In addition to the dose modification and hyperglyce mia treatment guidelines in Table 4-1: 

Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases   [10JUN2016] 
 
68 
 • Under the supervision of an endocrinologist, an ins ulin regimen should be initiated 
according to institutional standard of care or the Treat-To-Target Algorithm for 
Lantus®(Riddle, Rosenstock, and Gerich 2003).   
• For any hyperglycemia ≥ grade 1, the patient should continue to follow die tary 
guidelines provided by the American Diabetes Associ ation (American Diabetes 
Association 2004). 
• For each patient, a maximum of 2 dose reductions wi ll be allowed after which the 
patient should be discontinued from the study. In a ddition, a patient must discontinue 
treatment with buparlisib, if after treatment is re sumed at a lower dose, hyperglycemia 
recurs at a worse severity. 
• For each patient, once a dose level reduction has o ccurred, the dose level may not be 
re-escalated in that patient during future treatmen t cycles with buparlisib. 
• Based upon the results of preliminary clinical data  and actual laboratory values (e.g., 
glucose, insulin) generated, the treatment recommen dations for study drug induced 
hyperglycemia may be modified as needed.  
 
4.1.2.5  Cardiac events 
Cardiac safety studies, conducted in vitro and in v ivo, did not indicate a prominent 
electrophysiological risk. The only effect consider ed relevant was a trend towards an increase 
in systolic and diastolic blood pressure, observed in two dog telemetry studies. As a 
precaution in the first-in-man study with buparlisi b no patients with a severe or unstable 
cardiac disease or cardiac disease requiring contin uous treatment, and no patients with 
uncontrolled hypertension will be enrolled in early  clinical studies. In addition, HER2 positive 
patients will be assessed for cardiac diseases befo re start of treatment, while HER2 positive 
patients enrolled in the trial will undergo regular  cardiac monitoring throughout the conduct 
of the trial. For the treatment of acute cardiac ev ents occurring under buparlisib treatment 
investigators are advised to adhere to the protocol  guidelines. Vital signs, including pulse rate 
and blood pressure, will be closely followed during  the early clinical studies. 
4.1.2.5.1  Management of Cardiac events  
At the screening visit a 12-lead electrocardiogram (ECG), will be performed to assess 
eligibility. Repeat ECGs will be performed at scree ning and as clinically indicated.  
At the screening visit an echocardiogram or MUGA (E CHO/MUGA) for HER2 positive 
patients only will be performed to assess eligibili ty. Cardiac imaging will be repeated at 4 
months and then every 4 months thereafter for HER2 positive patients only.  End of 
Treatment ECHO/MUGA not required.  There is window of +/- 7 business days for an 
ECHO/MUGA.  Any delay within this window is NOT a d eviation as per the visit schedule 
(Table 4-12). 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases   [10JUN2016] 
 
69 
 4.1.2.5.2  Management of Pneumonitis  
Pneumonitis is a known side effect of rapamycin ana logues. Based on the literature, the class 
of PI3K inhibitors has not previously been associat ed with the development of Pneumonitis. 
Clinically significant Pneumonitis is typically acc ompanied by non-specific symptoms 
including dyspnea, nonproductive cough, fatigue, an d fever. Diagnosis is generally suspected 
in individuals who develop these symptoms or in asy mptomatic individuals in whom a routine 
chest CT scan reveals a new ground glass or alveola r infiltrate.  
 
In ongoing clinical trials with buparlisib in the s ingle agent setting two cases of Pneumonitis 
occurred. In the study BKM120X2101 one patient expe rienced Pneumonitis (grade 2) eight 
weeks after the first dose of buparlisib at 100mg w hich resolved in 7 days after antibiotic 
therapy and discontinuation of the study treatment due to fatigue. In the Japanese study 
BKM120X1101 one case of Pneumonitis occurred in a p atient (given 100 mg) one month 
after the start of study medication with buparlisib . The patient experienced Pneumonitis with 
fatal outcome which was concomitant to progression of underlying malignancy including the 
progression of existing and the appearance of new l esions in combination with increasing 
pleural effusion (please see current Buparlisib Inv estigators Brochure for more details). 
 
All patients participating in clinical trials admin istering buparlisib will be routinely asked 
about the occurrence of adverse events which could include new or changed pulmonary 
symptoms (consistent with lung abnormalities). CT s cans and pulmonary function test should 
be done, as clinically indicated, or if there are s ymptoms that indicate that the patient has 
developed Pneumonitis. In case of a documented Pneu monitis, the guidelines (including the 
dose modifications) in Table 4-5 should be followed . Consultation with a pulmonologist is 
highly recommended for any Pneumonitis case identif ied during the study. 
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases   [10JUN2016] 
 
70 
 Table 4-5 Management of pneumonitis 
Worst 
Grade 
Pneumonitis  Required Investigations  Management of 
Pneumonitis  Buparlisib  
Dose Adjustment  
Grade 1 CT scans with lung 
windows. Repeat at least 
every 8 weeks until return 
to within normal limits. No specific therapy 
is required Administer 100% of buparlisib 
dose. 
Grade 2 CT scan with lung 
windows. Consider 
pulmonary function testing 
includes: spirometry, DL CO , 
and room air O 2 saturation 
at rest. Repeat at least every 
8 weeks until return to 
within normal limits. 
Consider a bronchoscopy 
with biopsy and / or BAL.  Symptomatic only. 
Consider 
corticosteroids if 
symptoms are 
troublesome. Reduce buparlisib dose by 1 
dose level (see Table 4-0) until 
recovery to < Grade 1. Study 
treatment may also be 
interrupted if symptoms are 
troublesome. Patients will 
discontinue study treatment if 
they fail to recover to <  Grade 1 
within 3 weeks. 
Grade 3 CT scan with lung windows 
and pulmonary function 
testing includes: 
spirometry, DL CO , and 
room air O 2 saturation at 
rest. Repeat at least every 6 
weeks until return to within 
normal limits. 
Bronchoscopy with biopsy 
and / or BAL is 
recommended. Consider 
corticosteroids if 
infective origin is 
ruled out. Taper as 
medically 
indicated. Hold treatment with buparlisib 
until recovery to <  Grade 1. 
May restart study treatment 
within 3 weeks at a reduced 
dose (by one level) if evidence 
of clinical benefit. 
Grade 4 CT scan with lung windows 
and required pulmonary 
function testing, if possible, 
includes: spirometry, DL CO , 
and room air O 2 saturation 
at rest. Repeat at least every 
6 weeks until return to 
within normal limits. 
Bronchoscopy with biopsy 
and / or BAL is 
recommended if possible. Consider 
corticosteroids if 
infective origin is 
ruled out. Taper as 
medically 
indicated. Discontinue treatment with 
buparlisib. 
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases   [10JUN2016] 
 
71 
 4.1.2.5.3  Management of Liver Toxicities  
Monitoring Cycle 1 and 2 : every other week  (if visit schedule allows a more frequent 
monitoring this should be considered) or more frequ ently if clinically indicated especially for 
patients with borderline acceptable AST/ ALT/ bilir ubin values. 
 
Monitoring Cycle 3 and more:  monthly  or more frequently if clinically indicated. In cas e of 
any occurrence of ALT/ AST/ bilirubin increase ≥ grade 2  the liver function tests must be 
monitored weekly  or more frequently if clinically indicated until resolved to ≤ grade 1. 
 
In case of any occurrence of ALT/ AST/ bilirubin in crease ≥ grade 3   the liver function tests 
must be monitored weekly  or more frequently if clinically indicated until resolved to ≤ grade 
1; hereafter the monitoring should be continued every other week  or more frequently if 
clinically indicated until the end of treatment with study medication. 
Patients who discontinued study treatment should be  monitored weekly, including LFTs or 
more frequently if clinically indicated until resolved to ≤ grade 1 or stabilization  (no 
CTCAE grade change over 4 weeks). 
4.1.3  Criteria for capecitabine dose modification 
A capecitabine dose reduction will be administered as described in Table 4-6 . For grade ≥2 
capecitabine-related toxicities (hand/foot syndrome , mucositis, diarrhea), capecitabine 
treatment should be delayed until resolution to gra de 0 or 1, then resumed at the next lower 
dose level. For each patient, a maximum of 2 dose r eductions will be allowed after which the 
patient will be discontinued from treatment with ca pecitabine. The dose of capecitabine does 
not need to be reduced for toxicities that the phys ician believes are due to buparlisib.  Initial 
dosing, as well as delays and/or dose reductions wi ll be recorded on the patient diary and the 
EDC. 
Table 4-6 Dose modification steps for Capecitabine 
Capecitabine dose levels Dose* and schedule 
Starting dose level 1000** mg/m 2 BID days 1-14 of 21 
day cycle 
Dose level -1 750** mg/m 2 BID days 1-14 of 21 day 
cycle  
Dose level -2 750** mg/m 2 mg BID days 1-7 of 14 
day cycle 
* Dose reduction should be based on worst preceding  toxicity 
** Rounded down to nearest 500 mg pill  
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases   [10JUN2016] 
 
72 
 4.1.4  Trastuzumab – Cardiac Monitoring and Cardiomyopathy  Management 
Guidelines 
 
Trastuzumab dose modifications will be per physicia n’s discretion and standard of care. 
Left ventricular ejection fraction (LVEF) should be  assessed prior to initiation of trastuzumab 
and at regular intervals during treatment. Withhold  trastuzumab and capecitabine/buparlisib 
dosing for at least 4 weeks for either of the follo wing: 
 
• ≥ 16% absolute decrease in LVEF from pre-treatment v alues 
• LVEF below institutional limits of normal and ≥ 10% absolute decrease in LVEF from 
pretreatment values. 
 
Trastuzumab plus capecitabine/buparlisib may be res umed if, within 4−8 weeks, the LVEF 
returns to normal limits and the absolute decrease from baseline is ≤ 15%. Permanently 
discontinue trastuzumab and capecitabine/buparlisib  for a persistent (> 8 weeks) LVEF 
decline or for suspension of trastuzumab dosing on more than 3 occasions for 
cardiomyopathy. If trastuzumab is stopped for toxic ity other than cardiac toxicity, 
capecitabine/buparlisib may be continued until PD o r intolerable toxicity. 
 
4.1.5  Reasons off treatment 
Patients will be taken off treatment if any of the following occur: 
1. Disease progression  
2. Intolerable toxicity  
Note: If any patient goes off study treatment due t o any adverse event, regardless 
of grade, the reason for off treatment will be docu mented as an “Adverse event” 
in eDC; the toxicity (regardless of grade) must be documented in the toxicity 
section of eDC with the action code entered that is  appropriate for discontinuation 
of study treatment. 
3. Physician decision. An intercurrent illness, which would in the judgment of the 
Investigator affect assessments of clinical status to a significant degree or require 
discontinuation of study treatment, non protocol th erapy, or non-compliance. 
4. Becomes pregnant 
5. Patient refuses to continue treatment (patient will  continue to be followed for survival) 
6. Normal completion of treatment portion of the proto col 
 
The date of and reason for discontinuation must be noted on the Change of Status page of the 
eCRF. Every effort should be made to complete the a ppropriate assessments. 
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases   [10JUN2016] 
 
73 
 4.1.6  Reasons for taking patients “off study” 
Patients will be considered “off study” if any of t he following occur:  
1. Termination of the study by Delta and/or the Sponso r decision 
2. Withdrawal of consent (patient will not be contacte d and no further information will 
be collected)  
Note: If the patient withdraws consent, then no addition al data will be collected 
without his/her explicit consent; all data collecte d prior to withdrawal of consent may 
be used in the data analysis. The only exception to  the collection of data after 
withdrawal of consent is collection of date of death  and cause of death (if available) 
when the endpoint of the study is mortality. 
3. Lost to follow-up (3 attempts should be documented in the patient’s source document 
before the site considers the patient as LFU.) 
4. Death 
5. Discontinuation of the patient when determined by t he Study Investigator that 
continuation of the patient on study is no longer i n the best medical interest of the 
patient.   
The appropriate information must be completed on th e Change of Status page of the eCRF. 
4.2  Treatments 
4.2.1  Study treatment administration 
Buparlisib 
The study drug buparlisib will be self-administered  (by the patients themselves). The 
investigator will instruct the patient to take the study drug exactly as specified in the protocol. 
Buparlisib will be administered on a continuous onc e daily dosing schedule. Patients should 
be instructed to take the dose of buparlisib daily in the morning, one hour after a light 
breakfast (morning meal) at approximately the same time each day. Buparlisib should be 
taken with an 8 oz glass of water consumed over as short a time as possible. Patients should 
swallow the capsules whole and not chew them.  Pati ents should not crush the capsule. 
Patients should continue to fast for 2 hours after the administration of each buparlisib dose. 
If vomiting occurs during the course of treatment, no re-dosing of the patient is allowed 
before the next scheduled dose.  The occurrence and  frequency of any vomiting during a 
treatment cycle must be noted as an adverse event.   
If the patient forgets to take her/his dose until A FTER 6:00 PM, then the dose should be 
withheld that day and buparlisib should be restarte d the following day.  
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases   [10JUN2016] 
 
74 
 Patients must avoid consumption of St. John’s Wort,  Seville oranges, grapefruit or grapefruit 
juice, grapefruit hybrids, pummelos and exotic citr us fruits from 7 days prior to the first dose 
of study medication and during the entire study tre atment period due to potential CYP3A4 
interaction with the study medication. Patients mus t avoid concomitant intake of strong and 
moderate CYP3A4/5 inhibitors and inducers. See Tabl e 4-8. Orange juice is allowed. 
All dosages prescribed and dispensed to the patient  and all dose changes during the study 
must be recorded. If a patient requires a buparlisi b dose delay of > 21 days from the previous 
dose, the patient must be discontinued from treatme nt completely and will only require a 28 
day follow up visit for study completion. 
Medication labels will comply with US legal require ments and will be printed in English. 
They will supply no information about the patient. The storage conditions for study drug will 
be described on the medication label. 
Capecitabine 
Capecitabine will be supplied according to local pr actice. Capecitabine is commercially 
available as film-coated tablets (500 mg) for oral administration. Capecitabine will be dosed 
1000 mg/m 2 PO BID 14 days on/7 days off (dose rounded down to  nearest 500 mg pill). 
Capecitabine will be stored in accordance with labe led storage conditions at 25°C (77°F), with 
excursions permitted from 15 to 30°C (59 to 86°F) [ controlled room temperature].  
The appropriate number of capecitabine tablets (500  mg) to make up a 14-day course will be 
prescribed to subjects to be self-administered at h ome. Capecitabine will not be supplied on 
this trial but will be obtained by prescription as a standard of care drug.  
Treatment will be administered on an outpatient bas is. Tablets should be taken with water, at 
approximately 12-hour intervals, within 30 minutes after breakfast and dinner. As stated in the 
labeling for Xeloda® (capecitabine), care should be  exercised when capecitabine is 
coadministered with CYP2C9 substrates.  
Full details for capecitabine can be found in its P ackage Insert. 
Trastuzumab 
Patients with HER2+ MBC will receive trastuzumab 6 mg/kg IV every 3 weeks along with 
capecitabine and buparlisib as detailed above.   Pa tients who require a loading disease may 
receive 8 mg/kg IV trastuzumab for their first dose . Trastuzumab dose modifications will be 
per physician’s discretion and standard of care. 
4.2.2  Dosing regimen  
All eligible patients will receive buparlisib 100 m g administered orally once daily on a 
continuous dosing schedule starting on Cycle 1 Day 1 in combination with capecitabine      
1000 mg/m 2 PO BID Days 1-14 of a 21 day cycle.  (Table 4-7)   Patients with HER2+ MBC 
will also receive trastuzumab every 3 weeks.  Patie nts who require a loading disease may 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases   [10JUN2016] 
 
75 
 receive 8mg/kg IV trastuzumab for their first dose.   Patients will then receive trastuzumab 
6mg/kg IV every 3 weeks along with capecitabine and  buparlisib.   
A complete cycle of treatment is defined as 21 days  of once daily continuous treatment of 
buparlisib in combination with capecitabine twice d aily on Days 1-14. 
The suggested timing is for patients to eat a light  breakfast followed by the morning dose of 
capecitabine within 30 minutes. Buparlisib should b e taken 1 hour after the light breakfast, 
after which the patient should fast for 2 hours (wa ter allowed). The evening dose of 
capecitabine should be taken within 30 minutes foll owing dinner. An oral medication diary 
will be provided (Appendix 5). 
 
Table 4-7 Buparlisib and Capecitabine (and Trastuzu mab for HER2+ MBC) Dose and 
treatment schedule 
Study drugs  Pharmaceutical form 
and route of 
administration  Dose b Frequency and/or Regimen  
Buparlisib  Capsules for oral use  100 mg 
(2x 50mg 
capsules a)  Daily  
Capecitabine  Film-coated tablets for 
oral use  1000 
mg/m 2 
BID c  Days 1-14 followed by 7 days 
off  
Trastuzumab  IV 6 mg/kg d Every 3 weeks 
a In case of patient supply difficulties, any combin ation of buparlisib 50 mg or 10 mg capsules may be taken to 
constitute a dose of 100 mg/day (or dose reduction level). 
b Dose reduction levels for buparlisib will be admin istered accordingly. For example, buparlisib 80 mg should 
preferentially be administered as 1x50mg size capsu le, and 3x10 mg size capsule. 
c Capecitabine dose should be rounded down to the ne arest 500 mg pill. 
d  A loading dose of 8 mg/kg of trastuzumab may be a dministered with the first cycle if required. 
 
4.2.3  Concomitant therapy 
All medications taken within 4 weeks prior to the a dministration of buparlisib and all 
concomitant therapy administration during the study  with reasons for therapy should be 
recorded. All prior chemotherapy; biologic, immunol ogic or radiation therapy; and surgery 
within 4 weeks prior to the administration of study  drug, will be recorded.      
Patients on chronic medications that can be given c oncomitantly with buparlisib should be 
maintained on the same dose and dose schedule throu ghout the study period, as medically 
feasible. The investigator should instruct the pati ent to notify the study site about any new 
medications he/she takes after the start of the stu dy drug. All medications (other than study 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases   [10JUN2016] 
 
76 
 drug) and significant non-drug therapies (including  physical therapy and blood transfusions) 
administered after the patient starts treatment wit h study drug, and any changes in dosing 
should be recorded. 
In general, the use of any concomitant medication/t herapies deemed necessary for the care of 
the patient is permitted with the following excepti ons described in Section 4.2.3.1.  
4.2.3.1  Drugs that are prohibited 
• Other investigational therapies must not be used wh ile the patient is on the study. 
• Anticancer therapy (chemotherapy, biologic or radia tion therapy, and surgery) 
other than the study treatments must not be given t o patients while the patient is 
on the study. If such agents are required for a pat ient then the patient must be 
discontinued from the study. 
• In v i t r o  metabolism studies suggest that oxidative metaboli sm of buparlisib is 
predominantly mediated by CYP3A4 (fm>0.9), with onl y minor contributions of 
CYP1A1. As buparlisib is a sensitive CYP3A4 substra te, co-administration of 
buparlisib with any strong and moderate CYP3A4 inhi bitors and CYP3A4 
inducers is prohibited.  Refer to Table 4-8 for a l ist of prohibited drugs.  Please 
note this list may not be comprehensive. 
• Based on in vitro studies, co-administration of bup arlisib with CYP3A4 inducers 
is predicted to decrease the systemic exposure to b uparlisib, thereby increasing 
the risk of exposing the patient to subtherapeutic drug levels.  Refer to Table 4-8 
for a list of prohibited CYP3A inducers.  Please no te that this list may not be 
comprehensive. Therapeutic doses of warfarin sodium (Coumadin®) or  any 
other coumadin-derivative anticoagulants are not pe rmitted. 
• If a patient requires the concomitant use of any me dication included in Table 4-9 
entitled “List of Prohibited QT prolonging drugs” ( i.e., drugs that are generally 
accepted by the Qtdrugs.org Advisory Board of the A rizona CERT to have a risk 
of causing Torsades des de Pointes), study treatmen t administration must be 
interrupted as long as the patient requires therapy  with the QT prolonging agent. 
• Herbal preparations/medications are not allowed thr oughout the study.  These 
herbal medications include, but are not limited to St. John’s wort, Kava, ephedra 
(ma huang), ginko biloba, dehydroepiandrosterone (D HEA), yohimbe, saw 
palmetto, and ginseng.  Patients should stop using these herbal medications 7 
days prior to first dose of study drug. 
• Hormonal contraceptives may be affected by cytochro me P450 interactions, and 
are therefore not considered effective in this stud y. 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases   [10JUN2016] 
 
77 
  
Table 4-8  List of prohibited CYP3A Inhibitors and Inducers  
Strong CYP3A 
inhibitors Moderate CYP3A 
inhibitors Strong CYP3A 
inducers Moderate CYP3A 
inducers 
clarithromycin aprepitant avasimibe bosentan 
conivaptan atazanavir carbamazepine efavirenz 
grapefruit juice cimetidine Phenobarbital 
(barbiturates) etravirine 
indinavir ciprofloxacin phenytoin modafenil 
itraconazole darunavir rifabutin nafcillin 
ketoconazole diltiazem rifampin  ritonavir 
lopinavir erythromycin St. John's Wort  talviraline  
mibefradil fluconazole  tipranavir 
nefazodone tofisopam   
nelfinavir verapamil   
posaconazole amprenavir   
ritonavir fosamprenavir   
saquinavir elvitegravir   
telithromycin tipranavir   
troleandomycin    
voriconazole    
This database of CYP inhibitors was compiled from t he Indiana University School of 
Medicine’s “Clinically Relevant” Table and from the  University of Washington’s Drug 
Interaction Database based on i n  v i t r o  studies. Strong inhibitors are predicted to increa se 
buparlisib AUC > 5-fold, and moderate inhibitors ar e predicted to increase buparlisib AUC ≥ 
2-fold but < 5-fold.  
This database of CYP inducers was compiled from the  FDA’s “Guidance for Industry, Drug 
Interaction Studies;” from the Indiana University S chool of Medicine’s “Clinically Relevant” 
Table; and from (Pursche et al. 2008).  
 
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases   [10JUN2016] 
 
78 
 Table 4-9 List of prohibited QT prolonging drugs  
All QT-prolonging drugs listed in Table 4-9 are pro hibited for all patients from screening 
through permanent discontinuation of study treatmen t.  Table 4-10 lists drugs with a known 
risk for Torsades de Pointes (TdP) as well as sensi tive CYP3A substrates (with narrow TI) 
with a possible or conditional risk for TdP. 
 
Prohibited QT Prolonging Drugs 
Drug QT risk(*) Comment 
Amiodarone Known risk for TdP Females>Males,TdP ris k regarded as low 
Arsenic trioxide Known risk for TdP  
Astemizole Known risk for TdP No Longer available i n U.S. 
Bepridil Known risk for TdP Females>Males 
Chloroquine Known risk for TdP  
Chlorpromazine Known risk for TdP  
Cisapride Known risk for TdP Restricted availabilit y; Females>Males. 
Disopyramide Known risk for TdP Females>Males 
Dofetilide Known risk for TdP  
Domperidone Known risk for TdP Not available in the  U.S. 
Droperidol Known risk for TdP  
Halofantrine Known risk for TdP Females>Males 
Haloperidol Known risk for TdP When given intravenously or at h igher-than- 
recommended doses, risk of sudden death, QT 
prolongation and torsades increases. 
Ibutilide Known risk for TdP Females>Males 
Levomethadyl Known risk for TdP  
Mesoridazine Known risk for TdP  
Methadone Known risk for TdP Females>Males 
Pentamidine Known risk for TdP Females>Males 
Pimozide Known risk for TdP Females>Males 
Probucol Known risk for TdP No longer available in U.S. 
Procainamide Known risk for TdP  
Quetiapine Possible risk for TdP Prohibited as this drug is a sensitive 3A4 
substrate 
Quinidine Known risk for TdP Females>Males 
Sotalol Known risk for TdP Females>Males 
Sparfloxacin Known risk for TdP  
Tacrolimus Possible risk for TdP Prohibited as this drug is a sensitive 3A4 
sibstrate with narrow TI 
Terfenadine Known risk for TdP No longer available in U.S. 
Thioridazine Known risk for TdP  
Vardenafil Possible risk for TdP Prohibited as this drug is a sensitive 3A4 
substrate 
(*) Classification according to the Qtdrugs.org Adv isory Board of the Arizona CERT 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases   [10JUN2016] 
 
79 
 Prohibited QT Prolonging Drugs 
Drug QT risk(*) Comment 
Sensitive substrates: Drugs whose plasma AUC values  have been shown to increase 5-fold or higher when co-
administered with a potent inhibitor of the respect ive enzyme. 
 
4.2.3.1 Drugs to be used with caution 
Preliminary in vitro metabolism studies suggest tha t buparlisib is a weak, reversible inhibitor 
of CYP3A4/5 (Ki=13.6 µM, [I]/Ki= 0.4 where [I] is the average C max  at steady-state following 
100 mg daily dose) and a weak reversible inhibitor of CYP2C8/2C9/2C19 (IC 50 =34 µM, 
[I]/IC 50 =0.15). Note: that with the data available, we are not able to confirm whether such 
interactions will occur in patients. Therefore, inv estigators, at their discretion, may administer 
concomitant medications known to be metabolized by CYP3A4/5, CYP2C8, CYP2C9 and 
CYP2C19. Patients receiving such medications must b e carefully monitored for potentiation 
of toxicity due to any individual concomitant medic ations, and may require dose titration or 
reduction of the drug substrate. Please refer to Ta ble 4-11 for a list of CYP450 substrates and 
carefully consider their co-administration with bup arlisib. 
Particular caution is advised when buparlisib is co -administered with: 
• Drugs which are substrates for CYP3A4, CYP2C8, CYP2 C9 or CYP2C19 and which 
have a narrow therapeutic index. 
• Oral anti-diabetic drugs which are metabolized by C YP2C8 or CYP2C9 can possibly 
result in hypoglycemia. Patients who develop diabet es mellitus during the study 
should be treated according to the American Diabete s Association guidance. It is 
recommended that treatment start with metformin.  
• If a patient, after study enrollment, requires the concomitant use of any QT prolonging 
medication with a possible or conditional risk for Torsade de Pointes then the 
investigators, at their discretion, may co-administ er such medications. Patients 
receiving such medications must be monitored.  Refe r to Table 4-10 for a list of QT 
prolonging medications to be used with caution.  
Note: please refer also to Table 4-9 for a list of prohibited QT prolonging 
medications.  
• Please refer to Table 4-11 for a list of CYP450 sub strates and carefully consider their 
co-administration with buparlisib.  
• Concomitant treatment with corticosteroids and bupa rlisib should be avoided, 
whenever possible, during this study. A short durat ion (< 2 weeks) of systemic 
corticosteroids is allowed (e.g. for chronic obstru ctive pulmonary disease, or as an 
anti-emetic).  Chronic dosing of corticosteroids is  known to induce CYP3A enzymes, 
thereby increasing the risk or reducing buparlisib overall exposure to sub-therapeutic 
levels. Topical applications (e.g. rash), inhaled s prays (e.g. obstructive airways 
diseases), eye drops or local injections (e.g. intr a-articular) are allowed.   
  
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases   [10JUN2016] 
 
80 
 Table 4-10 List of QT prolonging drugs to be used w ith caution 
Drug QT risk Comment 
Alfuzosin possible risk for Torsades de Pointes  
Amantadine possible risk for Torsades de Pointes  
Amitriptyline conditional risk for Torsades de Poin tes  
Azithromycin possible risk for Torsades de Pointes  
Chloral hydrate possible risk for Torsades de Point es  
Citalopram conditional risk for Torsades de Pointes   
Clomipramine conditional risk for Torsades de Point es  
Clozapine possible risk for Torsades de Pointes  
Desipramine conditional risk for Torsades de Pointe s  
Diphenhydramine conditional risk for Torsades de Po intes  
Dolasetron possible risk for Torsades de Pointes  
Doxepin conditional risk for Torsades de Pointes  
Dronedarone possible risk for Torsades de Pointes  
Felbamate possible risk for Torsades de Pointes  
Flecainide possible risk for Torsades de Pointes  
Fluoxetine conditional risk for Torsades de Pointes   
Foscarnet possible risk for Torsades de Pointes  
Fosphenytoin possible risk for Torsades de Pointes  
Galantamine conditional risk for Torsades de Pointe s  
Gatifloxacin possible risk for Torsades de Pointes  
Gemifloxacin possible risk for Torsades de Pointes  
Granisetron possible risk for Torsades de Pointes  
Imipramine conditional risk for Torsades de Pointes   
Indapamide possible risk for Torsades de Pointes  
Isradipine possible risk for Torsades de Pointes  
Levofloxacin possible risk for Torsades de Pointes  
Lithium possible risk for Torsades de Pointes  
Mexiletine conditional risk for Torsades de Pointes   
Moexipril/HCTZ possible risk for Torsades de Pointe s  
Moxifloxacin possible risk for Torsades de Pointes  
Nicardipine possible risk for Torsades de Pointes  
Nortriptyline conditional risk for Torsades de Poin tes  
Octreotide possible risk for Torsades de Pointes  
Ofloxacin possible risk for Torsades de Pointes  
Ondansetron possible risk for Torsades de Pointes  
Oxytocin possible risk for Torsades de Pointes  
Paliperidone possible risk for Torsades de Pointes  
Paroxetine conditional risk for Torsades de Pointes   
Perflutren lipid possible risk for Torsades de Pointes  
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases   [10JUN2016] 
 
81 
 Drug QT risk Comment 
microspheres 
Protriptyline conditional risk for Torsades de Poin tes  
Ranolazine possible risk for Torsades de Pointes  
Risperidone possible risk for Torsades de Pointes  
Roxithromycin* possible risk for Torsades de Pointe s *not available in the 
United States 
Sertindole possible risk for Torsades de Pointes  
Sertraline conditional risk for Torsades de Pointes   
Solifenacin conditional risk for Torsades de Pointe s  
Tizanidine possible risk for Torsades de Pointes  
Trazodone conditional risk for Torsades de Pointes  
Trimethoprim-Sulfa conditional risk for Torsades de  Pointes  
Trimipramine conditional risk for Torsades de Point es  
Venlafaxine possible risk for Torsades de Pointes  
Ziprasidone possible risk for Torsades de Pointes  
(*) Classification according to the Qtdrugs.org Adv isory Board of the Arizona CERT 
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases   [10JUN2016] 
 
82 
 Table 4-11 List of CYP450 Substrates to be used wit h caution 
CYP2C8 CYP2C9 CYP2C19 CYP3A** 
amodiaquine celecoxib amitriptyline Adinazolam felo dipine 1 
cerivastatin diclofenac citalopram alfentanil1,2  fentanyl2 
pioglitazone flurbiprofen clobazam alpha-
dihydroergocryptine 1 flunitrazepam 
repaglinide fluvastatin clomipramine Alprazolam flu ticasone 1 
rosiglitazone glibenclamide 
(glyburide) clopidogrel  Amlodipine lovastatin 1 
torasemide gliclazide diazepam Aripiprazole maravir oc 1 
troglitazone glimepiride fluoxetine Atorvastatin mi dazolam 1 
 glipizide imipramine Brecanavir nifedipine 
 indomethacin lansoprazole brotizolam 1 nisoldipine 
 irbesartan mephobarbital budesonide 1 nitrendipine 
 ketobemidone moclobemide buspirone 1 perospirone 1 
 lornoxicam omeprazole Capravirine quinine 
 losartan pantoprazole Cerivastatin sildenafil1 
 meloxicam progesterone Chlorpheniramine simvastati n 1 
 naproxen quazepam cyclosporine 2 sirolimus 1,2  
 nateglinide rabeprazole darifenacin 1 tolvaptan 
 piroxicam sertraline Diazepam trazodone 
 rosiglitazone S-mephenytoin diergotamine 2 triazolam 1 
 S-ibuprofen  ebastine 1  
 sulfamethoxazole   eletriptan 1  
 tenoxicam  eplerenone 1  
 tolbutamide  ergotamine 2  
 torasemide  Estazolam  
 valdecoxib  everolimus 1  
* This database of CYP substrates was compiled from  the Indiana University School of 
Medicine’s “Clinically Relevant” Table, and from (Z hou et al. 2009) 
** CYP3A substrates were compiled from the Indiana University School of Medicine’s 
“Clinically Relevant” Table; and supplemented by th e FDA’s “Guidance for Industry, Drug 
Interaction Studies” and the University of Washingt on’s Drug Interaction Database. 
1 Sensitive substrates: Drugs whose plasma AUC value s have been shown to increase 5-fold 
or higher when co-administered with a potent inhibi tor of the respective enzyme. 
2 Substrates with narrow therapeutic index (NTI): Dr ugs whose exposure-response indicates 
that increases in their exposure levels by the conc omitant use of potent inhibitors may lead to 
serious safety concerns (e.g., Torsades de Pointes) . 
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases   [10JUN2016] 
 
83 
 4.2.3.2  Bisphosphonates and denosumab 
The use of bisphosphonates or denosumab is allowed provided patients have been on stable 
doses for at least 4 weeks prior to treatment start . Stable dose and same brand should be 
maintained during the treatment period. Patients re quiring initiation of bisphosphonates or 
denosumab treatment during the course of the study should be discontinued due to progressive 
disease unless disease progression can be completel y ruled out and is clearly documented in 
the patients’ source documentation. 
4.2.3.3  Palliative radiotherapy 
Local radiotherapy for analgesic purposes or for ly tic lesions at risk of fracture may be carried 
out if required provided no lung tissue will be inc luded in the radiation portal, and no or 
minimal GI tissue will be included in the radiation  portal. If palliative radiotherapy is initiated 
after start of study treatment, the reason for its use must be clearly documented and 
progression as per RECIST 1.1 must be ruled out. No  dose modification of study treatment is 
needed during palliative radiotherapy. 
4.3  Visit Schedule and Assessments 
4.3.1  Visit schedule 
Table 4-12 lists all of the assessments and indicat es with an “X” when the visits are to be 
performed. All data obtained from these assessments  must be recorded in the patient’s source 
documentation.  
 
Sections 4.3.2 - 4.3.13 lists all of the assessment s required for the collection plan for Imaging, 
Clinical Laboratory parameters, and PHQ-9/GAD-7 pat ient self-reported questionnaires. The 
outlined schedule should be adhered to for all anal yses. In general, where possible, every 
effort must be made to follow the schedule outlined  in Table 4-12 and in subsequent tables.
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
84 
 Table 4-12  Schedule of Events 
 
Schedule of Events 
 Screening 
phase Treatment phase 
(cycle is defined as 21 days ± 3 business days) Post-treatment 
follow up phase 
(± 7 business days) Survival phase 
(± 7 business days) 
Cycle 
 Cycle 1 Cycle 2 Cycle 3  Preceding 
cycles  
(Day 1 of 
Each 
Cycle) End of 
treatment 
(± 7 
business 
days) Endpoint follow up (safety and efficacy 
follow up) Survival follow up 
(every 2 months 
and more frequent 
if required) 
Days  -28  
to -1 1 1 1 1     
Obtain study Informed Consent and HIPAA X        
Collect and send tumor biopsy (archival paraffin blocks/slides or fresh biopsy)  X 
(Day -28 to 
-1)        
Demography X        
Inclusion/exclusion criteria X        
ER and PgR status X        
HER2 status X        
Relevant medical history/current medical conditions (to include GPA components) X        
Diagnosis and extent of cancer X        
Prior antineoplastic therapy (surgery, medication, radiotherapy) X        
Physical examination X X* X X X X   
Performance status (ECOG) X X* X X X X   
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
85 
 Schedule of Events 
 Screening 
phase Treatment phase 
(cycle is defined as 21 days ± 3 business days) Post-treatment 
follow up phase 
(± 7 business days) Survival phase 
(± 7 business days) 
Cycle 
 Cycle 1 Cycle 2 Cycle 3  Preceding 
cycles  
(Day 1 of 
Each 
Cycle) End of 
treatment 
(± 7 
business 
days) Endpoint follow up (safety and efficacy 
follow up) Survival follow up 
(every 2 months 
and more frequent 
if required) 
Days  -28  
to -1 1 1 1 1     
Height X        
Weight  X X* X X X X   
Vital signs X X* X X X X   
Hematology X X* X X X X   
Biochemistry (CMP) 3 X X* X X X X   
Urinalysis X     X   
Amylase and Lipase  X Repeat every 8 weeks   
Fasting plasma glucose 4  X X* X X X X   
Glycosylated Hemoglobin (HbA1c) X as clinically ind icated X   
Coagulation PT or INR,PTT 5 X Repeat at week 4, then every 8 weeks thereafter   
Serum/Urine Pregnancy Test X As clinically indicated 1  
12-lead ECG/EKG X As clinically indicated 
ECHO/MUGA  HER2+ patients Only X Cardiac imaging to repeat every 4 months for 
HER2+ patients on Herceptin Only    
Brain MRI X 8 weeks after initiation of treatment, then every 8  
weeks thereafter 
(Assessments window is ± 7 business days.)  X Per Standard of 
Care for patients 
off all study 
treatment  
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
86 
 Schedule of Events 
 Screening 
phase Treatment phase 
(cycle is defined as 21 days ± 3 business days) Post-treatment 
follow up phase 
(± 7 business days) Survival phase 
(± 7 business days) 
Cycle 
 Cycle 1 Cycle 2 Cycle 3  Preceding 
cycles  
(Day 1 of 
Each 
Cycle) End of 
treatment 
(± 7 
business 
days) Endpoint follow up (safety and efficacy 
follow up) Survival follow up 
(every 2 months 
and more frequent 
if required) 
Days  -28  
to -1 1 1 1 1     
CT or MRI (Chest, abdomen) X 8 weeks after initiation of treatment, then every 8  
weeks thereafter 
(Assessments window is ± 7 business days.)  X Per Standard of 
Care for patients 
off all study 
treatment  
CT or MRI for any site of measurable disease (excluding bone) X
6 If lesion at screening, 8 weeks after initiation of  
treatment, then every 8 weeks thereafter 
(Assessments window is ± 7 business days.)  X  
(if lesion at 
screening) Per Standard of 
Care for patients 
off all study 
treatment  
Bone scan  X If bone lesion at screening, 8 weeks after initiati on 
of treatment, then every 8 weeks thereafter 
(Assessments window is ± 7 business days.)  As clinically 
indicated As clinically 
indicated  
Skin – color photography Only if 
skin lesions 
at 
screening If skin lesions at screening, 8 weeks after initiat ion 
of treatment, then every 8 weeks thereafter 
(Assessments window is ± 7 business days.)  Mandated 
only if skin 
lesions at 
screening Per Standard of 
Care for patients 
off all study 
treatment  
RECIST version 1.1 X Performed every 8 weeks after initiation of 
treatment, thereafter 
(Assessments window is ± 7 business days.) 
Tumor response will be assessed locally according 
to Response Evaluation Criteria in Solid Tumors X As clinically 
indicated  
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
87 
 Schedule of Events 
 Screening 
phase Treatment phase 
(cycle is defined as 21 days ± 3 business days) Post-treatment 
follow up phase 
(± 7 business days) Survival phase 
(± 7 business days) 
Cycle 
 Cycle 1 Cycle 2 Cycle 3  Preceding 
cycles  
(Day 1 of 
Each 
Cycle) End of 
treatment 
(± 7 
business 
days) Endpoint follow up (safety and efficacy 
follow up) Survival follow up 
(every 2 months 
and more frequent 
if required) 
Days  -28  
to -1 1 1 1 1     
MD Anderson Symptom Inventory – Brain Tumor (MDASI-BT) Assessment X 8 weeks after initiation of treatment, then every 8  
weeks thereafter 
(Window ± 3 business days) X   
Neuro-psychiatric assessment (self rating mood questionnaire)
2 X X X X X X   
Neurologic assessment X 8 weeks after initiation of treatment, then every 8  
weeks thereafter 
(Assessments window is ± 7 business days.) X   
Prior/concomitant medications X Continuous Up to 30 days after 
last dose of 
treatment  
Adverse events X Continuous Up to 30 days after 
last dose of 
treatment  
Antineoplastic therapies since discontinuation of study treatment       X X 
Buparlisib administration  Daily starting from Cycl e 1 Day 1    
Capecitabine administration  Daily 
days 1-14 Daily 
days 1-14 Daily days 
1-14 Daily days 
1-14    
Trastuzumab administration (HER2+ MBC  Every 3 weeks    
Patient diary  Continuous    
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
88 
 Schedule of Events 
 Screening 
phase Treatment phase 
(cycle is defined as 21 days ± 3 business days) Post-treatment 
follow up phase 
(± 7 business days) Survival phase 
(± 7 business days) 
Cycle 
 Cycle 1 Cycle 2 Cycle 3  Preceding 
cycles  
(Day 1 of 
Each 
Cycle) End of 
treatment 
(± 7 
business 
days) Endpoint follow up (safety and efficacy 
follow up) Survival follow up 
(every 2 months 
and more frequent 
if required) 
Days  -28  
to -1 1 1 1 1     
Survival follow up        X 
Note: Cycle 1 only, the baseline values for those a ssessments (laboratory, physical examination, perfo rmance status and vital signs) that are to be done prior to every cycle 
may be used for Cycle 1 assessments as long as they  are completed within 2 weeks prior to the patient receiving their first dose of study drug. If more t han 2 weeks have 
elapsed since the baseline assessment, the assessme nt must be repeated.  Assessments need to be put in  the order in which they appear in eCRF.  Treatment  must begin 
within 5 working days after patient registration to  the study, not including weekends or holidays. 
 
1 Serum/urine pregnancy test ( β-HCG) is required for all women of child-bearing po tential at screening, within 3 business days prior to the first dose of buparlisib. And as 
clinically indicated thereafter. 
2 Questionnaires PHQ-9 and GAD-7 will be completed at  each visit. Symptomatic patients ( ≥ CTCAE grade 1) must continue with questionnaires o n a weekly basis while 
active on the treatment portion of the study. 
3 Biochemistry (CMP) includes K+, Na+, Ca++, ALT, AS T, total bilirubin (direct and indirect), creatinin e, amylase, GGT, alkaline phosphatase (fractionated  if alkaline 
phosphatase is grade 2 or higher), bicarbonate, ure a or BUN, albumin, and total protein, to be obtaine d on the first day of each cycle.  Lab assessments may be performed up 
within 3 business days prior to the scheduled visit , but all other draws should occur within 24 hours of the intended visit.  
4 Patients must be fasting overnight for at least 8 h ours. Additional measurements may be performed as c linically indicated. 
5 Coagulation – PT, or INR, PTT, and C1D1 assessments  may be performed up to 72 hours prior to the sched uled visit. Additional assessments will be performe d on Day 1 
of Cycle 2 (within 3 business days prior to dosing)  and repeated every other cycle. A repeat coagulati on profile panel is required at the time of study t reatment 
discontinuation. Patient entering the study while r eceiving anti-coagulation therapy or those who have  the initiation of an anti-coagulation therapy shou ld have their 
coagulation test performed on a weekly basis. 
6 Mandated if suspected lesion at screening. 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
89 
  
4.3.2  Efficacy assessments 
Tumor response will be assessed locally according t o Response Evaluation Criteria in Solid 
Tumors (RECIST), Version 1.1 (Appendix 4). The loca l investigator’s assessment will be 
used for all endpoint analyses and for treatment de cision making with a +/- 7 day window.  
Any delay within this window is not a deviation.  
Table 4-13 Efficacy Assessments 
Procedure  Screening: 
Day−14 (up 
to -21) to Day 
-1 Treatment phase*  End of 
treatment*  Post-treatment follow-
up phase: Efficacy 
follow-up*  
CT or MRI 
(Chest, 
Abdomen) Mandated 8 weeks after initiation of 
treatment and then every 
8 weeks 
(Assessments window is 
± 7 business days.)  Mandated Per Standard of Care for 
patients off all study 
treatment 
CT or MRI for 
any site of 
measurable 
disease 
(excluding 
bone) Mandated if 
suspected 
lesion at 
screening If lesion at screening: 8 
weeks after initiation of 
treatment and then every 
8 weeks 
(Assessments window is 
± 7 business days.)  Mandated if 
lesion at 
screening Per Standard of Care for 
patients off all study 
treatment 
Brain MRI Mandated 8 weeks after initiation of 
treatment and then every 
8 weeks 
(Assessments window is 
± 7 business days.)  Mandated Per Standard of Care for 
patients off all study 
treatment 
Bone scan Mandated If bone lesions at 
screening 
8 weeks after initiation of 
treatment and then every 
8 weeks 
(Assessments window is 
± 7 business days.)  As clinically 
indicated As clinically indicated 
Skin -  color 
Photography Mandated if 
skin lesions at 
screening If skin lesions at 
screening 
8 weeks after initiation of 
treatment and then every 
8 weeks 
(Assessments window is 
± 7 business days.)  Mandated if 
skin lesions 
at screening Per Standard of Care 
for patients off all 
study treatment  
*Tumor evaluation at EOT is required for patients w ho discontinue study treatment before the first 
scheduled post-baseline tumor assessment and for pa tients whose previous tumor assessment did not 
demonstrate PD and was done at least 6 weeks (± 4 d ays) prior to end of treatment visit. Tumor assessm ents 
are to be done every 8 weeks after initiation of tr eatment. 
 
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
90 
 Neurologic Assessment 
Neurologic assessment should be performed at baseli ne, every 8 weeks following initiation of 
study treatment, and at the end of treatment visit.  Assessment should include cranial nerves 
exam, and motor and sensory exam. In addition, pati ents should be assessed both for ability 
to walk and for balance using the following criteri a: 
• Normal  
• Mildly impaired 
• Moderately impaired 
• Severely impaired (in wheelchair) 
 
Exploratory biomarker analysis – formalin-fixed Par affin-embedded (FFPE) tumor 
samples  
Tumor tissue (formalin fixed new biopsy or archival ) is required, and will be stored for future 
analysis of markers shown to be closely associated with the PI3K pathway, including but not 
limited to PTEN and INPP4B. One tumor block (prefer red) or a minimum of 15 paraffin-
dipped unstained slides is required. Fresh biopsy t issue from a resected brain metastasis is 
preferred but an archival sample from the primary b reast cancer may be submitted.  
 
Since the archival samples may not be located at th e institution where the original diagnosis 
was rendered, the investigational sites will be res ponsible for locating them and preparing the 
unstained slides (or having them prepared), if nece ssary. 
 
For all tumor samples, the sample collection inform ation must be captured on the  relevant 
eCRF page(s) and laboratory requisition form(s).  
 
Tumor samples will be sent to designated lab (check  CTI) for analysis. See Collection of 
Shipping Information provided by sponsor for more d etailed instruction on sample 
preparation and submission information. 
 
4.3.3  Safety assessments 
Safety assessments will consist of the following: m onitoring and recording of all adverse 
events and serious adverse events; the regular moni toring of hematology, blood chemistry, 
urinalysis; regular measurement of vital signs, oxy gen saturation, physical examination, 
including weight; and performance status. 
 
These assessments should be performed periodically throughout the study, except for adverse 
events that will be evaluated continuously. 
 
All patients who receive at least one dose of study  drug will be evaluated for safety. 
Toxicities will be graded and reported according to  the NCI Common Toxicity Criteria for 
Adverse Events (CTCAE) Version 4.03 (Appendix 3). I ncidence and type of AEs will be 
tabulated and summarized using descriptive statisti cs. 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
91 
 4.3.4  Treatment compliance 
Records of study medication used, dosages administe red, and intervals between visits will be 
recorded during the study. Drug accountability will  be noted and patients will be asked to 
return all unused study medication. 
4.3.5  Adverse events  
Information about all adverse events, whether volun teered by the subject, discovered by 
investigator questioning, or detected through physi cal examination, laboratory test or other 
means, will be collected and recorded and followed as appropriate. An adverse event is any 
undesirable sign, symptom or medical condition occu rring after starting study drug (or 
therapy) even if the event is not considered to be related to study drug (or therapy). Study 
drug (or therapy) includes the drug (or therapy) un der evaluation given during any phase of 
the trial. 
 
 If it is unclear what study treatment includes, li st all drug(s), other therapies, changes to 
existing therapy, diagnostic procedure, etc. that a re specified by the protocol. 
 
Medical conditions/diseases present before starting  study treatment are only considered 
adverse events if they worsen after starting study treatment (ie, any procedures specified in 
the protocol). Adverse events occurring before star ting study treatment but after signing the 
informed consent form are recorded at baseline. Abn ormal laboratory values or test results 
constitute adverse events only if they induce clini cal signs or symptoms or require therapy, 
and are recorded.  
 
4.3.6  Serious adverse events 
 
Information about all serious adverse events will b e collected and recorded on the FDA 
MedWatch 3500a form. To ensure patient safety, each  serious adverse event must also be 
reported to Delta within 24 hours of learning of it s occurrence. A serious adverse event is an 
undesirable sign, symptom, or medical condition whi ch : 
 
1. is fatal or life-threatening 
2. required or prolonged hospitalization 
3. results in persistent or significant disability/inc apacity  
4. constitutes a congenital anomaly or a birth defect 
5. is medically significant, may jeopardize the subjec t, and may require medical or 
surgical intervention to prevent one of the outcome s listed above. 
 
Events not considered to be serious adverse events are hospitalizations for the:  
 
• routine treatment or monitoring of the studied indi cation, not associated with any 
deterioration in condition  
• treatment, which was elective or pre-planned, for a  pre-existing condition that did not 
worsen  
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
92 
 • treatment on an emergency, outpatient basis for an event not fulfilling any of the 
definitions of serious given above and not resultin g in hospital admission.  
 
Pregnancy, although not itself a serious adverse ev ent, should also be reported on a serious 
adverse event form or pregnancy form and be followe d up to determine outcome, including 
spontaneous or voluntary termination, details of bi rth, and the presence or absence of any 
birth defects or congenital abnormalities. 
 
Any serious adverse event occurring after the patie nt has provided informed consent, has 
started taking the study medication, and until 4 we eks after the patient has stopped study 
participation must be reported. This includes the p eriod in which the study protocol interferes 
with the standard medical treatment given to a pati ent (e.g., treatment withdrawal during 
washout period, change in treatment to a fixed dose  of concomitant medication). The period 
after discontinuing study drug may be extended if t here is a strong suspicion that the drug has 
not yet been eliminated. 
 
For instructions about returning Serious Adverse Ev ent Report Forms to Delta refer to the 
protocol section entitled Instructions for Rapid No tification of Serious Adverse Events 
(Section 4.3.7). 
 
4.3.7  Instructions for rapid notification of serious adve rse events 
The principal investigator has the obligation to re port all serious adverse events to the IRB 
and the sponsor, (Delta Pharmaceuticals Drug Safety  and Epidemiology Department 
(DS&E)). Serious adverse events should also be repo rted to the FDA and IRB in accordance 
with regulations and IRB policy. 
 
The investigator must complete the FDA MedWatch 350 0A form and Delta SAE coversheet 
in English, assess the relationship to study treatm ent and send the initial completed 
MedWatch form and Delta SAE coversheet by Fax to 1. 888.299.4565 within 24 hours to the 
local Delta Drug Safety & Epidemiology (DS&E) Depar tment.  The investigator must then 
ensure that the form and coversheet are accurately and fully completed with follow-up 
information and fax those to Delta DS&E Department within 2 to 3 calendar days for deaths 
or life-threatening events and 5 calendar days for other serious adverse events. The original 
and the duplicate copies of the FDA MedWatch form, Delta SAE coversheet, and the fax 
confirmation sheet must be kept with the electronic  case report forms (eCRF) at the study 
site.  
  
In addition, all SAEs will be reported by telephone  to the Delta Central Safety Department as 
soon as study personnel become aware of the SAE. Th e SAEs should be reported by 
facsimile within 24 hrs to the Delta Central Safety  Department. The site will supply as much 
information as is available at the time of the init ial Fax to the Delta Central Safety 
Department (study number, subject initials, subject  study number, event), during both 
business and nonbusiness hours, to: 
  
Delta Clinical Research Safety Department  
10101 Woodloch Forest 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
93 
 The Woodlands, TX 77380 
SAE Hotline: (281) 863-6503 
Safety Fax: (877) 571-8934 
  
Follow-up information should describe whether the e vent has resolved or continues, if and 
how it was treated, and whether the patient continu ed or discontinued study participation. 
The MedWatch form, Delta SAE coversheet, and fax co nfirmation sheet must be retained.  
  
Pregnancy follow-up should describe the outcome of the pregnancy, including any voluntary 
or spontaneous termination, details of the birth, a nd the presence or absence of any 
congenital abnormalities or birth defects.  
  
Adverse events will be recorded for the duration of  a patient’s study treatment. All AEs, 
regardless of causal relationship, are to be record ed in the source documentation. The 
Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. The diagnosis sh ould be documented as the AE/SAE and 
not the individual signs/symptoms. 
  
All AEs will be graded and reported according to th e NCI Common Toxicity Criteria 
(version 4.03). The relationship of each event to t he study drug will be assessed by the 
Investigator and recorded on the eCRF. Additional i nformation about each event, such as 
treatment required, whether or not the study drug h ad to be discontinued, and eventual 
outcome will also be recorded on the eCRF.  
 
Reporting to Novartis  
To ensure patient safety, every SAE, regardless of suspected causality, occurring after the 
patient has provided informed consent and until at least 30 days after the patient has stopped 
study treatment must be reported to Novartis within  24 hours of learning of its occurrence. 
Any SAEs experienced after this 30 days period shou ld only be reported to Novartis if the 
investigator suspects a causal relationship to the study treatment. Recurrent episodes, 
complications, or progression of the initial SAE mu st be reported as follow-up to the original 
episode within 24 hours of the investigator receivi ng the follow-up information. An SAE 
occurring at a different time interval or otherwise  considered completely unrelated to a 
previously reported one should be reported separate ly as a new event. 
Information about all SAEs is collected and recorde d on the Serious Adverse Event Report 
Form; all applicable sections of the form must be c ompleted in order to provide a clinically 
thorough report. The investigator must assess and r ecord the relationship of each SAE to each 
specific study treatment (if there is more than one  study treatment), complete the SAE Report 
Form in English, and send the completed, signed for m by fax within 24 hours to the oncology 
Novartis Drug Safety and Epidemiology (DS&E) depart ment (fax # 877-778-9739). . 
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
94 
 4.3.7.1  Pregnancies 
To ensure patient safety, each pregnancy occurring while the patient is on study treatment 
must be reported to Novartis within 24 hours of lea rning of its occurrence. The pregnancy 
should be followed up to determine outcome, includi ng spontaneous or voluntary 
termination, details of the birth, and the presence  or absence of any birth defects, congenital 
abnormalities, or maternal and/or newborn complicat ions. 
 
Pregnancy should be recorded on a Clinical Study Pr egnancy Form and reported by the 
investigator to the oncology Novartis Drug Safety a nd Epidemiology Department (DS&E). 
Pregnancy follow-up should be recorded on the same form and should include an assessment 
of the possible relationship of buparlisib  to any pregnancy outcome. Any SAE experienced 
during pregnancy must be reported on the SAE Report  Form. 
 
4.3.8  Laboratory evaluations 
Pregnancy Test 
A serum pregnancy test ( β-HCG) is required for all women of child-bearing po tential at 
screening, within 72 hours prior to the first dose of buparlisib. Note: Postmenopausal women 
must have been amenorrheic for ≥ 12 months in order to be considered “of non-childb earing 
potential”. This should be documented appropriately  in the patient’s medical history.  
Additional pregnancy tests should be performed as c linically indicated.  
Hematology 
Hematology includes the following parameters: compl ete blood count (CBC) consisting of 
red blood cell (RBCs), a total white blood cell cou nt (WBC) with differential (total 
neutrophil count including bands, lymphocyte, monoc yte, eosinophil, and basophil counts); 
hemoglobin (Hgb); and platelet count to be obtained  on the first day of each cycle.  Lab 
assessments may be performed within 3 business days  prior to the scheduled visit. 
Coagulation Profile 
The coagulation profile includes prothrombin time o r INR, and activated partial 
thromboplastin time to be drawn within 24 hours of the intended visit.  
Serum chemistry  
Biochemistry includes the K+, Na+, Ca++, ALT, AST, total bilirubin (direct and indirect), 
creatinine, GGT, alkaline phosphatase (fractionated  if alkaline phosphatase is grade 2 or 
higher), bicarbonate, glucose, urea or BUN, albumin , and total protein to be obtained on the 
first day of each cycle.  Lab assessments may be pe rformed within 3 business days prior to 
the scheduled visit.  
Because accurate serum glucose and lipid measuremen ts are required, patients should be 
fasting at the time of the blood sampling. 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
95 
 4.3.9  Vital signs 
Vital sign assessment consists of height (first vis it), pulse, blood pressure, respiration rate, 
temperature and weight. Blood pressure, pulse and r espiration rate should be measured on 
patients after at least 3 minutes in the sitting po sition as per the visit schedule.  
4.3.10  Physical examination 
Physical examination will be performed which must c omprise a total body examination 
(general appearance, skin, neck, including thyroid,  eyes, ears, nose, throat, lungs, heart, 
abdomen, back, lymph nodes, extremities and basic n ervous system). 
Significant findings made after the start of study drug which meet the definition of an 
Adverse Event must be recorded. 
4.3.11  Neuropsychiatric assessments 
Patient self-rating mood questionnaires for anxiety  and depression (PHQ-9, GAD-7) will be 
applied at: 
• Screening 
• Days 1 of Cycle 1 
• Day 1 of Cycle 2 
• Day 1 of Cycle 3 and subsequent cycles (only for pa tients who have not shown 
mood alterations during the first 2 cycles, patient s who did have mood 
alterations should continue to fill out the questio nnaire on a weekly base). 
• End of Study treatment 
Additional assessments may be done according to the  clinical judgment of the Investigator. 
Symptomatic patients ( ≥ CTCAE grade 1) must continue with questionnaires o n a weekly 
basis while active on the treatment portion of the study. The nurse or the CRC will provide 
the patient with the instruments and the instructio ns on how to complete the questionnaires, 
as well as how to determine the scores. See Appendi ces 5 and 6 for questionnaires. 
4.3.12  ECG/EKG –ECHO/MUGA 
A standard 12 lead ECG is to be performed at screen ing and as clinically indicated.   
An echocardiogram (ECHO) or MUGA will be performed to assess eligibility for HER2 
positive patients only. ECHO/MUGA will be repeated at 4 month intervals thereafter for 
HER2 positive patients only. There is window of +/-  7 business days for an ECHO/MUGA.  
Any delay within this window is NOT a deviation as per the visit schedule (Table 4-12). 
4.3.13  Performance status 
Performance status will be assessed at screening an d per the visit schedule. The ECOG 
Performance Status Scale will be used. (See Appendi x 2) 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
96 
 4.3.14  Disease-related symptom assessment 
Disease-related symptoms will be assessed at screen ing, every 8 weeks during treatment, and 
at the end of treatment. The MD Anderson Symptom In ventory – Brain Tumor (MDASI-BT) 
module will be used (see Appendix 6). 
4.3.15  Drug levels and pharmacokinetic assessments 
 
No pharmacokinetic assessments will be performed.  
 
5 Data management 
5.1  Data collection 
Investigators must record the information required by the protocol.  
 
6 Statistical methods 
6.1  Populations for analysis 
6.1.1  Analysis populations 
 
Intent-To-Treat (ITT) Population: Includes all patients registered on the study (elig ible 
and ineligible). This ITT population will be includ ed in overall patient listings, in summary 
tables of patient demographics and baseline disease  characteristics, and also in the list of 
treatment discontinuations after enrollment. This p opulation will also be used for analyses of 
overall survival (OS) and time to progression (TTP) .  
 
Evaluable Population:  Includes all eligible patients who meet the protoc ol-specified 
efficacy analyses requirements and who have receive d at least 1 dose of study drug. This 
population will comprise those with a CR, PR, SD, P D, or NE response.  
 
Safety Population:  Includes all patients (eligible and ineligible) wh o receive at least 1 dose 
of study drug. This safety population will also be used for the summaries and analysis of all 
safety parameters (drug exposure, tables of adverse  events information, including serious 
adverse events, etc).  
 
6.1.2  Patient characteristics 
All patients entered in the study will be accounted  for in the summation. Patient 
demographics and baseline characteristics such as a ge, race, sex, ECOG PS, and 
ER/PR/HER2 status will be described. Disease stage and histology at baseline, medical 
history, and prior treatment, including WBRT and SR S, will also be summarized. Mean, 
standard deviation, median, minimum and maximum val ues will be presented for continuous 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
97 
 variables, and frequency tables showing numbers and  percentages will be presented for 
categorical variables. 
 
6.1.3  Patient disposition 
Patient disposition including the number of patient s enrolled, completed, and discontinued 
from the study will be summarized by numbers and pe rcentages. The reasons for 
discontinuation will also be summarized in the same  manner. 
 
6.2  Hypothesis and endpoints 
This is an open-label, one arm, multicenter phase 2  trial of buparlisib plus capecitabine in  
breast cancer patients with brain metastases that h ave been previously treated with WBRT or 
SRS or both.  
 
CBR will be the primary endpoint for this study and  is defined as objective response (CR + 
PR) plus stable disease ≥24 weeks. ORR, OS, TTP, safety, time to deteriorati on of 
neurologic function, changes in symptom occurrence,  and a correlation between PI3K 
pathway-related biomarkers and clinical response ar e the secondary endpoints and will also 
be followed and described in this study.   
6.3  Sample size and projected study duration 
14 patients will be entered into each of 3 patient cohorts: ER+/HER2-, HER2+, and triple 
negative disease.    If the true CBR is 30% in any of the 3 cohorts, observing 3 of 10 patients 
achieving clinical benefit will yield a 90% confide nce interval for CBR from 6-54%. If the 
true CBR is 15% in any of the 3 cohorts, observing 3 of 10 patients achieving clinical benefit 
will yield a 90% confidence interval for CBR from 1 -34%.    If 3 or more of the 14 patients . 
in any cohort has clinical benefit from the combina tion, we will discuss with Novartis the 
potential of expanding that cohort to enroll additi on patients. With an estimated accrual rate 
of 3 patients per month, a follow-up of 12 months, and an additional 6 months for data lock 
and report development, the total time to the initi al release of findings would be around 2.5 
years. 
 
6.4  Statistical methods 
6.4.1  Primary efficacy analysis 
CBR in the patients following WBRT or SRS or both w ill be the primary endpoint and is 
calculated as the total number of responders (CR or  PR) plus stable disease greater than or 
equal to 24 weeks (CR + PR + SD ≥ 24 weeks) divided by the total number of evaluable  
patients.  .   
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
98 
 6.4.2  Secondary efficacy analysis 
The incidence of responses of CR, PR, ORR, SD, PD, and NE (using RECIST 1.1) with 95% 
CI will be tabulated and summarized using descripti ve statistics by the exact-binomial 
method in the evaluable population. Time to respons e and duration of response will be 
calculated.  
 
OS will be measured from the date of registration t o the date of death for patients who die. If 
a patient is still alive or is lost to follow up, t he patient will be censored at the last contact 
date. OS will be estimated using the Kaplan-Meier m ethod  and Breast-GPA-estimated 
method in the ITT population. Number of Patients wh o died, and causes of death will be 
reported. The Graded Prognostic Assessment (GPA) wi ll be calculated by Karnofsky PS, 
subtype of breast cancer, and age group (Appendix 1 ).  TTP will be calculated from the date 
of registration to the date of the first documented  progression or the date of death due to 
disease progression, whichever comes first. If the patient did not progress or die due to 
disease progression, the patient will be censored a t the date of last contact. TTP will be 
summarized using the Kaplan-Meier method in the ITT  population.  
 
Toxicity profiles will be tabulated in the safety p opulation. Toxicities will be graded 
according to the NCI Common Terminology Criteria fo r Adverse Events (version 4.0). 
Subjects enrolled in this study will be carefully m onitored during the entire treatment phase 
and will be followed as is appropriate. Incidence a nd type of adverse events, including 
serious adverse events, will be tabulated. Adverse events that occur >30 days after the 
administration of last treatment will not be report ed. Median cycles received, median drug 
delivered per dose and cumulative doses, dose compl iances, dose modifications, and reasons 
of the dose modifications will be summarized.  
 
Time to deterioration of neurologic function will b e estimated using Kaplan-Meier method in 
safety population. Results of the PHQ-9 Depression Scale will be tabulated, as well as the 
MDASI-BT questionnaire results. 
 
In addition, a correlation between PI3K pathway-rel ated biomarkers and clinical responses 
will also be assessed as a secondary objective in t his study.  
 
 
7 Protocol and Data Development 
7.1  Ethics 
7.1.1  Institutional review board 
This trial can be undertaken only after review and full approval of the protocol and a Patient 
Informed Consent Form has been obtained from a prop erly constituted IRB. This written 
approval must be dated and it must clearly identify  the protocol, any amendments, the Patient 
Informed Consent Form, Investigator’s Brochure, the  name of the Principal Investigator (PI) 
and any applicable recruiting materials and subject  compensation programs approved. 
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
99 
 The decision concerning the conduct of the study wi ll be made in writing to the SI.  Copies of 
this decision and of all IRB correspondence will be  kept on file at the study site; copies will 
be provided to the sponsor, Delta Clinical Research , LLC. 
 
During the trial, the PI is required to send variou s documents to the IRB for review for: 
1. Changes to the current protocol. 
2. Changes to the Investigator’s Brochure. 
3. All protocol amendments and Patient Informed Consen t Form revisions. 
4. Reports of AEs/SAEs that are serious, unexpected, a nd associated with the 
investigational drug, and any life-threatening prob lems, or death. 
5. Required progress reports. 
 
If local IRB approval is acquired, the Delta Regula tory Affairs Office should be informed via 
research Standard Operation Procedures (SOP). 
 
Particular attention is drawn to the FDA regulation s regarding the IRB. The SI provides Delta 
with the necessary assurance that an IRB is respons ible for the initial and continuing review 
and approval of the proposed clinical study in acco rdance with these regulations. At least 
once a year, the IRB will be asked to review and re -approve the clinical trial protocol; the 
request must be documented in writing. At the end o f the trial, the SI will notify the IRB that 
the trial has been completed. 
7.1.2  Patient informed consent 
The informed consent should meet the requirements o f the latest version of the Declaration of 
Helsinki and any applicable regulations and guideli nes. It must be approved by an 
institutional ethics committee/IRB. 
 
Prior to entry into the trial and before any protoc ol-required procedures are performed, the 
Treating Physician must explain the nature of the t rial, its intended purpose, and the 
implications of participation to potential patients  or to their legal representatives. They will 
be told about the possible risks and benefits, and the possible adverse experiences. They will 
be informed that patients’ participation is volunta ry, and that they may withdraw consent to 
participate at any time. They will also be informed  that if patients choose not to participate in 
the trial, alternative treatments are available; su ch refusal will not prejudice further treatment 
of their disease. Potential patients or their legal  representatives must be given the opportunity 
to ask questions about the trial protocol and the p rocedures involved. 
 
Finally, each patient will be told that his or her records may be accessed by authorized 
personnel of Delta and other authorized individuals  without violating the patient’s 
confidentiality, to the extent permitted by the app licable laws and/or regulations. By signing 
the written Patient Informed Consent Form, the pati ent or his or her legal representative is 
authorizing such access. Following this explanation  and prior to entry into the trial, the 
written, dated, and signed Patient Informed Consent  Form must be obtained from each 
patient or his or her legal representative; a copy will be given to the person signing the form. 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
100 
 7.1.3  Confidentiality of records 
The Treating Physician is required to retain, in a confidential manner, sufficient information 
on each patient (i.e., full name, current address, and social security number) so that the 
patient may be contacted by the FDA or by Delta sho uld the need arise. 
7.2  Study Records 
7.2.1  Documentation 
For each patient treated with the study drug(s), th e Research Coordinator is required to 
prepare and maintain case histories that include al l observations and other data pertinent to 
the investigation. This will include all source doc uments needed to verify the accuracy of all 
observations and other data contained in the eCRFs on each study patient. 
 
The Treating Physician or his/her designee is requi red to retain the records related to the trial 
for a period of 2 years following the date a market ing application is approved for the 
indication being investigated. If no marketing appl ication is to be filed or if the application is 
not approved for such indication, the records must be retained until 2 years after the 
investigation is discontinued and the regulatory ag encies are notified. 
 
The Treating Physician shall retain study drug disp osition records, copies of eCRFs (or 
electronic files), and source documents for the max imum period required by the site in which 
the study will be conducted, or for the period spec ified by Delta, whichever is longer. The 
Investigator must contact Delta prior to destroying  any records associated with the study. 
 
If the Investigator withdraws from the study (e.g.,  relocation, retirement), the records shall be 
transferred to a mutually agreed upon designee (e.g ., another investigator, IRB). Prior notice 
of such transfer will be given in writing to Delta.  
 
7.2.2  Electronic case report form procedures 
 
Data will be entered at the site using eCRFs. The T reating Physician or his/her designee is 
responsible for recording all data relating to the trial on the eCRFs. The Treating Physician 
must verify that all data entries on the eCRFs are accurate and correct. eCRFs must be 
completed within 7 calendar days  of the end of each cycle and within 7 calendar days  
following completion of study therapy. 
 
If an item is not available or is not applicable, i t should be documented as such; no blank 
spaces should be left on any eCRF. 
 
For patients removed from study, their eCRFs must t hen be completed within 7 calendar 
days  of the date of removal from the study. Long-term s urvival information will be collected. 
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
101 
 7.3  Monitoring/Site Visits 
Study sites are subject to be monitored by the stud y sponsor or their designee, and/or by the 
Food and Drug Administration (FDA) or other regulat ory agencies. To ensure accuracy, a 
minimal data set from the eCRFs will be compared wi th a subset of the original patient source 
documents during site visits. The monitor may also review case histories, laboratory 
certifications, IRB records, drug accountability re cords, and other source documentation. At 
all times, patients’ confidentiality will be mainta ined. 
Monitoring will take place at different sites. The monitoring plan will be developed by the 
study sponsor or their designee. 
7.4  Modification of Protocol 
Any changes to this protocol that affect study obje ctives, study design, study procedures, 
patient population, or significant administrative p rocedures will require a formal amendment 
to the protocol. Any proposed protocol amendments m ust be sent in writing to the applicable 
IRB. Prior to implementation, an amendment must be agreed upon by the SI and by Delta 
and approved by the applicable IRB. 
 
General administrative changes to the protocol are minor corrections and/or clarifications that 
do not affect the manner in which the study is to b e conducted. Such administrative changes 
will be agreed upon by the SI and will be documente d in a memorandum. The applicable IRB 
will be notified of administrative changes accordin g to applicable IRB guidelines. 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
102 
 8 References 
 
Adamo B, Deal AM, Burrows E, et al. Phosphatidylino sitol 3-kinase pathway activation in 
breast cancer brain metastases. Breast Cancer Res. 2011; 13(6):R125. 
 
Anders CK, Deal AM, Miller CR, et al. The prognosti c contribution of clinical breast cancer 
subtype, age, and race among patients with breast c ancer brain metastases. Cancer. 
2011;117(8):1602-11. 
 
Bachelot T, Romieu G, Campone M, et al. Lapatinib p lus capecitabine in patients with 
previously untreated brain metastases from HER2-pos itive metastatic breast cancer 
(LANDSCAPE): a single-group phase 2 study. Lancet O ncol. 2013;14(1):64-71. 
 
Bae SY, La Choi Y, Kim S, et al. HER3 status by imm unohistochemistry is correlated with 
poor prognosis in hormone receptor-negative breast cancer patients. Breast Cancer Res Treat. 
2013;139(3):741-50. 
 
Barnholtz-Sloan JS, Yu C, Sloan AE, et al. A nomogr am for individualized estimation of 
survival among patients with brain metastasis. Neur o Oncol. 2012;14(7):910-8. 
 
Beaulieu JM, Gainetdinov RR, Caron MG. Akt/GSK3 sig naling in the action of psychotropic 
drugs. Pharmacology and Toxicology 2009;49:327-47. 
 
Bendell JC, Rodon J, Burris HA, et al. Phase I, Dos e-Escalation Study of BKM120, an 
Oral Pan-Class I PI3K Inhibitor, in Patients With A dvanced Solid Tumors. J Clin Oncol. 
2912;30(3):282-290. 
 
Breast Cancer: Prevention and Control. World Health  Organization. Available at: 
http://www.who.int/cancer/detection/breastcancer/en /index1.html.  Accessed January 30, 
2012. 
 
Campbell RA, Bhat-Nakshatri P, Patel NM, et al. Pho sphatidylinositol 3-
kinase/AKTmediated activation of estrogen receptor alpha: a new model for anti-estrogen 
resistance. J Biol Chem 2001;276:9817–9824. 
 
Chow L, Baker S. PTEN function in normal and neopla stic growth. Cancer Lett. 
2006;241(2):184-96.  
 
Craig DW, O'Shaughnessy JA, Kiefer JA, et al. Genom e and transcriptome sequencing in 
prospective metastatic triple-negative breast cance r uncovers therapeutic vulnerabilities. Mol 
Cancer Ther. 2013;12(1):104-16. 
 
Crowder RJ, Phommaly C, Tao Y, et al. PIK3CA and PI K3CB inhibition produce synthetic 
lethality when combined with estrogen deprivation i n estrogen receptor-positive breast 
cancer. Cancer Res.2009;69 (9):3955-3962. 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
103 
  
Cully M, You H, Levine AJ, et al. Beyond PTEN mutat ions: the PI3K pathway as an 
integrator of multiple inputs during tumorigenesis.  Nat Rev Cancer. 2006;6(3):184-192. 
 
Da Silva L, Simpson PT, Smart CE, et al. HER3 and d ownstream pathways are involved in 
colonization of brain metastases from breast cancer . Breast Cancer Res. 2010;12(4):R46. 
 
Doi T, Ando Y, Bando H, et al Phase I dose-escalati on study of BKM120, an oral 
panclass I PI3K inhibitor, in Japanese patients wit h advanced solid tumors. Molecular Cancer 
Therapeutics 2011;10(11) (Supplement 1, Abstract B1 59). 
 
Eichler AF, Kuter I, Ryan P, et al. Survival in pat ients with brain metastases from breast 
cancer: the importance of HER-2 status. Cancer. 200 8; 112(11):2359-67. 
 
Ekenel M, Hormigo AM, Peak S, et al. Capecitabine t herapy of central nervous system 
metastases from breast cancer. J Neurooncol. 2007;8 5(2):223-7. 
 
Fabi A, Vidiri A, Ferretti G, et al. Dramatic regre ssion of multiple brain metastases from 
breast cancer with Capecitabine: another arrow at t he bow? Cancer Invest. 2006;24(4):466-8. 
 
Fedele CG, Ooms LM, Ho M, et al. Inositol polyphosp hate 4-phosphatase II regulates 
PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci U S A. 
2010; 107(51):22231-6. 
 
Gewinner C, Wang ZC, Richardson A, et al. Evidence that inositol polyphosphate 4-
phosphatase type II is a tumor suppressor that inhi bits PI3K signaling. Cancer Cell. 
2009;16(2):115-25. 
 
Grana B, Burris HA, Rodon J, et al. Oral PI3 kinase  inhibitor BKM120 monotherapy in 
patients (pts) with advanced solid tumors: An updat e on safety and efficacy. J Clin Oncol 
2011;29:(suppl; abstract/poster 3043). 
 
Hernandez-Aya LF and Gonzalez-Angulo AM. Targeting the phosphatidylinositol 3-kinase 
signaling pathway in breast cancer. Oncologist. 201 1; 16(4):404-14. 
 
Hikino H, Yamada T, Johbara K, et al. Potential rol e of chemo-radiation with oral 
capecitabine in a breast cancer patient with centra l nervous system relapse. Breast. 
2006;15(1):97-9. 
 
Ibrahim YH, García-García C, Serra V, et al. PI3K i nhibition impairs BRCA1/2 expression 
and sensitizes BRCA-proficient triple-negative brea st cancer to PARP inhibition. Cancer 
Discov. 2012;2(11):1036-47. 
 
Juvekar A, Burga LN, Hu H, et al. Combining a PI3K inhibitor with a PARP inhibitor 
provides an effective therapy for BRCA1-related bre ast cancer. Cancer Discov. 
2012;2(11):1048-63. 
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
104 
 Kaplan EL, Meier P. Nonparametric estimation from i ncomplete observations. J Am Stat 
Assoc 1958; 53:457-481. 
 
Katso R, Okkenhaug K, Ahmadi K, et al. Cellular fun ction of phosphoinositide 3- kinases: 
implications for development, homeostasis, and canc er. Cell Dev Biol. 2991;17:615-75.  
  
Kennecke H, Yerushalmi R, Woods R, et al. Metastati c behavior of breast cancer subtypes. J 
Clin Oncol. 2010; 28(20):3271-7. 
 
Kwiatkowski DJ. Rhebbing up mTOR: new insights on T SC1 and TSC2, and the 
pathogenesis of tuberous sclerosis. Cancer Biology & Therapy 2003;2(5):471-6. 
 
Lin NU, Winer EP. Brain metastases: the HER2 paradi gm. Clin Cancer Res. 
2007;13(6):1648-55. 
 
Lin NU, Claus E, Sohl J, et al. Sites of distant re currence and clinical outcomes in patients 
with metastatic triple-negative breast cancer: high  incidence of central nervous system 
metastases. Cancer. 2008; 113:2638-45. 
 
Lin NU, Diéras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain 
metastases from HER2-positive breast cancer. Clin C ancer Res. 2009;15(4):1452-9. 
 
Liu P, Cheng H, Roberts TM, et al. Targeting the ph osphoinositide 3-kinase pathway in 
cancer. Nat Rev Drug Discov. 2009;8:627-44. 
 
López-Knowles E, O'Toole SA, McNeil CM, et al. PI3K  pathway activation in breast cancer 
is associated with the basal-like phenotype and can cer-specific mortality. Int J Cancer. 2010; 
126(5):1121-31. 
 
Mackean M, Planting A, Twelves C, et al. Phase I an d pharmacologic study of intermittent 
twice-daily oral therapy with capecitabine in patie nts with advanced and/or metastatic cancer. 
J Clin Oncol. 1998 Sep;16(9):2977-85. 
 
Maira SM1, Pecchi S, Huang A, et al (2012) Identifi cation and characterization of 
NVPBKM120,and orally available pan-class I PI3-kina se inhibitor. Mol Cancer Ther. 2012 
Feb;11(2):317-28. doi: 10.1158/1535-7163.MCT-11-047 4. Epub 2011 Dec 21. 
 
Marty B, Maire V, Gravier E, et al. Frequent PTEN g enomic alterations and activated 
phosphatidylinositol 3-kinase pathway in basal-like  breast cancer cells. Breast Cancer Res. 
2008;10(6):R101. 
 
McCubrey JA, Steelman LS, Abrams SL, et al. Roles o f the RAF/MEK/ERK and 
PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme 
Regul. 2006;46:249-79. 
Miller TW, Balko JM, Arteaga CL (2011) Phosphatidyl inositol 3-kinase and antiestrogen 
resistance in breast cancer. J.Clin.Oncol.2011;29 ( 33):4452-4461. 
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
105 
 Moulder SL. Does the PI3K pathway play a role in ba sal breast cancer? Clin Breast Cancer. 
2010; 10 Suppl 3:S66-71. 
 
Nam BH, Kim SY, Han HS, et al. Breast cancer subtyp es and survival in patients with brain 
metastases. Breast Cancer Res. 2008; 10(1):R20. 
 
Nanni P, Nicoletti G, Palladini A, et al. Multiorga n metastasis of human HER-2+ breast 
cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor. PLoS One. 
2012;7(6):e39626. doi: 10.1371/journal.pone.0039626 . 
 
O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the 
phosphatidylinositol 3' kinase inhibitor GDC-0941 i n breast cancer preclinical models. Clin 
Cancer Res. 2010; 16(14):3670-83. 
 
O'Brien NA, McDonald K, Von Euw E, et al. Combined Targeting of the PI3K Pathway and 
HER2 Overcomes Acquired and De Novo Trastuzumab Res istance. Cancer Res. 2011;71(24 
Suppl):Abstract nr P1-12-03. 
 
O’Shaughnessy JA, Blum J, Moiseyenko V, et al. Rand omized, open-label, phase II trial of 
oral capecitabine (Xeloda) vs. a reference arm of i ntravenous CMF (cyclophosphamide, 
methotrexate and 5-fluorouracil) as first-line ther apy for advanced/metastatic breast cancer. 
Ann Oncol. 2001;12(9):1247-54. 
 
Osipo C, Meeke K, Cheng D, et al. Role for HER2/neu  and HER3 in fulvestrant-resistant 
breast cancer. Int J Oncol. 2007;30(2):509-20. 
 
Perou CM, Sørlie T, Eisen MB, et al. Molecular port raits of human breast tumours. Nature. 
2000; 406(6797):747-52. 
 
Pistilli B, Urruticoechea A, Chan S, et al: Ph IB/I I study of BKM120 plus trastuzumab in 
patients with trastuzumab-resistant HER2+ advanced breast cancer. 2012 ESMO Congress. 
Abstract 3180. Presented October 1, 2012. 
 
Riddle MC, Rosenstock J, Gerich J, et al. The treat -to-target trial: randomized addition of 
glargine or human NPH insulin to oral therapy of ty pe 2 diabetic patients. Diabetes Care 
2003;26(11):3080-6. 
 
Rodon J, Bendell JC, Abdul Razak AR, et al. Safety Profile and Clinical Activity of 
Single-Agent BKM120, a Pan-Class I PI3K Inhibitor, for the Treatment of Patients with 
Metastatic Breast Carcinoma. (2011) SABCS Abstract P3-16-01. 
 
Rogers LR, Remer SE, and Tejwani S. Durable respons e of breast cancer leptomeningeal 
metastasis to capecitabine monotherapy. Neuro Oncol . 2004 Jan;6(1):63-4. 
 
Sanchez CG, Ma CX, Crowder RJ, et al. Preclinical m odeling of combined 
phosphatidylinositol-3-kinase inhibition with endoc rine therapy for estrogen receptor-
positive breast cancer. Breast Cancer Res.2011;13:R 21. 
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
106 
 Saura C, Bendell J, Jerusalem G, et al. Phase I/II Study of BKM120 in Combination 
with Trastuzumab in Patients with HER2 Overexpressi ng Metastatic Breast Cancer Resistant 
to Trastuzumab-Containing Therapy. (2011) SABCS Abs tract PD09-03. 
 
Shoman N, Klassen S, McFadden A, et al. Reduced PTE N expression predicts relapse in 
patients with breast carcinoma treated by tamoxifen . Mod.Pathol.2005;18 (2):250-259. 
 
Sotiriou C, Pusztai L. Gene expression signatures i n breast cancer. N Engl J Med. 2009; 
360(8):790-800. 
 
Sperduto CM, Watanabe Y, Mullan J, et al. A validat ion study of a new prognostic index for 
patients with brain metastases: the Graded Prognost ic Assessment. J Neurosurg. 2008; 109 
Suppl:87-9. 
 
Sperduto PW, Kased N, Roberge D, et al. Summary rep ort on the graded prognostic 
assessment: an accurate and facile diagnosis-specif ic tool to estimate survival for patients 
with brain metastases. J Clin Oncol. 2012; 30(4):41 9-25. 
 
Sperduto PW, Kased N, Roberge D, et al. Effect of t umor subtype on survival and the graded 
prognostic assessment for patients with breast canc er and brain metastases. Int J Radiat 
Oncol Biol Phys. 2012; 82(5):2111-7. 
 
Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and 
proteomic analysis of PIK3CA, PTEN, and AKT mutatio ns in breast cancer. Cancer Res. 
2008; 68(15):6084-91. 
 
Tham YL, Hinckley L, Teh BS, et al. Long-term clini cal response in leptomeningeal 
metastases from breast cancer treated with capecita bine monotherapy: a case report. Clin 
Breast Cancer. 2006;7(2):164-6. 
 
The Cancer Genome Atlas Network. Comprehensive mole cular portraits of human breast 
tumours. Nature. 2012;490:61-70. 
 
Tsao M, et al. Radiotherapeutic and surgical manage ment for newly diagnosed brain 
metastasis(es): An American Society for Radiation O ncology evidence-based guideline. 
Practical Radiation Oncology. 2012 2(3):210-225.  
http://www.practicalradonc.org/article/S1879-8500(1 1)00380-8/abstract    
 
Umemura S, Yoshida S, Ohta Y, et al. Increased phos phorylation of Akt in triple-negative 
breast cancers. Cancer Sci. 2007; 98(12):1889-92. 
 
Wang ML, Yung WK, Royce ME, et al. Capecitabine for  5-fluorouracil-resistant brain 
metastases from breast cancer. Am J Clin Oncol. 200 1;24(4):421-4. 
 
Weigman VJ, Chao HH, Shabalin AA, et al. Basal-like  Breast cancer DNA copy number 
losses identify genes involved in genomic instabili ty, response to therapy, and patient 
survival. Breast Cancer Res Treat. 2012;133(3):865- 80. 
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
107 
 Wiens AL, Martin SE, Bertsch EC, et al. Luminal sub types predict improved survival 
following central nervous system metastasis in pati ents with surgically managed metastatic 
breast carcinoma. Arch Pathol Lab Med. 2014;138(2): 175-81. 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
108 
 APPENDICES 
Appendix 1 – Breast Cancer-Graded Prognostic Assess ment (GPA) 
 
Prognostic 
Factor GPA Scoring Criteria 
Patient 
Score 0 0.5 1.0 1.5 2.0 
Karnofsky 
Performance 
Score ≤50 60 70-80 90-100 n/a  
Subtype Basal n/a LumA HER2 LumB  
Age, years ≥60 <60 n/a n/a n/a  
Sum total  
Median survival (months) by GPA: 0-1.0 = 3.4; 1.5-2 .0 = 7.7; 2.5-3.0 = 15.1; 3.5-4.0 = 
25.3 
 
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
109 
 Appendix 2 - Performance Status Criteria 
 
 
ECOG Performance Status Scale 
 
Grade Description 
0 Normal activity. Fully active, able to carry on all  pre-disease 
performance without restriction. 
1 Symptoms, but ambulatory. Restricted in physically strenuous 
activity, but ambulatory and able to carry out work  of a light or 
sedentary nature (e.g., light housework, office wor k). 
2 In bed < 50% of the time. Ambulatory and capable of  all self-
care, but unable to carry out any work activities. Up and about 
more than 50% of waking hours. 
3 In bed >50% of the time. Capable of only limited se lf-care, 
confined to bed or chair more than 50% of waking ho urs. 
4 100% bedridden. Completely disabled. Cannot carry o n any self-
care. Totally confined to bed or chair. 
5 Dead. 
 
 
 
 
 
 
 
 
 
 
 
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
110 
 Appendix 3 – CTCAE Grading 
 
NCI COMMON TERMINOLOGY CRITERIA 
FOR ADVERSE EVENTS (CTCAE) 
Version 4.0 
Published: May 28, 2009 (v4.03: June 14, 2010) 
 
 
 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-0 6-
14_QuickReference_5x7.pdf    
 
DO  NOT  USE  CTC  VERSION  2.0  OR  3.0  TO  GRADE  TOXICITIES  IN  
THIS  STUDY! 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
111 
 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
112 
 Appendix 4 – Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 
 
 
New response evaluation criteria in solid tumors: R evised RECIST guideline 
(version 1.1) Eisenhauer EA, Therasse P, Bogaerts J , et al. Eur J Cancer. 2009 
Jan;45(2):228-47. 
 
http://ctep.cancer.gov/protocolDevelopment/docs/rec ist_guideline.pdf 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
113 
 Appendix 5 – Oral Medication Diary 
 
  
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
114 
 Drug Administration Record – to be completed by pat ient and returned at each visit 
Please begin entries by checking the appropriate bo x that corresponds to the date treatment 
was started (Calendar Date). For example: If the pa tient starts treatment on January 24, 2014, 
check the box next to “24” under Calendar Date and continue entries from that date forward.  
 
Patient Initials   
Arm   
Patient ID #   
Month   
Year   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please return all copies of this  
form to the Clinical Research 
Coordinator at each clinic visit. 
 
 
 
 
 Calendar  Drug Taken  
Date  Yes  No  
1   
2   
3   
4   
5   
6   
7   
8   
9   
10    
11    
12    
13    
14    
15    
16    
17    
18    
19    
20    
21    
22    
23    
24    
25    
26    
27    
28    
29    
30    
31    US Oncology, Inc                                                 Study# 11-025 
Delta Clinical Research, LLC  Study No. CBKM120ZUS3 9T 
BKM120 for TNBC with Brain Metastases  [24JUN2016] 
  
 
115 
 Appendix 6 – M.D. Anderson Symptom Inventory-Brain Tumor (MDASI – BT) 
 
(The MD Anderson Symptom Inventory- Brain Tumor Modu le *Screening, every 8 weeks 
during treatment, End of Treatment (Window ± 3 busi ness days). Any delay within this 
window is not a deviation.)  
 

  
 
Delta Clinical Research, LLC   Study No. CBKM120ZUS 39T 
BKM120 for TNBC with Brain Metastases  [24JUN2016]  
 
116 
  
 
 
